Neurodegeneration and Neuroplasticity of the Intrinsic Innervation of the Gut in Severe Dysmotility by Karunaratne, Tennekoon Mudiyanselage Prasantha Buddhika
Alma Mater Studiorum –– Università di Bologna 
 
DOTTORATO DI RICERCA IN 
SCIENZE MEDICHE GENERALI E DEI SERVIZI 
 
Ciclo XXX° 
 
Settore Scientifico Disciplinare: MED/09 
 
 
Neurodegeneration and Neuroplasticity of the Intrinsic Innervation of the 
Gut in Severe Dysmotility 
 
Presentata da: Dr. Tennekoon B. Karunaratne 
 
 
 
 
 
 
 
Coordinatore Dottorato: 
Chiar.mo Prof. Fabio Piscaglia                                                                         Supervisore: 
Chiar.mo Prof. Vincenzo Stanghellini 
 
Correlatore: 
Chiar.mo Prof. Roberto De Giorgio 
 
 
Esame finale anno 2018 
2 
 
INDEX…………………………………………………..……………..…………………………… 2  
ABSTRACT...................................................................................................................................... 4            
LIST OF ABBREVIATIONS…………………………………………………………………... 7 
 
Chapter 1. GASTROINTESTINAL NEUROMUSCULAR DISEASES …..…...………….. 10 
 
Chapter 2. MORPHOLOGICAL BASIS OF GASTROINTESTINAL MOTILITY…… 12 
2.1 The Enteric Nervous System (ENS) ………………………………...……….. 15 
2.2 Smooth muscle electrical activity and regulatory mediators……..………… 29 
 
Chapter 3. PERISTALSIS AND MAIN MOTOR PATTERNS OF  
GASTROINTESTINAL MOTILITY …………………………………………………….. 31 
3.1 Contractile patterns of the small intestine  ..………………………...……… 32 
3.2 Postprandial motility of the small intestine ……………………………….... 34 
3.3 Interdigestive motility of the small intestine ………………………...……… 35 
 
Chapter 4. IN VIVO ASSESSMENT OF INTESTINAL MOTILITY ………………... 38 
4.1 Small intestinal manometry …………………………………………………  39 
4.2 Normal antroduodenal manometry findings ……………...………………... 40 
4.3 Abnormal antroduodenal manometry findings …………...……………….. 41 
 
Chapter 5. CLINICAL ASPECTS OF NEUROINTESTINAL DISEASE: 
PATHOPHYSIOLOGY, DIAGNOSIS, AND TREATMENT …………………………..  45 
 
 
3 
 
Chapter 6. CHRONIC INTESTINAL PSEUDO-OBSTRUCTION …………………… 69 
 6.1 Diagnosis and therapeutic options ………………………………………… 69 
 6.2 Management ……………………………………………………………...… 93 
 
Chapter 7. COMPARISON BETWEEN SMALL BOWEL MANOMETRIC  
PATTERNS AND FULL-THICKNESS BIOPSY HISTOPATHOLOGY  
IN SEVERE INTESTINAL DYSMOTILITY …………………….…………………… 103 
 
Chapter 8. QUANTITATIVE CHANGES OF ENTERIC NEURONS  
CORRELATE WITH CLINICAL FEATURES IN PATIENTS  
WITH SEVERE DYSMOTILITY …………………………………………………….... 122 
 
 
CONCLUSIONS …………………………………………………………………………….... 138 
 
REFERENCES ……………………………………………………………………….... 140 
 
ACKNOWLEDGEMENTS …………………………………………………………… 195 
 
 
 
  
4 
 
ABSTRACT 
Abnormalities in the gastrointestinal neuromuscular apparatus including interstitial cells of 
Cajal (ICC) is presumed to underlie a clinically heterogeneous group of disorders collectively 
termed gastrointestinal neuromuscular diseases (GINMDs). A subset of these patients may 
manifest clinically with recurrent intestinal sub-occlusive episodes, which occur in the 
absence of demonstrable mechanical causes, leading to numerous hospitalizations as well as 
useless and potentially harmful surgical interventions. Taken together clinical and 
radiological signs make up a condition referred to as chronic intestinal pseudo-obstruction 
(CIPO). This is a rare and intractable chronic digestive disease that can result from 
abnormalities of smooth muscle cells (effectors of contractility / relaxation), ICC (pace-
makers of gut motility and regulators of neuronal input to smooth muscle cells), and neurons 
(either intrinsic – the enteric nervous system- or extrinsic nerve pathways).  
The present thesis was thought to provide a translational view by characterizing dysmotility 
and establishing attendant histopathological defects in CIPO and determine whether a 
correlation exists between clinical features, motility patterns and neuromuscular changes, 
using qualitative and quantitative morphological approaches.  
 
Summary of published and submitted papers pertinent to this thesis 
In this thesis I provided an update on neurointestinal diseases, with special focus on 
diagnostic, therapeutic and management aspects of CIPO, which have been published during 
the PhD course. My senior dissertation deals with major neurogastroenterological aspects, 
such as those involving the most severe forms of the functional GI disorder spectrum, i.e. 
those patients with prominent abnormalities of gut propulsion. A better understanding of 
these cases will cast hope about patient management and newly applicable therapeutic 
intervention. Briefly: 
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1. Clinical Aspects of Neurointestinal Disease: Pathophysiology, Diagnosis, and 
Treatment 
In this review we considered ENS disorders from a clinical perspective and highlighted the 
advancing knowledge regarding their pathophysiology. The enteric nervous system (ENS) is 
involved in the regulation of virtually all gut functions. Conditions referred to as enteric 
neuropathies are the result of various mechanisms including abnormal development, 
degeneration or loss of enteric neurons that affect the structure and functional integrity of the 
ENS. Clinical and molecular research has led to important conceptual advances in our 
knowledge of the pathogenetic mechanisms of these disorders. 
 
2. Chronic intestinal pseudo-obstruction in children and adults: diagnosis and 
therapeutic options 
Chronic intestinal pseudo-obstruction (CIPO) represents the most severe form of 
gastrointestinal dysmotility with debilitating and potentially lethal consequences. The present 
article aims to provide pediatric and adult gastroenterologists with an appraisal about clinical 
features, diagnosis and therapeutic options for CIPO. There is no single diagnostic test or 
pathognomonic finding of CIPO, thus a stepwise approach including radiology, endoscopy, 
laboratory, manometry and histopathology should be considered in the diagnostic work-up. 
Treatment of patients with CIPO is challenging and requires a multidisciplinary effort. 
 
3. Chronic intestinal pseudo-obstruction: progress in management? 
CIPO is often due to derangement of the innervation / smooth muscle / interstitial cells of 
Cajal with recurrent episodes of intestinal sub-occlusion mimicking a mechanical obstruction. 
Management is a critical aspect in CIPO patient care. Promising data indicate that 
percutaneous endoscopic gastro-jejunostomy (PEG-J) can be proposed as a measure for 
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intestinal decompression, thereby improving CIPO-associated abdominal symptoms, 
including pain. The present mini-review tackles management options, with a major emphasis 
on PEG-J, for CIPO patients. 
 
4. Comparison between small bowel manometric patterns and full-thickness biopsy 
histopathology in severe intestinal dysmotility 
In this original paper I contributed to assess 38 patients with severe intestinal dysmotility 
using intestinal manometry and a subsequent full-thickness intestinal biopsy. Patients with 
abnormal intestinal manometry had abnormal histopathological findings in 73% of cases. 
However, manometric patterns did not match with the specific neuromuscular abnormalities. 
The key finding was that manometrically defined small bowel dysmotility was often 
associated with abnormal neuromuscular findings, although this aspect did not correlate with 
specific histopathology. 
 
5. Quantitative changes of enteric neurons correlate with Clinical features in patients 
with severe dysmotility 
This original submitted / under peer review paper follows the previous one. Here I have 
contributed to define the role of quantitative analysis in enteric neuromuscular disorders. 
Specifically, the intrinsic innervation of the gut, i.e. the enteric nervous system, can reveal 
significant decrease of both myenteric and submucosal cell bodies in patients with severe 
dysmotility, even in those cases in whom a previous evaluation did not identify clear-cut 
histopathological abnormalities. An overall 50% decrease of myenteric and submucosal 
neuronal cell bodies correlated with clinical features, e.g. pain and bloating.  
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LIST OF ABBREVIATIONS 
 
5-HT 5-hydroxytryptamine 
ACh acetylcholine 
AHPs after hyperpolarizing potentials 
AN apparently normal 
ARM anorectal manometry 
ATP Adenosine triphosphate 
BN bombesin 
CALB calbindin 
CCK cholecystokinin 
CCSH congenital central hypoventilation syndrome 
CGRP calcitonin gene-related peptide 
ChAT choline acetyltransferase 
CI colonic intertia 
CIPO chronic intestinal pseudo-obstruction 
CM circular muscle layer, 
CNS central nervous system 
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ECs enterochromaffine cells 
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GFAP glial fibrillary acidic protein 
GI gastrointestinal 
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nNOS neuronal nitric oxide synthase 
NO nitric oxide 
NOS nitric oxide synthase 
NPY neuropeptide Y 
PACAP pituitary adenylyl-cyclase activating peptide 
PVG prevertebral ganglion 
SCLC small cell lung carcinoma 
SD severe dysmotility 
SFGID severe functional GI dysmotility 
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SMP submucosal plexus 
SOM Somatostatin 
Sox SRY-box 
SP substance P 
STC slow-transit constipation 
UES upper esophageal sphincter 
VIP vasoactive intestinal peptide 
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Chapter 1 
GASTROINTESTINAL NEUROMUSCULAR DISEASES 
Gastrointestinal neuromuscular diseases (GINMDs) are a clinically heterogeneous group of 
chronic conditions associated with impaired gut motility in which signs and symptoms are 
presumed or proven to originate from underlying dysfunction of the gastrointestinal (GI) 
neuromuscular compartment, including interstitial cells of Cajal (ICC)1,2. These conditions 
have a profound impact on healthcare systems since they are quite disabling and associated 
with high social and economic burdens due to direct and indirect costs 3,4. The underlying 
neuromuscular dysfunction may result from morphological and /or functional alterations 
affecting the enteric nervous system (ENS) and / or the muscularis propria and / or ICC, with 
histopathologic pictures ranging from severe damage to more subtle abnormalities which may 
lack evident microscopic changes to neurons 5-7, enteric glial cells (EGC) 8,9, smooth muscle 
10-12, and ICC 13-15. GINMDs may encompass a wide range of pathologic conditions and they 
can vary largely in terms of their etiopathogenesis, clinical picture, histopathologic patterns, 
and region of gut involvement. These disorders are characterized mainly by clinical 
symptoms related to altered gut functions and patients with GINMDs represent still a clinical 
challenge because there are no established or widely accepted classifications so far available. 
A classification of GINMDs is based on morphological findings and requires signs and 
symptoms of impaired motor activity accompanied by demonstrable motor abnormalities, for 
example manometric abnormalities with or without radiological evidence of visceral 
dilatation 16. Some of these disorders may occur due to relatively rare congenital defects, i.e. 
Hirschsprung’s disease, where some causative genes have been identified and their 
neuropathophysiological role elucidated 17, whereas most GINMDs are acquired during 
lifetime as a primary (otherwise unknown) diseases or can be secondary to another 
established disease. Such disorders that belong to the area of GINMDs include oesophageal 
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achalasia 18,19, gastroparesis 20,21, enteric dysmotility (ED) 16 and chronic idiopathic intestinal 
pseudo-obstruction (CIPO) 22-25, slow-transit constipation (STC) 26,27 and idiopathic non-
Hirschsprung megacolon 28,29. Although they are distinct entities, for the purposes of this 
thesis CIPO and ED are collectively referred to as severe functional GI dysmotility (SFGID). 
Secondary GINMDs, clinically similar to primary disorders which arise as a complication or 
in association with other diseases can include CIPO occurring as a paraneoplastic syndrome, 
most commonly in association with small cell lung carcinoma (SCLC) 30-32, but also in cases 
of bronchial carcinoid 33, thymoma 34, ganglioneuroblastoma and neuroblastoma 35,36 and 
ovarian carcinoma 37; Chagas’ disease (South American trypanosomiasis) due to the systemic 
disease caused by infection with Trypanosoma cruzi 38,39; connective tissue disorders such as 
scleroderma 40-42 and some endocrine and metabolic disorders, e.g. diabetes mellitus-related 
gastroenteropathy 43 and dysmotility associated with amyloidosis 44,45.  
The characterisation and management of SFGID are challenging since there is limited 
correlation between symptoms and clinical findings or investigations. Dysmotility is a broad 
term without a universally accepted definition and covers a spectrum of disorders, which 
include ED, CIPO and pathologically defined neuromuscular disease, with significant degrees 
of overlap among them. Therefore, the term dysmotility is often reserved for patients 
presenting with severe symptoms without any objective evidence of abnormal bowel 
structure or function. For practical purpose, severe dysmotility can be defined as the presence 
of clinical morbidity (severe symptoms, nutritional compromise, poor response or refractory 
to treatment) with presence of abnormal manometry or transit test with or without 
histopathology showing intestinal neuromuscular disorder in a patient where mechanical 
obstruction and active mucosal pathology has been excluded.  
In the next paragraphs of my thesis, I would like to provide the reader with a cellular 
knowledge on the neuro-muscular and ICC general aspects as a basis for a better 
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understanding of abnormal gut physiology and in particular motility which will be detailed 
afterwards. 
Key points of Chapter 1: 
• Gastrointestinal neuromuscular diseases (GINMDs) are a clinically heterogeneous 
conditions characterized by impaired gut motility 
•  Signs and symptoms of GINMDs may originate from underlying dysfunction of the 
gastrointestinal (GI) neuromuscular compartment. 
• Patients with GINMDs impact profoundly on healthcare systems since their disabling 
disease is associated with high social and economic burdens.  
 
Chapter 2. 
MORPHOLOGICAL BASIS OF GASTROINTESTINAL MOTILITY 
Nutrients constantly supply cells with substances necessary to maintain the energy balance of 
any living organisms. That is possible as the GI tract exerts a vast repertoire of physiological 
functions necessary for digestion and absorption. Muscular sphincters compartmentalize the 
bowel, dividing it into functionally distinct regions with different luminal environments. The 
upper esophageal sphincter (UES) maintains the highest resting pressure of all sphincters, 
preventing air from entering the esophagus. It consists of striated muscle, is under control of 
the swallowing center in the medulla in the brain, and relaxes during swallowing to permit 
food to enter the esophagus. The lower esophageal sphincter (LES) separates the esophagus 
and the stomach and consists of smooth muscle that relaxes during swallowing. It functions 
to coordinate the passage of food into the stomach after swallowing and prevent the reflux of 
gastric contents, including acid, into the esophagus. The pyloric sphincter separates the 
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stomach from the duodenum, and its resting pressure contributes to regulate gastric emptying 
and prevent duodenal-gastric reflux. The ileocecal sphincter is a valve-like structure that 
separates the ileum and cecum, preventing back flux of colonic contents into the ileum. 
Finally, the internal (smooth muscle) and external (skeletal muscle) anal sphincters control 
elimination of waste products. A constant detection of luminal contents allows for ingested 
material to be transported caudally at a physiological rate, allowing each region of the gut to 
perform their respective function. Smooth and skeletal (in the esophagus and anus) muscle 
contractions are thus coordinated into activity patterns, such as segmentation (small intestine) 
or haustration (colon) that grind, mix, and propel aborally the ingested food. Secretory 
mechanisms exert a pivotal role in order to maintain an appropriate pH and regulated 
concentrations of electrolytes, enzymes, and mucous. The pH of the highly acidic chyme in 
the stomach reaches 1.5 to 3.5. At this pH, the hydrogen ion concentration is around 3 million 
times that of the arterial blood. Secretion of hydrogen carbonate ion into the lumen of the 
duodenum by the exocrine pancreas neutralizes the acidic chyme delivered from the stomach 
to duodenum. These changes are necessary to promote digestion, absorption, and 
detoxification of ingested materials. A continuously regenerated semipermeable epithelial 
barrier separates the lumen from the internal milieu of the body. This barrier promotes 
absorption, but also avoid the leakage of unnecessary molecules into the intestinal lumen as 
well as the transit of digestive enzymes, toxins, and germs into the body from the lumen. 
Clearly, this highly organized structure of the GI tract (Fig. 1) and its related physiological 
functions require a sophisticate degree of regulation and coordination, provided by the ENS. 
This is also referred to as “brain-in-the-gut”, since it exhibits control ability of a vast array of 
digestive functions even when severed from the central nervous system (CNS). Within the 
ENS, nerve cells and glia are organized in plexuses, either non-ganglionic (bundles of nerves) 
or ganglionic, i.e., myenteric (Auerbach’s) and submucosal (Meissner’s) ganglia, which are 
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interconnected by nerve fascicles (Fig. 2). An intact ENS is essential for body homeostasis in 
order to control motility, secretion / absoprtion, blood flow, cross-talk with the immune 
system as well as plays a role in the maintenance of epithelial barrier. Another noteworthy 
aspect pertains to the interplay between the ENS and the gut microbiota, i.e. the trillion of 
germs dispersed throughout the lumen of the gut, mainly concentrated in the most distal 
segments. 
Fig. 1. Cross-section of the intestinal wall. The picture shows the four principal layers and 
associated structures: mucosa, submucosa, muscularis and serosa. Although different areas of 
the GI tract have specialized functions, the basic structure of the wall remains similar. From 
Patton KT, Thibodeau GA: Anatomy & physiology, 8th edition. 
 
Thus, since the ENS contributes significantly to body homeostasis, it is not surprising that 
any noxae perturbing ENS maintenance and integrity can result in a variety of disorders some 
of them so severe to be life threatening and / or hinder significantly the patients’ quality of 
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life. The next paragraph will detail some essential aspect of the ENS, such as structure, 
neurochemistry and morpho-functional aspects. 
 
 
 
 
 
 
 
 
 
Fig. 2. Schematic representation of a transverse section through the small intestine showing the 
two main ganglionated plexuses. As recognizable in the drawings, enteric neurons are organized in 
ganglia (green background), i.e. an outer myenteric plexus, which develops first and occupies a 
position between the longitudinal and circular muscle layers; and an inner submucosal plexus which 
forms later in gestation and resides within the submucosa. From Pachnis 2007. 
 
2.1 The Enteric Nervous System (ENS)  
The entire structure of the ENS is arranged into ganglia, connected by interganglionic 
strands, in order to form two plexuses: the myenteric (Auerbach’s) and the submucosal 
(Meissner’s) 46,47. The outer myenteric plexus (MP) is located between the longitudinal and 
circular smooth muscle layers and is (although not exclusively) involved in the control of gut 
motor patterns. The inner submucosal plexus (SMP) resides within the submucosa and is 
involved with local fluid secretion and absorption 48,49. Taken together the network formed by 
the two ganglionated plxuses is constituted by about 100 million neurons in the guinea pig 
(likely 400-500 millions in humans) and even more supporting cells (EGC) outnumbering 
from 3 to 5 times enteric neurons 50. 
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The MP forms a network around the gut, which extends from the upper esophagus to the 
internal anal sphincter. The MP is embedded within the two layers of the muscularis externa, 
i.e. the circular and longitudinal coats, and composed by a neuronal cell bodies and related 
nerve processes 50. The MP shows numerous differences in its morphological organization, 
among GI segments of different species 51-53. In the MP, ganglia are bigger than the SMP in 
terms of number of neurons, and are linked by interconnecting strands (or primary strands), 
which constitute the primary plexus 50. The MP are located in parallel to the circular muscle 
layer, although this feature can vary among species 54; primary interconnecting strands show 
longitudinal course, an organization that seems to be a distinctive feature of the MP in most 
small and large mammals 50,55-60. The other two components of MP are the secondary and 
tertiary plexuses 50. The secondary plexus is constituted by fine bundles of nerve fibers 
running parallel to the circular muscle layer and primary plexus 50,61. The tertiary plexus is 
made by thin interconnecting strands (the smallest in size) supplying the longitudinal muscle 
layer 50,55,61. 
The SMP is well developed in the small and large intestine, while only a few submucous 
ganglia can be found in the esophagus (third inferior part) and stomach particularly in large 
mammals, including humans 50,62-65. The interconnecting strands of the SMP are usually thin 
and SMP ganglia are small. The SMP is organized in a single layer in small mammals 66, 
whereas it shows a multilayered (two or three layers) organization in large mammals 67. In 
these species two different ganglionated plexuses can be identified, namely the internal 
submucous plexus and the external submucous plexus 58,68-73. External and internal SMP are 
separated by a thin connective tissue layer 69,74-76 and by submucosal blood vessels 76. The 
external and internal SMPs appear different among the investigated species. Generally, they 
can be distinguished on the basis of their location, architecture, meshwork density, size and 
form of the ganglia, and light microscopic appearance 77-81. The external SMP shows the most 
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irregularly organized nerve meshwork, while the internal meshwork is smaller and more 
regular compared to the external SMP 61,69,75,82,83. Additionally, the two compartments of 
SMP neurons also show differences in the content of neurochemical messengers / 
transmitters, being the external SMP more similar to that of myenteric neurons 84,85. In 
addition to the mucosa, some neurons of the external SMP also supply the muscular layer 
48,66,73,86-88. The internal SMP neurons supply the mucosa and only a small number have 
projections to the muscle layers 66,88. Thus, in conclusion the external and internal SMP 
neurons overlap in terms of functional control of fluid movements, local blood flow and 
sensory functions, while the external SMP can also affect gut motility 83. 
Enteric neurons are able to synthesize and release about 30 different mediators / bioactive 
substances that may act as messengers, i.e. neurotransmitters, neuromodulators and 
neuropeptides (Table 1). Studies over the years have clearly shown that each subclass of 
enteric neurons can be characterized on the basis of the combination of messengers. This 
property is known as neurochemical coding and turned to be a feature of the ENS that is 
maintained through most animal species 89. 
Primary neurotrasmitters exert the same role in different species and along the GI tract. These 
substances include acetylcholine (ACh) and tachykinins in enteric excitatory motor neurons, 
and nitric oxide (NO), vasoactive intestinal polypeptide (VIP) and others messengers (see 
below) in inhibitory motor neurons. Inhibitory motor neurons may be 
immunohistochemically identified by the presence of the neuronal nitric oxide synthase 
(nNOS), the neuronal isoform of the enzyme synthesizing NO, the primary neurotransmitter 
released by inhibitory motor neurons, while excitatory motor neurons may be 
immunohistochemically identified by the presence of the synthesizing enzyme choline 
acetyltransferase (ChAT). Secondary neurotransmitters or modulators include substances 
which may vary among different groups of neurons depending on the GI tract and the species 
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considered 50. Research performed in the last thirty years has shown that classification of the 
several classes of enteric neurons is the result of a combination of various technical 
approaches and criteria. These features include: neuronal shape; histochemical and 
immunohistochemical staining; projections; and electrophysiological and functional 
properties. 
 
Table 1. Multiple transmitters of functionally distinct enteric neurons in the gut. 
 
Abbreviations: 5-HT, 5-hydroxytryptamine; ACh, acetylcholine; CCK, cholecystokinin; ChAT, 
choline acetyltransferase; CGRP, calcitonin gene-related peptide; GRP, gastrin releasing peptide; ND, 
not determined; NPY, neuropeptide Y; NOS, nitric oxide synthase; PACAP, pituitary adenylyl-
cyclase activating peptide; VIP vasoactive intestinal peptide. From Furness 2012. 
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Fig. 3. Types of neurons in the small intestine. The types of neurons in the small intestine, all of 
which have been defined by their functions, cell body morphologies, chemistries, key transmitters, 
and projections to targets. Neuron Types: Ascending interneurons (1); Myenteric intrinsic primary 
afferent neurons (IPANs) (2); Intestinofugal neurons (3); Excitatory longitudinal muscle motor 
neurons (4); Inhibitory longitudinal muscle motor neurons (5); Excitatory circular muscle motor 
neurons (6); Inhibitory circular muscle motor neurons (7); Descending interneurons (local reflex) (8); 
Descending interneurons (secretomotor and motility reflex) (9); Descending interneurons (migrating 
myoelectric complex) (10); Submucosal IPANs (11); Non-cholinergic secretomotor/ vasodilator 
neurons (12); Cholinergic secretomotor/vasodilator neuron (13); Cholinergic secretomotor (non-
vasodilator) neurons (14); Uni-axonal neurons projecting to the myenteric plexus (15); motor neuron 
to the muscularis mucosa (16); innervation of Peyer’s patches (17). Abbreviations: LM longitudinal 
muscle, MP myenteric plexus, CM circular muscle, SM submucosal plexus, Muc mucosa. From 
Furness 2012. 
 
According to their shape, enteric neurons were classified by Dogiel in three types, referred to 
as Dogiel type I, II and III 90. Many other authors proposed additional classifications based on 
individual neuronal morphology revealed by silver staining, immunoreactivity for 
neurofilaments and / or other markers 91-95. Taken together, these studies confirmed and 
extended the Dogiel’s classification from three up to seven types of neurons in addition to 
‘mini-neurons’. The possibility to correlate the morphological appearance of a given neuron 
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to its neurochemical code, as well as bioelectrical / functional properties has also refueled the 
importance of studying the morphology of the enteric nerve cells. 
From a functional standpoint, enteric neurons can be divided in motor neurons, interneurons, 
intrinsic primary afferent neurons (IPANs) 47,96, and intestinofugal afferent neurons (IFANs) 
97 (Fig. 3). 
 
Motor neurons. This includes excitatory and inhibitory neurons directed to the GI 
musculature; secretomotor / vasodilator neurons are able to regulate mucosal secreting cells 
and vasodilation / vasoconstriction of the intestinal vasculature. Furthermore, another subset 
is represented by secretomotor neurons and neurons innervating entero-endocrine cells 96. 
The motor neurons innervating the smooth muscle of digestive tract are located within the 
MP of rodents 98,99 and within myenteric and external and internal submucous plexuses of 
large mammals [MP > external SMP > internal SMP] and humans [MP > external SMP > 
internal SMP] 83,86-88,100. These neurons could be distinguished in circular muscle motor 
neurons, longitudinal muscle motor neurons, and motor neurons innervating the muscularis 
mucosae. According to the peristaltic reflex, the excitatory motor neurons are especially 
localized aborally to the innervated circular and longitudinal muscle 101,102, while the 
inhibitory motor neurons are generally localized orally to the innervated circular and 
longitudinal muscle 102-108. However, the polarized projection patterns of enteric neurons are 
apparently species- and region-dependent. Based on the distance from their target(s), motor 
neurons can be distinguished in short- and long-axon (both excitatory and inhibitory) cell 
types 101,109. Other well preserved features of enteric motor neurons can be found in their 
neurochemical code. In fact, it is well established that the primary transmitter of excitatory 
muscle motor neurons include Ach often colocalized with tachykinins (especially substance 
P, SP) 110-113. The NO is considered the main transmitter of inhibitory muscle motor neurons; 
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however it is clear that different transmitters are implicated in the inhibitory 
neurotransmission 96 including Adenosine triphosphate (ATP) 114,115, VIP 116,117, NO 
62,87,88,118-124, pituitary adenylate cyclase-activating polypeptide (PACAP) 125,126 and carbon 
monoxide 127 often colocalized in the same neuronal cells. Finally, many similarities exist in 
the ENS organization of small and large mammals. Muscle motor neurons with analogous 
functions can release the same neurotransmitters in different species, however important 
differences in the distribution of these cells can be observed by comparing the same 
gastrointestinal region in different mammals. 
This neuronal organization represents a general rule applicable to the ENS of all studied 
species. For example, concerning the swine and horse ileum and the human descending and 
sigmoid colon, (segments with high tone and propulsive functions) the number of cholinergic 
neurons is higher than that of nitrergic ones 53,95,128-131. In contrast, in the human ascending 
colon (a segment with a low tone and accommodation and mixing function) 128,129, the MP 
contains a number of nitrergic neurons greater than the cholinergic ones 131.  
Two important subgroups of motor neurons include secretomotor and vasomotor neurons. 
Hens et al. showed that in all the ganglionated plexuses of the pig small intestine there are 
mucosal projecting neurons (internal SMP 78% > external SMP 10% ≈ MP 12%) 85. Dogiel 
type II cells exhibiting calcitonin gene-related peptide (CGRP) immunoreactivity (-IR) 
(MP>ESMP>ISMP) are probably afferent cells; however other mucosal projecting neurons, 
showing different morphology and phenotype, are present in MP and in both divisions of 
SMP. The majority of internal SMP neurons projecting to mucosa are ChAT/SP- or 
VIP/Galanin-IR minineurons 85; 66,132, whereas in both external SMP and MP most of neurons 
projecting to mucosa are multidendritic in morphology and displaying ChAT/Somatostatin 
(SOM)-IR 85. Hens et al. showed that in human jejunum the highest proportion of mucosal 
projecting neurons is located in the ESMP (ESMP 54% > MP 23% > internal SMP 10%) 100. 
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However, in both species most of these neurons are located in the SMP, while in rodents, 
mucosal projecting neurons are more equally distributed between the SMP and MP [61% 
SMP and 39% MP in the mouse; 50% SMP and 50% MP in the guinea-pig 133. 
Considering the dense network of SP-IR nerve fibers found in the mm, as well as 
pharmacologic data showing an involvement of SP as mediator in excitatory response of the 
mm 134-137, it has been suggested that SP-IR small neurons could mainly be involved in the 
mm innervation, rather than of the epithelium 8. However, SP is also widely distributed in the 
nerve fibers in relationship to the cores of the villi, intestinal glands, and muscular sheath of 
blood vessels 53,138-141. The anatomical distribution of a dense network of VIP-IR nerve fibers 
in the intestinal villi, together with the evidence of its secretory actions in porcine intestine 
142,143, suggests that VIP minineurons are secretomotor neurons. SOM-IR nerve fibers in the 
lamina propria have been described in both human 144 and pig 83 small intestine. 
Pharmacological and physiological evidence suggests an antisecretory role for SOM-IR 
neurons 145,146. Furthermore, the presence of specific SOM binding sites on the basolateral 
membranes of enterocytes indicates a direct action of SOM onto the epithelium 147-149. 
Although mucosal projecting neurons show different topographical organization between 
small and large mammals, these cells seem to show a certain degree of consistency in their 
neurochemical code. In fact, in all studied species, small neurons expressing VIP-IR are 
mucosal projecting neurons that are likely to be involved in secretory processes 100,150. 
The distribution of SP and VIP has been widely studied in some other large mammals, while 
SOM has been less studied than the other two substances. In the horse and cattle intestine, 
both SP and VIP neurons have been especially detected in the SMP; furthermore a rich 
network of SP and VIP nerve fibers has been also detected in the muscularis mucosae, the 
lamina propria of the villi and the intestinal glands 51,52,58,61,151-153. These data reflect a 
possible secretory role for these neurons. 
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Interneurons. These enteric neurons show the longest projections. These cells, which have 
been identified with certainty only in the guinea-pig 47, mouse, rat, and human are mainly 
localized in the MP. Interneurons form long functional chains of ascending and descending 
elements through which information travel for short or long distances 154. Interneuron 
projections extend up to 14 mm anally and up to 136 mm orally in guinea pig small intestine 
99. It is worth noting that interneurons may also function also as mechanoceptors 155-158. So 
far, four types of interneurons have been identified in the guinea-pig small intestine: one 
ascending and three types of descending interneurons. The ascending interneurons are MP 
Dogiel type I cholinergic neurons 96,109 and may contain also calretinin, SP, neurofilament 
triplet protein (NFP), and enkephalin 105. Descending MP interneurons (5% of all ENS cells 
in the guinea-pig) are phenotypically cholinergic neurons further distinct into three types 
based on their immunoreactivity for NOS/VIP, SOM and 5 hydroxytryptamine (5HT) 
99,109,159. nNOS / VIP / ChAT positive Dogiel type I interneurons can contain also 
neuropeptide Y (NPY) 160, gastrin releasing peptide (GRP), bombesin (BN) 109 and the 
enzyme alkaline phosphatase 161. SOM/ChAT immunoreactive Dogiel type III MP neurons 
99,159 project to other MP ganglia and also to SMP ganglia 109. Also, 5HT/ChAT 
immunoreactive Dogiel type I MP neurons send their projections to MP and SMP and seem 
to have significant roles in excitatory pathways regulating both motility and secretion 162. 
Data on human interneurons are scanty but it seems that MP interneurons project up to 36 
mm anally and up to 70 mm orally. In the human colon, 90% of orally projecting 
interneurons contain ChAT alone, whereas the others are ChAT- and nNOS-negative; three 
main types of anally projecting interneurons have been identified: neurons co-expressing 
ChAT and NOS, neurons immunoreactive for NOS alone, and neurons immunoreactive for 
ChAT-IR alone 163. Descending NOS interneurons of the human gut may co-express VIP 94.  
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Intrinsic primary afferent neurons (IPANs). The IPANs are the first neurons of the reflex 
pathways in the intestine 164. They are involved in the control of physiological functions as 
motility, blood flow and secretion, being responding to several stimuli, such as distention, 
luminal chemistry and mechanical stimulation of the mucosa 50. IPANs have typical 
electrophysiological properties. In fact, they have broad action potentials that are related to 
both sodium and calcium currents and are followed by early and late (slow) after 
hyperpolarizing potentials (AHPs) 164. Their targets are represented by mucosa and other MP 
and SMP neurons 165-168. Cell bodies of multi-axonal IPANs are 10-30% of neurons in SMP 
and MP ganglia of the small and large intestine; no IPANs are detected in the esophagus and 
they are rare in the stomach, where motility is primary controlled by vagal efferents 169. All 
the IPANs in the intestine of the guinea pig and other species show Dogiel type II 
morphology (non-dendritic, multi-axonal type II neurons) 166,170-173. A large percentage (82-
84%) of myenteric IPANs of the guinea pig ileum expresses the calcium-binding protein 
calbindin (CALB) 89,174,175 and almost all MP and SMP IPANs express cytoplasmic neuronal 
nuclei (NeuN) 176,177. Furthermore, all of them show positivity for ChAT 178,179. Notably, only 
30% of submucosal IPANs of the guinea pig ileum appear to be positive for CALB 133,175,180, 
and that CALB is not confined to the IPANs since it is also localized in 50% of submucosal 
calretinin-IR secretomotor / vasodilator neurons 180. Many researchers studied CALB also in 
other species, with the aim to establish whether CALB could be considered a marker for 
IPAN. In the pig small intestine, CALB cannot be considered a marker of IPANs, being 
mainly localized in interneurones and intestinofugal neurons 132,181. Dénes and Gábriel 
described CALB containing myenteric neurons in the rabbit small intestine 182. These cells 
showed Dogiel type I morphology, ChAT labeling and were identified as interneurons. Also 
in the mouse colon, CALB cannot be considered a good marker of IPANs, while CGRP 
immunolocalization is the most specific feature of these cells. Non-dendritic multiaxonal type 
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II neurons involved in mucosal innervations have been demonstrated also in porcine 85 and 
human 100 small intestine. Unlikely from guinea-pig, mouse, porcine and human IPANs 
express CGRP, which has been considered a specific marker of type II neurons in these 
species 55,71,76,85,183,184. However, Brehmer et al. showed that in human small intestine only a 
minority of type II neurons displayed distinct reactivity for CGRP, while most of them were 
immunoreactive for SOM, calretinin and SP181. Notably, in the human small intestine this 
neurochemical code is common also to Dogiel type V neurons; thus, the morphological 
distinction has an important role to recognize IPANs.  
In pig small intestine, Krammer et al. and Balemba et al. showed that also anti-neurofilament 
200 KDa (NF200) antibody identifies type II neurons 76,185. A difference between small and 
large mammals is in the localization of neurons with mucosal projections: in guinea pig and 
mouse intestine these neurons are localized approximately in equal amount in the SMP and 
MP. In the pig intestine IPANs are especially localized in internal SMP (about 80%) 85, 
whereas in the human intestine most of these neurons are localized in the external SMP 100. 
Another important difference between small and large mammals is in the proportion of 
IPANs and secretomotor neurons. In fact, almost all neurons with mucosal projections in the 
MP of the guinea-pig small intestine exhibit type II morphology, and are thought to be IPANs 
167. In both pig and human small intestine, the number of IPANs in the external SMP and MP 
represents only a minority (less than 30%) of the total number of neurons 66. 
Intestinofugal primary afferent neurons (IFANs). Intestinofugal neurons represent a 
unique subset of enteric neurons with their cell body located in the myenteric ganglia and 
projections giving off the intestinal wall 186. Most of them show a Dogiel type I morphology, 
whereas a minority have Dogiel type II features 123,187. IFANs act as mechanoceptors, being 
able to detect changes in volume and to respond to the stretching (but not to the tension) of 
the smooth muscle cells 188-190. Once activated, IFANs usually release Ach in the in the 
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prevertebral ganglion (PVG) thereby evoking nicotinic fast postsynaptic potentials 191. A 
subset of IFANs responds to colonic distention by releasing gamma amino butyric acid 
(GABA), which facilitate Ach release from cholinergic IFANs in the PVG. Because of 
IFANs activation, the response of the entero-PVG reflex circuitry is the release of 
noradrenaline by sympathetic neurons in GI wall. This effect modulates smooth muscle 
contraction or myenteric neuron activity 192-194. The functional significance of this reflex arc 
is to counteract large increases in tone and intraluminal pressure during filling 186. 
Enteric glia. The term ‘enteric glial cell’ was used for the first time by Giorgio Gabella in his 
original research work made along 10 years 195-197. Other studies, which have used 
immunohistochemical markers to locate enteric glia, revealed that these cells are common in 
the ganglia and nerve fiber bundles. Enteric glia express glial fibrillary acidic protein 198,199 
and the S-100 Ca2+-binding protein 200, both of which are typical of CNS astrocytes. Glial 
cells in other autonomic ganglia do not contain glial fibrillary acidic protein 198. Electron 
microscopy studies also confirmed that glial cells are reminiscent of the astrocytes in the 
CNS and distinct from Schwann cells of other peripheral ganglia or nerve trunks 195-197,201.203. 
Specifically, glial cells partly surround nerve cell bodies and axons in the ganglia, leaving 
bare large areas of neuronal membrane at the surface of ganglia; also, their processes contain 
bundles of gliofilaments and are surrounded by a single basement membrane (none of these 
aspects are detectable in Schwann cells). There is a marked difference in the glial cell-to-
axon relationship between small (guinea pig, rat) and large mammals (such as cat or human). 
In small mammals, glial cell processes fail to penetrate into the interstitium between nerve 
cell bodies as well as axons in the neuropil 196,203. In fact, many nerve processes show direct 
membrane-to-membrane contacts with each other; the glial cells only separate them into 
groups and rarely form a sheath around an individual axon. In contrast, in enteric ganglia of 
human and monkey, axons are separated from one another by intervening glial cell processes 
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204. It is noteworthy that Auerbach (1864) had recognized the different relationships between 
neurites and supporting cells in humans as compared to those of other mammals. Glial cells 
in nerve strands of the myenteric plexus of small mammals give rise to radiating lamellae 
which divide the axons into large bundles, and up to 600 neurites may be associated with one 
glial cell 197. The ratio of glial to nerve cells numbers increases with species size, e.g. from 
1.1 to 4.5 in the MP and from 0.6 to 1.5 in SMP of mice and sheep, respectively 205. In the 
human SMP and MP the glia-to-neuron ratio ranges from 1.3 to 1.9 and from 5.9 to 7.0, 
respectively 203,206,207. Glial cell nuclei can readily be distinguished from those of neurons. 
The glial nuclei have conspicuous clumps of chromatin, particularly adjacent to the nuclear 
envelope, and the nuclear surface often displays deep invaginations. The most prominent 
distinguishing feature of the majority of enteric glial cells is the numerous 10 nm 
gliofilaments. The cytoplasm also contains smooth and rough endoplasmic reticulum, 
numerous free ribosomes, mitochondria, lysosomes, and microtubules. Groups of 
gliofilaments criss-cross the cell bodies and run parallel to the long axes of the cell processes. 
The gliofilaments appear to be anchored to dense aggregations of material adjacent to the 
surface membrane. There are sites of apposition between glial cells and between glial cells 
and neurons where small areas of cytoplasmic density can be identified inside each plasma 
membrane. Gap junctions between enteric glia are not often seen, but dye filling indicates 
that they are coupled to each other 208. 
Compared with other peripheral glial cells (e.g., Schwann cells), enteric glial cells do not 
form basal laminae and they ensheath nerve bundles and not individual axons 209. In addition 
to the previously mentioned glial fibrillary acidic protein (GFAP) and S100b, other available 
immunohistochemical markers for glial cell labeling in the adult gut include and Sox (SRY-
box) 8/9/10, the first two being the most frequently used 206,207. Recently, marker expression 
analysis showed that the majority of glia in the myenteric plexus co-express GFAP, S100b, 
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and Sox10 210. However, a considerable fraction (up to 80%) of glia outside the myenteric 
ganglia, did not show labeling for these markers. The alternative combinations of markers 
reflect dynamic gene regulation rather than lineage restrictions, revealing an extensive 
heterogeneity and phenotypic plasticity of enteric glial cells 211.  
Enteric glial cells have long been thought to exert a mere mechanical property by supporting 
neurons. Many evidence, however, indicates that these cells exhibit a number of functions, 
ranging from support to neurotransmission to enteric neuronal maintenance and survival 211-
214. In fact, glial cells are involved in many crucial tasks, such as synthesis of 
neurotransmitter precursors, uptake and degradation of neuroligands (i.e., detoxification of 
glutamate and g-aminobutyric acid), and expression of neurotransmitter receptors, thereby 
contributing to neuron-glia cross talk and neurotransmission 212.  
Fig. 4. Enteric glial cells are central regulators of gut homeostasis and can play a role in 
gut diseases. (A) In normal conditions, glia control a number of neuronal aspects, i.e. 
neuroprotection, neuromediator expression, or neuronal renewal via liberation of different 
mediators. In addition, glia exhibit a key role in intestinal epithelial barrier integrity through 
the release of function-specific messengers (gliomediators). Taken together these features 
indicate that enteric glia possess protective and reparative properties in the gastrointestinal 
tract. (B) In pathological conditions, such as inflammation or bacterial stimulation, a 
phenomenon, known as reactive enteric gliosis (similar to astrogliosis in the brain) can occur. 
This contributes to the development of intestinal inflammation, but also participate in 
protection/repair of intestinal epithelial barrier/neuronal lesions evoked by these mechanisms. 
(C) Enteric glia death (induced by specific viruses or pathogens) or abnormal enteric gliosis 
could contribute to neuronal degeneration or barrier dysfunctions observed in some chronic 
intestinal or extraintestinal diseases. From Neunlist et al. 2014. 
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Furthermore, glial cells exhibit immunological properties 206,215,216, participate in epithelial 
barrier functions 217-222 and evoke neuroprotection 214 (Fig. 4). In addition, enteric glial cells 
have neurogenic potential being capable of generating enteric neurons in response to injury 
223,224. Recent works also demonstrated that enteric glial cells can respond to 
neurotransmitters by changes in intracellular Ca2+, such as purinergic (ATP) 213,225,226 
serotonergic and cholinergic signaling mechanisms 227. 
 
2.2 Smooth muscle electrical activity and regulatory mediators 
Gut smooth muscle cells form a morpho-functional syncytium throughout the length of the 
GI tract. They exhibit two types of electrical activity: i) ‘slow waves’ that set the basic 
electrical rhythm; and ii) spike potentials. The ICC cells initiate the slow waves in the smooth 
muscle cells, which spreads via the gap junctions in aboral direction. Motility patterns depend 
on the slow waves of the smooth muscle cells except the giant contractions, which are 
independent of the electrical slow waves and are exclusively controlled by the ENS 228. The 
frequency of the slow waves and the intestinal contractions decreases from the duodenum 
(the highest frequency) down to the ileum (the lowest), and this phenomenon is associated 
with an increase of the resistance to the electrical spread of the slow waves along the intestine 
228.  
Concerning bioactive substances able to affect gut motility, the enterochromaffine cells (ECs) 
found in the mucosal layer play a key role in transmitting chemical or mechanical stimulation 
of the mucosa to ENS. The ECs release serotonin / 5-HT, triggered by the mechanical and 
chemical stimuli, in the basolateral compartment from where 5-HT eventually activates 
underneath neurons, e.g. the IPANs, displaying specific serotonin receptors, and synaptically 
connected with ascending and descending interneurones, and thereby activating 
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motorneurons which orchestrate the initiation of peristalsis (see below). Excitatory motor 
neurons release Ach and SP, evoking a muscle contraction proximal to the stimuli, whereas 
inhibitory motor neurons release of inhibitory neurotransmitters e.g. NOS and VIP, evoking 
relaxation distal to the stimuli 50,169. Other paracrine and endocrine hormonal mechanisms 
including motilin, opioids, peptides and SOM, are intimately involved in short and long-term 
regulation of contractile patterns albeit to varying degrees and in different regions of the 
intestine. CCK and gastrin stimulates the peristaltic activity whereas neurotensin mainly 
produces stationary segmenting contractions. 
 
Key points: 
• The regulatory system through which the gut exhibits its functions is given by a 
number of specialized cells, i.e. neurons, glia, interstitial cells of Cajal (ICC), smooth 
muscle cells and neuroendocrine cells of the mucosal lining. 
• Among these cells, neurons are at the top of the herarchy as they provide control on 
virtually all gut functions, including motility. 
• Current knowledge indicates that intrinsic innervation of the gut is supplied by the 
enteric nervous system (ENS), roughly constituted by 500 million neurons distributed 
in two major ganglionated (i.e., myenteric and submucosal) plexuses. 
•  Functionally distinct classes of myenteric and submucosal neurons include, e.g. 
motorneurons, interneurons and intrinsic primary afferent neurons and other subtypes, 
each exhibiting a peculiar neurochemical cocktail. 
• Enteric neurons are outnumbered by a significant amount of glial cells, which are now 
recognized being endowed with many regulatory functional effects. 
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Chapter 3. 
PERISTALSIS AND MAIN MOTOR PATTERNS OF GI MOTILITY 
GI motility is a major aspect of the digestive and absorptive processes, governed by a 
multitude of cooperating mechanisms. In 1899, using isolated segments of small bowel / 
colon of the dog, two eminent English physiologists, namely William Bayliss and Ernest 
Starling showed the existence of a basic intestinal behaviour that they name it ‘law of the 
intestine’ 229. Bayliss and Starling showed that mechanical stimulation of the intestinal wall 
resulted in an oral contractile response associated with a relaxation of the aboral segment. 
Since this phenomenon occurred regularly in the presence of identical stimulation, they were 
keen to refer to it as a ‘law’ as detectable by a segment of the intestine completely 
disconnected by any extrinsic neural input 230. Both Bayliss and Starling were well aware of 
the existence of an intrinsic innervation supplying the gut, thus the brilliantly inferred what 
they observed as a result of a neurally mediated activity. Later on, other distinguished 
physiologists, such as Paul Trendelenburg developed a special set up to better investigate the 
law of the intestine and to our knowledge he was first to use the term ‘peristalsis’ (from the 
ancient Greek  meaning ‘push all around’) 231. Like the heartbeat, peristalsis is 
fundamental for life and many highly integrated mechanisms can contribute to its genesis and 
maintenance, including neuro-immune mechanisms as recently demonstrated 232. 
Investigations during the last 35 years allowed for a better understanding of at least the basic 
neural mechanisms underlying peristalsis as previously outlined (see section 2.2) and 
summarized in Fig. 5. 
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Fig. 5. Regulation of peristalsis. Chyme causes smooth muscle contraction above the bolus and 
relaxation below, so that a peristaltic wave moves chyme in aboral direction. The ENS controls 
peristalsis and can work independently, but complex digestive process requires the ENS and CNS 
coordination. Adapted from Perkins JA. Netter's Illustrated Pharmacology, Updated Ed. Philadelphia, 
PA: Elsevier, 2014. 
 
3.1 Motor patterns of the small intestine 
There are various types of motility pattern in the gut (Fig. 6). Stationary segmenting 
contractions are the non-propulsive annular contraction of the circular muscle layer, which is 
a common type of mixing motility seen predominantly in the small intestine. Together with 
alternating contraction and relaxation of the LM, it provides effective mixing of its content 
through its squeezing action. Clusters of contractions also known as the migrating 
myoelectric complex (MMC), are waves of fluctuating contractions and relaxations that cause 
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back and forth movement to facilitate the transportation of chyme from the stomach, through 
the small intestine, past the ileocecal sphincter, and into the colon in a regular cycle during 
fasting.  
       
Fig. 6. Types of contractile and motor patterns of the small intestine.  Different 
contractile patterns recordable in the human small bowel. Adaptded from “The Moving Gut” 
by Hans Jörg Ehrlein and Michael Schemann, Technische Universität MünchenLehrstuhl für 
Humanbiologie. 
 
Giant contractions (or stripping waves) occur in ileum during the fasting or interdigestive 
period in which slowly propagating contractions with large amplitude and long duration 
completely occlude the intestinal lumen and push the luminal contents distally in an aboral 
direction cleaning the intestine. The giant contractions when occurring in the postprandial 
period represents a pathological contractile pattern and often the motor precursor of vomiting. 
Retropulsion or anti-peristaltic waves are a pathological contractile pattern occurring seldom 
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causing expulsion of noxious substances from the system through vomiting 46. In addition to 
that, tonic contractions in sphincters of the gut allow the luminal contents to pass at 
appropriate times. Further discussion of these patterns in the context of small intestine 
function is provided below.  
 
3.2 Postprandial motility of the small intestine 
The small intestine produces different muscular contractile patterns in response to extrinsic 
and intrinsic factors. Entry of gastric chyme into the proximal small intestine cause it to 
distend and this stimulates a mixture of stationary segmenting contractions, clustered 
contractions and short peristaltic-like waves (mostly confined to the upper small bowel) 
which are modulated by the nutrient content in the chime (Fig. 7).  
Fig. 7: Postprandial contractile patterns of the small intestine. Ingesting meal convert the 
fasting pattern to postprandial pattern characterized by the sustained but irregular contractile 
phasic pressure activity  
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As the chyme start to fill the distal intestinal segments the proximal intestine motility is 
inhibited, and the number of peristaltic waves decreases while the number of stationary 
segmenting contractions increases. This feedback-regulation initiated by the nutrients 
entering the distal small intestine reduce gastric emptying and the flow rate of chyme along 
the gut.                                 
                       
3.3  Interdigestive motility of the small intestine 
In normal healthy subjects the digestion and absorption process take about 12 hours and 
during the remaining period the stomach and small intestine are remain empty. This interval 
period is referred to as the interdigestive period and during this time a specific pattern of 
propulsive motor activity in the stomach and small intestine can be observed (Fig. 8). This 
pattern is characterized by rhythmically recurring cycles of motor activity which are called 
the interdigestive motility that migrate from stomach to distal ileum. The interdigestive 
motility cycle consists of a period of motor quiescence (phase I), followed by a period of 
irregular electrical and mechanical activity (phase II), and finally by a short phase of striking 
intestinal contractile pattern, MMC (phase III). The duration of the interdigestive cycles 
differs among species and the frequency of MMC varies with the time of day and activity, 
being slowest in sleep and more active during the day.  
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Fig. 8: Normal interdigestive motility pattern. The phase III of the interdigestive motility 
or migrating motor complex (MMC) represents a c complex contractile pattern consisting of 
long peristaltic waves that migrates aborally. 
 
In average phase III occurs about every 90 min and travel through the intestine at a rate of 
approximately 5 cm/m (velocity declines along the intestine). The phase III originates 
simultaneously at the stomach and duodenum. The MMC of the antrum is characterised by 1-
3 forceful tonic contractions per minute (1- 3 cpm) occurring at intervals of 2-3 min. During 
the lumen occluding antral contraction, antroduodenal co-ordination cause the wide opening 
of the pylorus the relaxation of the duodenal bulb. These powerful gastric contractions and 
the antroduodenal co-ordination force the chyme and secretions into the duodenum. When a 
MMC originates at the duodenum, the contractions in the stomach cease and the peristaltic 
waves occurring at 11 to 12 cpm in the duodenum slowly migrates aboral along the entire 
small intestine to the ileum sweeping the lumen clean as it moves. In addition to the cleaning 
activity enhanced by the secretion of gastric and bilio-pancreatic juice occurring immediately 
before its onset, the MMC also prevents a bacterial overgrowth in the small intestine.  
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The activities of the alimentary tract are controlled via combination of hormones secreted by 
specialized cells in the gut and the neuronal control mediated by ENS with the cooperation of 
the CNS. This complex modulation of the GI tract and its accessory organs is referred to as 
neurohumoral regulation. Hormones secreted by cells in GI segment are either exclusively 
endocrine, exclusively neural or both and they serve regulatory functions with the digestive 
system. Although the ENS can act independently, it receives afferent and efferent input from 
both sympathetic and parasympathetic arms of the autonomic nervous system allowing the 
CNS to exert control over GI functions and the GI system to communicate alimentary tract 
status to the brain. In general, parasympathetic stimulation tends to enhance nearly all 
functions of the alimentary tract while sympathetic activity tends to inhibit nearly all 
functions of the alimentary tract including motility and secretion. 
 
Key points: 
• Effective propulsion is the main aspect chraterizing all mammalian species, humans 
included. Peristalsis is by far the best recognized propulsive pattern. Lack of 
peristalsis, as it occurs in aganglionosis of the ENS, is incompatible with life. 
• A retrograde peristalsis, as in vomiting, represents an ontogenetically defensive motor 
behaviour of major mammals. Pendular (or mixing) movements of the small bowel 
may contribute to enhance absorption.  
• Other motor patterns include migrating motor complex of the small bowel, high 
amplitude propagated contractions (or ‘mass movements’) of the colon and other 
coordinated patterns.  
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Chapter 4. 
IN VIVO ASSESSMENT OF INTESTINAL MOTILITY 
The accurate assessment of small intestinal motility constitutes one of the most important 
issues in gastroenterology and the small intestine still represents a clinical challenge due to 
the restricted access to this organ. The current standard technique for the evaluation of small 
intestinal motility is the intestinal manometry 233,234 but other techniques such as transit tests, 
MRI and wireless capsule endoscopy are also used to assess and diagnose motor functions of 
the gut. The current available tests to evaluate intestinal motility are generally 
complementary to each other. The application of small intestinal manometry in diagnosing 
the small intestinal motility has been restricted to few referral centres around the world owing 
to the complexity of the procedure and the lack clinical expertise demanded in the 
interpretation of the results. High resolution manometry (HRM) represents a significant 
technological advancement for the evaluation of motor patterns along the alimentary canal 
that has already allowed to overcome limitations of conventional manometry, thus leading to 
improved knowledge of esophageal, anorectal and colonic physiologic and pathologic motor 
patterns 235-237. In comparison to conventional manometric catheters, HRM catheters have 
closely placed sensors that are more sensitive to detect the frequency and direction of 
intestinal contractile activity 238. However, the application of HRM to the small bowel has not 
been intensively investigated and currently no data are available on small intestinal motor 
abnormalities in healthy individuals and patients with small intestinal motility disorders. 
Transit tests such as breath tests, scintigraphy and Smartpill can be used to indirectly estimate 
intestinal motility. These tests are relatively inexpensive and widely available and thus they 
tend to be used frequently to facilitate the clinical diagnosis small intestinal motility 
evaluation since the testing with manometry is not readily available. Manometry usually 
follows transit tests to identify possible dysmotility patterns and may be most helpful in 
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excluding dysmotility as a cause of symptoms. Average small intestinal transit time in 
healthy subjects has shown a wide inter- and intra subject variability and for this reason only 
extreme values can be considered abnormal and diagnostic. Dynamic imaging with MRI 
technology has also being applied to measure the motor function of the small intestine as it is 
able to measure accommodation, wall motion and emptying at the same time 239,240. In 
addition to the static imaging, recently the cine-MRI technology has also shown to be useful 
in detecting the reduced intestinal contractility in CIPO patients 241-243. Wireless capsule 
endoscopy is a small, weight less pill like device using imaging technology to visualize the 
GI tract and has shown to reliably detect intestinal dysmotility. This non-invasive tool can 
measure and quantify contractile events, non-contractile patterns, type of content and motion 
of wall 244-246. The clinical utility of this standardized radiation free method is yet unclear and 
its use in severe dysmotility disorders is cautioned due the risk of capsule retention. 
 
4.1 Small intestinal manometry   
Intestinal manometry was introduced to clinical practice several decades ago 247,248 and still 
the current gold standard technique for the evaluation of small intestinal motility. The 
diagnosis of small intestinal motor disorders currently relies on manometric findings that can 
provide clinically meaningful information to help differentiate neuropathic from myopathic 
dysfunction 249,250. This invasive but still well tolerated test may be performed with a water-
perfused manometric catheter introduced orally under fluoroscopic and/or endoscopic 
guidance and placed it laying just beyond the ligament of Treitz or about 20 cm length in 
small intestine to adequately evaluate the antral and duodenal activities. In difficult cases, 
catheter placement can be done using a guidewire with endoscope. Catheter placement 
assisted by endoscopy requires the administration of sedative medications that may alter gut 
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motor activity. In such cases midazolam can be given intravenously without significant 
interference with intestinal motility. The standard manometric catheter incorporates six 
manometric ports spanned at 10-cm intervals in comparison to the HRM catheter which 
incorporates 24 water perfused channels with recording sites spaced at 1 cm intervals. These 
ports register the amplitude and duration of phasic pressure waves produced by the intestinal 
contractions and the pressure changes will be displayed as traditional pressure tracings or 
contour plots. The studies are performed after an overnight fast. Medications that affect GI 
tract motility must be withheld for 48 hours prior to the test. The total recording time for 
stationary manometry is at least 8 hours; 6 hours for fasting period followed by standard meal 
ingestion and next 2 hours for studying post-prandial period. The meal should be at least 400 
kcal. and it may be required to the adjust meal according to the digestive capacities of 
patients. Some variations on the protocol procedure have been introduced by various 
specialized groups such as use of longer or shorter recordings, including ambulatory or 
overnight recordings. The solid-stat catheter has the microtransducer sensors which are vary 
in the sensor number and the spacing of each sensor and these solid-state systems are highly 
portable and more comfortable for patients. Thus, they can be used for monitoring with long 
observation periods such as 24-hour ambulatory manometry. 
 
4.2  Normal antroduodenal manometry findings 
The criteria for analysing and interpreting manometric tracings have been developed from 
observation of normal patterns in healthy subjects and contrasting patterns observed in 
patients with clinical proven intestinal dysmotility. Several specialized patterns occur during 
the fasting and postprandial periods. During fasting, the presence of 3 distinct phases of 
interdigestive period described above can be identified and the interpretation of the test 
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analyse their presence, propagation and duration. The most characteristic and the more easily 
recognized pattern is the phase III contraction. The fasting period is terminated immediately 
after meal ingestion and the distinct fasting pattern is converted to the post-prandial 
contraction pattern or fed-response. The fed response consists high amplitude and irregular 
contractions in gastric antrum which represent the mixing and grinding of solid food and 
irregular contractions with lower amplitude in duodenum. The duration of this phase is 
dependent on food calories and consistency and the fed period ends when the phase III MMC 
returns. 
 
4.3  Abnormal antroduodenal manometry findings  
Motor patterns that differ from the normal motor patterns should be recognized carefully 
since they usually carry clinical and pathological significance. These abnormal motor patterns 
include: propagated contractions, ultra-rapid contractions, propagated clustered contractions, 
bursts of contraction, hypocontractility, hypercontractility (bursts and sustained 
uncoordinated pressure activity) and a failure to convert to the fed response 248,251. Three 
abnormal patterns have been recognized in patient with intestinal dysmotility: neuropathic 
patter, myopathic pattern and occlusive pattern.  
In intrinsic neuropathy, the loss of inhibitory motor neurons leads to un-coordinated or 
disorganized configuration or propagation of MMC or phase III but with preserved normal or 
even increased amplitude contractions (Fig. 9). In contrast, patients with in the extrinsic 
(autonomic) neuropathy, impairments in the fed response and postprandial antral 
hypomotility are observed 252. In addition, other neuropathic patterns described in CIPO 
include bursts of non-propagated phasic pressure activity (duration > 2 minutes, amplitude > 
20 mmHg, frequency > 10 waves/minute) during fasting period and/or fed state, sustained in 
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coordinated fasting pressure activity (duration > 30 minutes) and inability of an ingested meal 
to convert fasting into fed pattern 253. 
  
Fig. 9. Manometric patterns suggestive of underlying neuropathy. A. During the phase of 
motor incoordination (phase II) intestinal motor activity is characterized by periods of 
hypercontractility of >2 min duration (i.e., bursts). During the phase III activity, MMC can be 
propagated in aboral sense (B) and the in this setting the MMC appears abnormal for 
conformation, uneven speed and durability (C). Extrinsic neuropathy is characterized by the 
inability of the meal to convert the fasting in to fed pattern (D). 
 
In patients with visceral myopathy, the MMC is often preserved but manometry demonstrates 
a decrease in frequency and very low amplitude contractions (< 20 mmHg) of the affected 
segment in both fed and fasting states and in the CIPO patients with myopathy there are co-
ordinated low amplitude pressures (<10 mm Hg) (Fig. 10) activities in early and mild stages 
and complete absence of contractions in advanced stages of the disease 254. However, in 
advanced stage of severe visceral myopathy, the normal MMC pattern may be absent or 
difficult identify due to very low amplitude. 
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Fig. 10. Manometric patterns suggestive of underlying myopathy. Normal propagation of 
MMC, A, and normal fed response, B, but with decreased contraction amplitude due to the 
dilated bowel loops do not allow occlusive contractions recordable by manometry. 
 
The manometric patterns of mechanical obstruction described include: periodic short bursts 
of non-propagated and prolonged contractile activity every 1–3 min in postprandial period 
(also named clustered contractions), giant prolonged contractions occurring simultaneously in 
recording sites at least 20 cm apart and mix of these patterns (Fig. 11). 
                                      
 
 
 
 
 
 
 
 
 
Fig. 11. Manometric patterns suggestive of mechanical obstruction. During the period 
of motor incoordination (phase II), record periods of 20 min >, characterized by springs 
of contractions regularly interspersed with motor quiescence (clustered contractions) 
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Key points: 
• In vivo assement of gut motility can be performed by stationary / ambulatory (24-hr) 
GI manometry in patients with severe digestive symptoms or recurrent sub-occlusive 
episodes. 
• Other non invasive methods to investigate patients with presumed or demonstrated 
dysmotility are cine-MRI and capsule endoscopy (the latter being carefully used in 
patients with severe digestive symptoms / sub-occlusive episodes). 
• A number of established manometric patterns have been identified to document 
possible underlying gut neuromuscular abnormalities (i.e., neuropathy, myopathy, 
occlusive patterns, and others).  
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CLINICAL ASPECTS OF NEUROINTESTINAL DISEASE: PATHOPHYSIOLOGY, 
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Introduction 
The principal function of the gastrointestinal (GI) tract is to ensure the proper digestion and 
absorption of nutrients and the expulsion of undigested residue and unwanted waste. This 
complex process requires the coordinated propulsion of endoluminal contents along the 
length of the GI tract, which in turn relies on the activity of specialized cells, including 
smooth muscle cells (SMC; final effectors of contraction and relaxation), interstitial cells of 
Cajal (ICC; gut pacemakers and regulators of neuronal input to the SMC), and a hierarchy of 
intrinsic and extrinsic neurons to regulate the motor programs 255. While the propagation, 
absorption, and excretion of food and waste have long been appreciated as key aspects of gut 
function, the GI tract also has a myriad of other critical roles necessary for maintaining health 
and homeostasis. These include its capacity to sense and respond to its luminal environment, 
its role in controlling immune activation (i.e. distinguishing nutrients and commensal bacteria 
from toxins, allergens, and pathogens) and initiating inflammation, as well as its ability to 
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monitor and control microbiota composition. All of these aspects of GI function share a 
common feature: they rely on the intestinal tract’s intrinsic network of neuronal and glial 
cells, referred to as the enteric nervous system (ENS). 
The ENS is a morphologically and functionally complex system that controls, largely 
independent of central and peripheral nervous system input, virtually all gut functions 50. It is 
comprised of a very large number of neuronal and glial cells (about the same number as are 
in the mammalian spinal cord) that arise from the embryonic neural crest and become 
organized into two major plexuses: the myenteric (Auerbach’s plexus), which extends along 
the entire length of the GI tract, and the submucosal (Meissner’s plexus), which is present 
from the stomach to the rectum. Enteric neurons can be classified into functionally distinct 
subpopulations (e.g. intrinsic primary afferent neurons, motor neurons, and interneurons) 
synaptically linked in reflex circuitries 50. The central nervous system (CNS) can modulate 
some intrinsic reflexes, particularly in the esophagus, stomach and rectum, via sympathetic 
and parasympathetic pathways 46. However, the ENS has the ability to control most gut 
functions independent of CNS input, including secretion, absorption, vascular tone, and 
motility. Any injury to the ENS, whether congenital or acquired, thus results in intestinal 
neuropathies that can cause clinical symptoms and lead to significant morbidity. 
This review focuses on neurointestinal diseases, which are those conditions associated with 
abnormalities of enteric innervation. From a biologic perspective, neuronal defects in the GI 
tract can arise from various etiologies. Developmental disorders represent one cause, in 
which any aspect of enteric neural crest cell development might be perturbed, including cell 
migration, proliferation, survival, differentiation, or patterning. Disordered ENS development 
typically gives rise to congenital enteric neuropathies and manifests in early childhood. 
Hirschsprung disease is the best characterized of these developmental conditions and 
therefore the first disease discussed in this review. Many other neurointestinal diseases are 
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acquired, and these are generally believed to be caused by neuronal degeneration, immune-
mediated inflammation, or infection. These factors, however, are often intertwined. 
Neurodegeneration can be associated with prominent inflammation in the enteric ganglia, 
whether as the cause of the inflammation or as its consequence. Infection can lead to 
autoantibodies against enteric neuronal antigens and subsequent loss of neurons. 
Understanding the normal biology of ENS development and maintenance, and defining the 
pathophysiology that underlies the various neurointestinal diseases, are essential in order to 
develop improved therapies for these conditions. 
It is important to note that the emphasis on the ENS in this review is not intended to 
undervalue the critical contributions of the SMC, ICC, or extrinsic innervation (autonomic 
nervous system, spinal cord and brain) to GI health and disease. Rather, it is only intended to 
focus the review on this specific area of interest. The reader is referred to excellent reviews 
on those topics 256,257. We have also taken a neuro-centric approach, which is not meant to 
ignore the importance of the enteric glia, but rather reflects our limited current understanding 
of their normal function and their role in intestinal disease. Thus, the broad objective of this 
review is to provide an update on the molecular and clinical features of neurointestinal 
diseases, to give an overview of therapeutic options for their management, and to present the 
potential future use of neuroregenerative approaches for their treatment. We hope that by 
presenting the basic biology of these diseases in a clinical context, the reader will appreciate 
the significant unmet needs faced by clinicians caring for patients with any form of 
neurointestinal disease and consequently identify areas where further fundamental research 
might contribute to improving clinical care. 
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Hirschsprung Disease 
Hirschsprung disease (HSCR) is a congenital enteric neuropathy that causes functional bowel 
obstruction as a result of distal intestinal aganglionosis 258. First described by Harald 
Hirschsprung in 1888, HSCR occurs in approximately 1 in 5000 births with a male 
predominance (4:1 male to female ratio in short-segment disease) 259. HSCR is characterized 
by the absence of enteric ganglion cells in the submucosal and myenteric plexuses along 
variable lengths of the distal bowel. In most cases, children present in the neonatal period 
with delayed passage of meconium beyond the first 24-48 hours of life. Other symptoms and 
signs are those of complete or partial intestinal obstruction, including feeding difficulties, 
abdominal distension, vomiting (which may be bilious), and constipation (or obstipation). 
The most common form is short-segment, affecting approximately 80% of cases and 
involving no more than the rectosigmoid colon. Less commonly, the aganglionic segment is 
longer, extending proximal to the rectosigmoid. The aganglionosis can involve the entire 
colon in 8-10% of patients, or, rarely, the entire intestine 260. 
 
HSCR is a classic example of a neurocristopathy, a disease arising from abnormalities of 
neural crest-derived cells. In HSCR, enteric neural crest-derived cells fail to complete their 
rostrocaudal migration along the length of the intestine, leaving variable lengths of distal gut 
without ganglion cells 261. The failure to complete migration can be caused by defects in 
neural crest cell migration, proliferation, survival, or differentiation. HSCR is most 
commonly an isolated finding, but can occur along with other disorders, most commonly 
Down syndrome, which is present in about 10% of cases 17. Since neural crest cells also give 
rise to melanocytes, abnormalities of pigmentation occasionally co-exist with HSCR. Shah-
Waardenburg syndrome, caused by mutations in SOX10, EDNRB, or ET3, is a 
neurocristopathy characterized by abnormal pigmentation of the hair, skin, and eyes, 
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intestinal aganglionosis, and congenital hearing loss due to absence of neural crest-derived 
cells in the cochlea of the inner ear 262. Congenital central hypoventilation syndrome (CCHS), 
in which autonomic control of spontaneous breathing is impaired, can co-exist with HSCR in 
a condition called Haddad syndrome 263. This neurocristopathy is associated with mutations 
in PHOX2B, a transcription factor expressed by neural crest cells, which give rise not only to 
the ENS but also to parts of the autonomic nervous system, accounting for the respiratory 
defects in this disease. Mowat-Wilson is a syndrome characterized by mental retardation, 
epilepsy, delayed motor development, and HSCR and has been associated with mutations in 
ZFHX1B, a zinc finger homeobox gene that encodes Smad-interacting protein 1 264. 
Several observations initially indicated the genetic origin of the disease, including: (i) 
average risk of recurrence in siblings of 3-4%, about 200-fold higher than in the normal 
population; (ii) increased prevalence in males; (iii) association with other genetic diseases 
and chromosomal abnormalities; and (iv) presence of genetic models of aganglionosis with a 
specific mode of inheritance. The high proportion of sporadic cases (~80%), variable clinical 
expression (i.e. variable lengths of aganglionosis among relatives), and incomplete 
penetrance (i.e. some mutation carriers do not have aganglionosis) support a multigenic 
model to explain the predominantly non-Mendelian inheritance pattern of non-syndromic 
cases. Linkage analyses in large HSCR families led to the identification of the RET gene 
(10q11.2) as the first gene shown to be involved in HSCR 265. Coding sequence mutations in 
RET account for 15-35% of patients with sporadic HSCR and 50% of familial cases 261. 
Recent data suggest that non-coding mutations in RET within a conserved enhancer-like 
sequence in intron 1 confer susceptibility to HSCR, whereas a variant in the 3'-untranslated 
region confers a "protective" haplotype that is underrepresented in HSCR 266,267. In addition 
to RET, mutations have been identified in over a dozen other genes, but these account for a 
minority of cases 261,268. While RET mutations are the major risk factor in this disease, 
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evidence suggests that they may not be sufficient on their own to result in aganglionosis 261. 
The majority of cases appear to be multigenic, comprising a combination of RET mutations 
with genetic abnormalities at other loci, with these interactions impacting the incidence and 
severity of the aganglionosis. These types of interactions have been observed for RET and 
EDNRB signaling and for EDNRB and SOX10 269,270. An important role has also been 
described for modifier genes. These are genes that, when mutated, do not result in a 
phenotype but, when present with a mutation in another gene, they worsen the effect.  
Examples of modifier genes include neuregulin 1 (NRG1) and L1CAM 268. These modifier 
genes may help to explain the phenotypic variability and incomplete penetrance characteristic 
of HSCR. 
The diagnosis of HSCR should be considered in neonates presenting with the delayed 
passage of meconium, or in older infants and children with severe constipation. The gold 
standard for the diagnosis of HSCR is histological assessment of tissue obtained by deep 
rectal biopsy (suction biopsy or full-thickness biopsy) showing the complete absence of 
submucosal (and myenteric) ganglion cells. The presence of hypertrophied 
acetylcholinesterase-positive nerve trunks, representing projections of extrinsic nerve fibers, 
in the muscularis mucosae and lamina propria provides additional confirmation 271, as does 
the absence of calretinin-positive nerve fibers in the lamina propria and submucosa 2,271,272. It 
is important to note that a physiologic zone of hypoganglionosis is normally present in the 
distal 1-3 cm of the rectum and may lead to false-positive results if that distal segment is 
biopsied 273. In contrast, if taken too proximally, rectal biopsy may miss a very short segment 
of clinically important aganglionosis 274. 
Anorectal manometry (ARM) should not be used as a sole diagnostic tool for HSCR in 
neonates and infants, but in older children may provide a useful screening test in patients 
presenting with symptoms suggestive of HSCR. Whereas the presence of a rectoanal 
51 
 
inhibitory reflex on ARM would reasonably exclude HSCR in older children, its absence 
should lead to a rectal biopsy to definitively make the diagnosis. Contrast enemas are useful 
radiologic studies that often suggest the diagnosis in the first place by demonstrating a 
tonically contracted distal colon, reflecting the aganglionic segment, and possibly also giving 
a rough indication of the length of aganglionosis prior to surgery. 
The standard treatment for HSCR involves surgical removal of the aganglionic bowel and 
transition zone, which refers to the relatively hypoganglionic bowel proximal to the 
aganglionosis. The normoganglionic intestine is then anastomosed to the rectum or anus, 
depending on the specific procedure performed. A number of techniques have been described 
to fashion the distal anastomosis, and these are named for their surgical pioneers, most 
notably Soave, Swenson, and Duhamel. For short-segment aganglionosis, a single-stage 
transanal operation is commonly performed 275. 
Surgical treatment of HSCR is undoubtedly life-saving and allows many children to live 
normal lives. For many patients, however, the long-term outcomes following surgery are far 
from perfect, with the main problem being fecal incontinence and the significant 
psychosocial impact that this can have 276-279. Severe constipation can also occur after 
surgery, possibly related to residual abnormalities in the remaining, presumably 
“normoganglionic” bowel, or to the failure of normal internal anal sphincter relaxation, which 
is associated with HSCR. Children with HSCR are also at risk for a potentially life-
threatening inflammatory process termed Hirschsprung-associated enterocolitis (HAEC), 
which can occur before or after surgical removal of the aganglionic segment 280. HAEC, 
which usually manifests with abdominal distension and diarrhea, often accompanied by fever 
and vomiting, can progress to sepsis. HAEC is usually treated with antibiotics and rectal 
irrigations to evacuate stool from the distal bowel. Since RET signaling is essential for 
formation of Peyer’s patches (aggregates of lymphoid tissue in the gut wall), patients with 
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HSCR and a RET mutation may have defects in intestinal immunity, which might contribute 
to the risk for HAEC 281,282. Several studies implicate alterations in the fecal microbiome as 
contributing to the pathogenesis of HAEC 283,284. This notion is supported by a recent 
prospective, multicenter, randomized controlled trial showing that administration of 
probiotics reduces both the frequency and severity of HAEC 285. 
 
Esophageal Achalasia 
Achalasia is a disorder of the esophagus characterized by the absence of peristalsis and 
impaired swallow-induced relaxation of the lower esophageal sphincter (LES), resulting from 
loss of intrinsic inhibitory neurons in the myenteric plexus. The clinical manifestation is 
characterized by dysphagia for both solid food and liquids, regurgitation of undigested food, 
respiratory complications, chest pain, and weight loss. The condition is characterized by a 
defect of intrinsic inhibitory neurons, which release nitric oxide (NO) and vasoactive 
intestinal polypeptide (VIP), both in the esophageal body and LES 286. The resulting 
imbalance between defective inhibitory innervation and apparently spared excitatory 
(cholinergic/ tachykininergic) neuronal components likely underlies the pathogenesis. It 
remains unclear why esophageal myenteric neurons are preferentially targeted and 
irreversibly damaged by the immune system, although several lines of evidence indicate that 
infectious and immune factors could underlie the etiopathogenesis of this neuropathy 19. 
These factors likely act independently and their influence may be different in different 
subsets of patients. The myenteric plexus in patients with end-stage achalasia has been found 
to have an extensive reduction in ganglion cells in association with lymphocytic and 
eosinophilic infiltrates 287. A follow-up study examined the histopathological features of 
esophageal specimens from patients with early-stage achalasia undergoing surgical myotomy. 
Inflammation was found in both stages, but fibrosis was only seen in end-stage disease, 
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suggesting a spectrum of histopathological changes during the course of the disease 288. These 
results are consistent with other reports that have shown myenteric inflammatory infiltrates 
(hence the term “myenteric ganglionitis”) represented by CD3+ and CD8+ T cells in both 
early- and end-stage achalasia, as well as a normal number of myenteric ganglion cells in the 
early stage of the disease 289,290. 
Infectious agents, possibly viruses, might trigger an immune response to esophageal 
myenteric neurons. This was demonstrated by previous work showing herpes zoster virus in 
patients with the sporadic form of achalasia, although this has been debated 291,292. A causal 
link between viral infections and neuropathological alterations has not been definitively 
demonstrated yet, although an increase in lymphocytic proliferation has been noted in 
esophageal biopsies of achalasic patients after exposure to herpes simplex 1, supporting a role 
for an immune response against viral agents infecting esophageal neurons in predisposed 
patients 293. 
Other studies have suggested that circulating autoantibodies might cause immune-mediated 
neuronal damage in patients with achalasia 294, although the autoantibodies could certainly be 
the consequence of neuronal injury and the expression of normally occult neuronal antigens. 
Serum of achalasic patients has been shown to contain anti-neuronal antibodies that react 
against rodent enteric neurons 295,296. In both studies, the immunohistochemical pattern was 
characterized by immunoreactivity toward the nucleus and cytoplasm of myenteric and 
submucosal neurons, although targets of this immune response are unknown. Intriguingly, the 
immunolabelling was specific for enteric neurons and was not detected in neurons of the 
spinal cord, sensory ganglia, or superior cervical ganglia 296. Another study of sera from 18 
achalasic patients showed that applying the sera to gastric fundus muscle strips of healthy 
individuals led to an abnormal neurochemical code with reduced nitrergic/VIPergic neurons, 
increased cholinergic neurons and altered relaxation response when electrical stimuli were 
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applied 297. These observations suggest that other factors, other than antineuronal antibodies, 
are present in the sera of achalasic patients and may contribute to the ENS dysfunction 298. 
Although achalasia is mainly sporadic in origin, a genetic predisposition has been suggested. 
Achalasia can be found in association with rare syndromic disorders with an autosomal 
recessive inheritance, including familial esophageal achalasia (OMIM 200400) and the 
achalasia microcephaly syndrome (OMIM 200450). Causative genes for these two conditions 
have not been identified yet, but for achalasia-addison-alacrima, also referred to as Allgrove 
syndrome (AAAS, OMIM 231550), the genetic basis has been elucidated. AAAS was 
originally reported in two pairs of siblings with achalasia of the cardia and glucocorticoid 
deficiency. Other clinical signs included defective tear formation (alacrima) and other signs 
of dysautonomia. The causative AAAS gene has been mapped to chromosome 12q13, 
encoding the protein ALADIN. Several AAAS mutations have been identified in patients with 
a broad spectrum of clinical presentations, while patients with sporadic achalasia do not carry 
AAAS mutations, indicating that different mechanisms can contribute to the pathogenesis of 
idiopathic achalasia 299. Based on the evidence collected to date, the current view suggests 
that idiopathic achalasia can be defined as an inflammatory/autoimmune disease of unknown 
etiology with loss of inhibitory neurons in the esophageal myenteric plexus. 
 
Patients presenting with dysphagia and regurgitation, classic hallmarks of achalasia, should 
be investigated with high-resolution esophageal manometry, which will show a lack of 
peristalsis and incomplete LES relaxation. According to the Chicago classification for 
esophageal motility dosorders, three manometrically distinct types of achalasia exist: type I, 
the “classic form" (usually with a markedly dilated esophagus), is characterized by an 
integrated relaxation pressure (IRP) above the upper limit of normal and complete lack of 
peristalsis throughout the esophagus; type II is characterized by esophageal compression 
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(mean IRP > upper normal limit), abnormal peristalsis and pan-esophageal pressurization 
with ≥20% of swallows; and type III, formerly referred to as “vigorous achalasia,” also 
exhibits mean IRP > upper limit of normal and abnormal peristalsis, with preserved 
fragments of distal peristalsis or premature (spastic) contractions with ≥20% of swallows 300. 
Although quite technical, this classification carries clinically meaningful implications, 
including certainty of diagnosis, treatment response with either dilatation or surgery, and the 
natural evolution of the disease 301,302. In clinical practice, fluoroscopic imaging during 
ingestion of a contrast agent will show the classic “bird beak” narrowing at the LES and also 
identify whether esophageal dilatation exists and to what extent. Because manometry and 
imaging allow for safe and accurate diagnosis in virtually all cases, histopathological 
examination of biopsies, other than for research protocols, is not indicated. An exception to 
this may occur in the small subset of patients with a suspected underlying paraneoplastic 
syndrome in whom myenteric ganglionitis might be identified at the tissue level. In those rare 
cases, a search for circulating antineuronal autoantibody should be undertaken, as well as 
imaging to search for a possible occult malignancy 289. 
In adults and children, medical treatment for patients with achalasia has limited efficacy and 
is used only as a temporizing strategy while the patient awaits either dilatation or surgery. 
Medical therapy is, however, appropriate for subjects deemed unsuitable for an interventional 
procedure. Pharmacological options include nitrates (nitroglycerin and isosorbide dinitrate), 
phospho-diesterase-5 inhibitors (e.g., sildenafil), calcium-channel blockers (e.g., nifedipine), 
and direct injection of botulinum toxin into the LES 303. Surgical myotomy, which involves 
longitudinally dividing the LES, or pneumatic dilatation to physically stretch the LES, remain 
the definitive treatments. A recent double-blind controlled trial showed that surgery 
(laparoscopic Heller myotomy) was not superior to pneumatic dilatation at a mean follow-up 
of 43 months in an international cohort of 210 patients with achalasia 304. In children, in 
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whom achalasia is much less common than in adults, a recent systematic review concluded 
that available data could not determine whether surgical myotomy or pneumatic dilatations 
were superior 305. It is important to note that while both interventions effectively reduce LES 
pressure in most patients, they do not restore esophageal peristalsis, which can continue to 
cause significant symptomatic dysphagia. 
 
Chagas disease 
Chagas disease is caused by the parasite Trypanosoma cruzi, a member of the 
Trypanosomatidae family, and is transmitted to humans by triatomine insects called 
Reduviidae beetles or “kissing bug” 306. The disease is endemic in South and Central America 
and causes >15,000 deaths annually 307. Acute symptoms go largely unattended and the 
infection subsides without treatment. However, some patients develop chronic infection, 
leading to cardiomyopathy and motor dysfunction of the gastrointestinal tract. Dilation of the 
esophagus (megaesophagus) and colon (megacolon) are the most common gastrointestinal 
findings, although the disease may progress to any segment of the bowel and extrahepatic 
biliary tract 306,307. Typical gastrointestinal symptoms include dysphagia, constipation, and 
abdominal pain. A progressive degeneration and loss of the intrinsic innervation of the gut 
represents the neuropathological hallmark of Chagas disease. This is thought to result from an 
immune cross-reactivity between the T. cruzi flagellar antigen Fl-160 (a surface protein of 
160-kilodalton) and a structurally similar 48-kilodalton protein expressed by mammalian 
axons and myenteric neurons 308. The histopathologic analysis shows an immune infiltrate in 
the myenteric plexus, which leads to enteric neuronal degeneration and loss in a fashion 
similar to that observed in idiopathic cases of enteric ganglionitis (see below). In addition to 
an immune cell–mediated response, patients with chronic Chagas disease show high titers of 
circulating antibodies directed against the type 2 muscarinic acetylcholine receptor, which is 
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widely expressed on smooth muscle cells, but not on neurons. These autoantibodies play a 
pathogenetic role in Chagasic achalasia as they bind to muscarinic receptors and evoke 
muscle contraction 309. Treatment options for chronic Chagas disease have not shown 
satisfactory results, with both nifurtimox and o-benznidazole yielding eradication of the 
infection in only 10% of treated patients. Surgical resection is still the mainstay of therapy in 
patients with end-stage megaesophagus or megacolon 310. 
 
Gastroparesis 
Gastroparesis, meaning “paralyzed stomach,” results in a significant delay in the emptying of 
solids and liquids from the stomach. Symptomatic gastroparesis is characterized by nausea, 
vomiting, bloating, early satiety, and epigastric pain. In adults, gastroparesis can be divided 
into two common forms: idiopathic gastroparesis, accounting for 50% of cases, and diabetic 
gastroparesis 311,312. In children, 70% of cases appear to be idiopathic, with the remainder 
accounted for by drugs, viral infections, or post-surgical 313,314. 
Nearly any pathological condition that disrupts the neuromuscular function of the stomach 
can result in gastroparesis. Alterations in the extrinsic neural supply to the stomach are 
known to contribute to its pathophysiology. While the pathogenesis of idiopathic 
gastroparesis is unknown, it has been proposed that abnormalities of intrinsic gastric 
innervation can also be causative 315,316. Recent data based on histopathological 
characterization of laparoscopic biopsies showed ICC depletion or abnormalities in 39% and 
48% of idiopathic and secondary (diabetic) gastroparesis cases, respectively, with 
neuropathic changes observed in 14% and 17% of cases 317. Tissue analysis of a patient who 
underwent total gastrectomy showed hypoganglionosis with features suggestive of neuronal 
dysplasia. In this report, abnormalities of myenteric and intramuscular ICC, along with 
neuronal alterations, were described, suggesting a more generalized process. Neuronal 
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inflammation, manifested as myenteric ganglionitis, has also been described in gastroparesis. 
Several conditions, including paraneoplastic syndromes, are associated with inflammatory 
neurodegenerative alterations and gastroparesis 318. Cases of idiopathic inflammatory 
neuropathies with gastroparesis have also been described. For example, a patient with 
intractable vomiting had a dense lympho-plasmacellular infiltrate in the gastric myenteric 
plexus 319. Treatment with steroids improved the symptoms, suggesting an important role for 
immunity and supporting the use of anti-inflammatory therapy in patients with proven 
myenteric ganglionitis 319. Additional causes include post-viral gastroparesis and 
mitochondrial disease, which were identified in 18% and 8%, respectively, of children with 
gastroparesis in a recent review 320. 
A diagnosis of gastroparesis can be made based on clinical assessment that includes (1) 
symptom evaluation (postprandial fullness, early satiety, nausea, vomiting, upper abdominal 
bloating), (2) exclusion of mechanical causes for delayed gastric emptying, such as 
hypertrophic pyloric stenosis in children, and (3) objective evidence from a gastric emptying 
assay performed using either 99Tc-scintigraphy or 13C octanoic acid breath test. Additional 
tests can be used to determine possible causes for the gastroparesis, such as electrolyte 
abnormalities or diabetes mellitus, which are among the most common secondary forms of 
gastroparesis 321. Gastric biopsies are not included in the diagnostic work-up for 
gastroparesis.  
 
The most common therapeutic strategies include dietary modification, nutritional 
supplements, and prokinetic drugs. The two most commonly used drugs, metoclopramide and 
domperidone (the latter not commercially available in the U.S.), have been shown to be 
effective in ameliorating symptoms in patients with gastroparesis 322. Both compounds, 
however, should be used with caution because of their extrapyramidal side effects 
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(metoclopramide) and increased risk of sudden cardiac death (domperidone). Promising 
results have been obtained using a ghrelin agonist (relamorelin), newly developed motilin 
agonist (camicinal), 5-HT4 receptor agonists (velusetrag), and neurokinin-1 receptor 
antagonists (aprepitant). These medications all deserve further investigation in clinical trials 
323. In medically refractory cases, operations, including pyloroplasty or gastrojejunostomy, 
can be performed to accelerate gastric emptying, but have been met with variable results 303. 
The evidence of a predominant reduction of ICC, rather than a neuropathy, in a considerable 
number of patients may provide a cellular basis for the efficacy of gastric pacing, which is 
generally reserved for the most severe and refractory cases 324. Interestingly, gastric pacing 
results in symptom control, but without improvement in gastric emptying time. 
 
Idiopathic hypertrophic pyloric stenosis 
Failure of the stomach to empty properly also occurs in a condition referred to as idiopathic 
hypertrophic pyloric stenosis (IHPS). This disease presents at around one month of age and 
affects approximately 1 in 500 children. The hallmark of the disease is the lack of nitric oxide 
synthase (nNOS) in myenteric ganglia of the pyloric region 325. The absence of muscle 
relaxation due to the inhibitory denervation results in a continuous tonic contraction of the 
pylorus followed by muscle hypertrophy, thereby impeding gastric emptying. The pathogenic 
role of deficient nitrergic innervation is supported by the Nos1-/- mouse model, which 
exhibits gastric obstruction similar to that occurring in the human disease 326. IHPS can be 
either sporadic or associated with several conditions, including Turner syndrome, 
phenylketonuria, and trisomy of chromosome 18 327. Although the hypertrophic muscle forms 
a palpable epigastric mass, the force exerted by antral contractions may be sufficient to 
overcome the malfunctioning pylorus and propel some gastric contents into the duodenum, at 
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least in the early phase of the disease. Surgery is the only therapeutic option currently 
available. 
 
Neuronal intranuclear inclusion disease (NIID) 
NIID is a progressive neurodegenerative disorder affecting the three main neuronal systems, 
including central, peripheral and enteric neurons. The neuropathological hallmark, 
represented by eosinophilic inclusions typically detectable within neuronal nuclei, is 
associated with neuronal loss of variable degree. Molecular studies reveal that these 
eosinophilic inclusions contain expanded polyglutamine tracts and are positive for ubiquitin 
and small ubiquitin-like modifier-1 (SUMO-1) 328. These factors post-translationally modify 
numerous proteins via processes called ubiquitination and sumoylation, respectively, altering 
protein localization, metabolism, and function. Abnormalities in these processes may account 
for the accumulation of intraneuronal protein aggregates (ie inclusion bodies) seen in this 
disease. Neurological manifestations usually start in childhood, although adult onset has also 
been reported. The clinical expression depends on the predominant central, peripheral, or 
enteric neuronal loss 329. When autonomic dysfunction characterizes the clinical picture, then 
the whole gastrointestinal tract can be affected with severe impairment of gut motility, 
including dysphagia, gastroparesis, and CIPO in combination with urinary abnormalities, 
such as neurogenic bladder 330. NIID is usually sporadic, although familial cases have been 
reported. Rectal or colonic biopsies with histopathological identification of eosinophilic 
inclusions in the submucosal ganglion cell bodies may help in the diagnostic work-up. 
Currently, there are no specific treatment options available other than general supportive 
measures. 
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Ganglioneuromatosis in MEN2B 
MEN2B is a rare autosomal dominant syndrome that affects 1 in 30,000 individuals and is 
characterized by an early-onset of an aggressive form of medullary thyroid carcinoma. 
Pheochromocytomas (50% of cases) and a marfanoid (tall and thin) body build are also seen 
in MEN2B. Mucosal neuromas involving lips (‘‘blubbery lips’’) and eyelids (leading to 
thickening and eversion) represent other features in these patients 331. Gastrointestinal 
symptoms, including constipation, megacolon, or CIPO, beginning in infancy or early 
childhood occur in up to 80% of patients, with diffuse ganglioneuromatosis of the 
gastrointestinal tract occurring in about 40% of cases 332. A specific germ-line point mutation 
(methionine to threonine) in exon 16 of the RET gene (M918T) occurs in 95% of patients 333. 
Other rarer mutations involve exon 15 (A833F) 334 or codon 691 (G691S) leading to isolated 
ganglioneuromatosis 335. Patients with intestinal ganglioneuromatosis involving both 
myenteric and submucosal plexus should be tested for RET mutation. In these positive cases, 
prophylactic thyroidectomy is indicated. Adrenal gland surveillance with ultrasound scanning 
and urinary fractionated catecholamines is recommended to identify the presence of a 
pheochromocytoma 336. 
 
Intestinal Neuronal Dysplasia (IND) 
IND represents a hotly debated entity, largely due to disagreement regarding its existence as a 
pathologic condition 337 and disagreement regarding its histopathology 338. IND type B, which 
comprises about 98% of described cases, presents in infants or older children as severe 
constipation. It can occur in isolation or proximal to the aganglionic segment in a patient with 
HSCR 339. Diagnostic criteria vary regarding the details, but broadly speaking are based on 
the presence of neuronal hyperplasia specifically in the submucosal plexus. One set of criteria 
includes the presence of giant submucosal ganglia, defined as containing >8 ganglion cells 
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per ganglion, in at least 20% of submucosal ganglia examined 340, and often also the presence 
of ectopic ganglia in the lamina propria 341,342. Interestingly, later descriptions of IND require 
that the child be >1 year of age for this diagnosis because of the recognition that the 
submucosal ganglia of infants contain a larger number of cells per ganglion due to their 
immaturity 340. Importantly, the diagnosis of IND applies only to patients with these 
histologic features in the large intestine, not the small intestine, where the importance of these 
findings is unknown. Most children with IND are treated conservatively for their 
constipation, with surgical removal of the abnormal colon reserved for the most severe cases. 
No definitive animal model of IND exists. Rats with a heterozygous mutation of EDNRB 
have histologic features reminiscent of IND, with larger and denser submucosal ganglia 
present in the colon 343. However, while the histology is consistent with IND, the rats have no 
intestinal dysmotility and develop normally. A recent study in avian embryos showed that 
inhibition of Shh signaling led to the development of large and ectopic submucosal ganglia 
344, suggesting the possibility that Shh may be associated with this condition. Since IND has 
been identified proximal to the aganglionic segment in HSCR 339, a search for mutations in 
HSCR-related genes (RET, GDNF, EDNRB, and ET3) was performed in 20 patients with 
IND, but failed to uncover any abnormalities 345. 
 
Chronic constipation 
Chronic constipation is a functional disorder of the gastrointestinal tract characterized by 
difficult and infrequent bowel movements. Depending on the definition used, estimates 
indicate that about 10-15% of adults and up to 30% of children in the general population 
suffer from constipation 346,347. Although in children no specific gender, age or 
socioeconomic associations are evident, in adults the condition most commonly affects 
women (female:male ratio of 2-3:1), elderly, non-whites, and those with a lower socio-
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economic status 347-349. From a pathophysiologic standpoint, three main subtypes of 
constipation exist: (1) normal transit (also referred to as functional constipation), (2) slow 
transit, and (3) obstructed defecation (also called dyssynergic defecation when no mechanical 
obstruction is present) 350. 
Data regarding neuromuscular abnormalities in chronic constipation have been obtained in 
the minority of patients who undergo surgery for the most severe forms of the disease, 
predominantly slow transit constipation (STC) with colonic inertia (CI), which mainly affects 
young women and has also been described in children without an obvious sex bias 351. Recent 
studies have shown that tissue analysis in STC/CI shows features indicative of an underlying 
enteric neuropathy, a finding previously predicted using gastrointestinal manometry to assess 
bowel motility in these patients 352,353. Alterations of colonic innervation in STC/CI were 
initially characterized by silver staining, showing a reduction in the total number of 
argyrophilic neurons and structural alterations in both neuronal perikarya and axons 354,355. 
Other reports described a reduction of enteric neural elements (cell bodies and/or processes) 
as a common feature in patients with STC/CI who underwent surgery 356-358. Furthermore, 
these neuronal abnormalities are often associated with reduced ICC and enteric ganglion cells 
14,359,360. In a cohort of patients with a severe and intractable form of STC, it has been found 
that: 1) ICCs were significantly decreased; 2) enteric neuronal loss was present, partly 
ascribed to apoptosis; and 3) enteric glial cell number was markedly reduced in both the 
submucosal and myenteric plexuses 361. However, in the same study, the examination of the 
terminal ileum of patients with intractable STC/CI revealed only a reduction of enteric glial 
cells, while neuronal and ICC alterations were not detected at this level 362. In a study of 
children with severe STC, abnormal contractile patterns present on high resolution colonic 
manometry were significantly associated with histopathological abnormalities primarily 
involving enteric neurons, but also included changes in ICCs and smooth muscle 351. Giorgio 
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et al 351 showed that a failure of motor quiescence between bisacodyl-induced high amplitude 
propagating sequences reliably predicted neuromuscular pathology. Other results suggest that 
colonic dysmotility in STC/CI patients can be attributable to more subtle imbalances of 
enteric neurotransmitters and neuropeptides. An excessive production of NO in the colonic 
myenteric plexus of patients with STC has been suggested as a pathophysiological 
mechanism eliciting a constant inhibition of propulsive contractile activity 363. However, this 
possibility is still debated, since other studies investigating mediators like VIP, substance P, 
neuropeptide Y, or serotonin gave contradictory results in tissue specimens of patients with 
STC 364-367. A major limitation to finding a consistent histopathological diagnosis and likely 
contributing to the wide spectrum of neuromuscular abnormalities reported is the large 
variability in disease phenotype, anatomic source of the sample, morphological methods for 
tissue evaluation, and the lack of normative data to detect subtle changes in enteric neuronal, 
glial, or muscular structure 368. The field would benefit from improved diagnostic methods 
and the development of a clear and comprehensive nosology to more accurately define 
subtypes of constipation. 
Current management of severe constipation primarily consists of laxatives, given orally or as 
suppositories. Many types of laxatives are used, based on their mechanism of action, 
including the following classes of agents (with examples): bulk-formers (fiber), stool 
softeners (docusate), lubricants (mineral oil), hyperosmotic agents (polyethylene glycol or 
lactulose), and stimulants (bisacodyl or senna). Other agents include serotonin agonists 
(prucalopride), which stimulate motility by activating 5-HT4 receptors on enteric neurons, or 
chloride channel activators (lubiprostone) or guanylatecyclase-C agonists (linaclotide), which 
soften stool by increasing fluid secretion by the gut epithelium. Other agents, including newer 
5-HT4 agonists (naronapride and velusetrag), the ileal bile acid transporter A3309 
(elobixibat), and ghrelin agonists (relamorelin), represent the forefront of treatment 369. In 
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children there is limited experience with many of these newer medications. A recent 
multicentre double-blind placebo-controlled trial of prucalopride in children with functional 
constipation failed to show any benefit, although it may be of value in some cases of severe 
constipation 370. Although lubiprostone showed some efficacy in pediatric constipation in an 
open-label study, this remains to be shown in a larger multicentre trial 371. When medical 
management fails, surgery can be considered in carefully selected patients. Subtotal 
colectomy has long been the standard approach for intractable constipation 372. In children, 
and possibly in adults, antegrade enemas via a catheterizable appendicostomy or a cecostomy 
tube have proven to be effective 373,374. In the most severe cases, total proctocolectomy with 
ileoanal anastomosis or diverting ileostomy have been used 375. A better understanding of the 
underlying causes of severe constipation is needed in order to develop improved 
pharmacotherapies that can target specific abnormalities in a given individual. 
 
Future therapies 
One of the most promising areas of research in neurointestinal disease is the development of 
novel cell-based therapies. Recent advances in cell biology and molecular genetics have 
enhanced the identification and isolation of stem cells from a variety of adult tissues, 
including the gut. In the human gastrointestinal tract, multipotent stem cells have been found 
to be present, not only during development, but also postnatally, well into late adult life 376. 
The identification of enteric neural stem cells represents an exciting opportunity to test new 
therapies for the ENS 377. Human enteric neural stem cells can be collected by relatively 
noninvasive techniques, such as routine endoscopy, and have been transplanted ex vivo into 
strips of aganglionic intestinal muscle, where they differentiate into enteric neurons and glial 
cells 378. 
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Autologous cell transplantation offers the possibility of using a patient’s own cells to replace 
missing or injured enteric neurons in a variety of neurointestinal diseases. Autologous cells 
would eliminate issues around immunologic rejection and ethical concerns raised by other 
sources of stem cells. Hotta et al 379 recently successfully isolated isogenic enteric neuronal 
progenitors from the ganglionated bowel of Ednrb-deficient mice and transplanted them into 
the postnatal aganglionic rectum of Ednrb-deficient hosts. In considering autologous 
transplantation as a potential therapy, one needs to consider that ENS stem cells obtained 
from HSCR patients might be impaired in their biological function 380. However, in HSCR 
the “abnormal” enteric neural crest-derived cells are able to migrate a significant distance 
along the bowel, from foregut to distal hindgut in the majority of cases, failing to colonize 
only the very distal end. In fact, in the recent study of isogenic cell transplantation into 
Ednrb-deficient mice, transplanted cells demonstrated a normal capacity for self-renewal and 
neuronal differentiation 379. However, this was an issue for mice carrying the monoisoformic 
Ret51 (miRet51) mutation, in which only the Ret51 isoform is expressed, resulting in a 
HSCR-like phenotype with distal colonic aganglionosis and intestinal obstruction 381. Enteric 
progenitors harvested from these mice show delayed differentiation compared to wild-type 
controls 381. These cells could be genetically modified to restore a normal phenotype, for 
example by restoring the Ret9 isoform within the miRet51 ENS progenitors, which has been 
shown to rescue the differentiation anomalies 381.  
 
An alternative source of autologous cells for transplantation is induced pluripotent stem cells 
(iPSC). Transfection of key transcription factors into a patient’s somatic cells (e.g. fibroblasts 
or peripheral blood leukocytes) allows these cells to reprogram into a multipotent-like state, 
and these cells are referred to as  iPSC 382. For cell therapy this technology offers the 
possibility of overcoming the need for harvesting ENS stem cells from the gut and instead 
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using an easily accessible source of autologous cells, such as the skin. iPSC can be expanded 
in vitro and genetically engineered, either by introduction of a normal gene to replace a 
mutant allele or by gene editing to correct a known mutation 383. iPSC were recently 
successfully induced to enteric neural crest progenitors, and subsequently differentiated into 
enteric neurons 384. These cells were able to migrate and differentiate appropriately in 
embryonic aneural chick intestine and to colonize adult mouse colon 384. In patients with a 
known mutation, a variety of techniques can be used to correct the mutation using 
homologous recombination or a genome editing tool, such as CRISPR, TALENs, or ZFNs 
385. Recent publications have demonstrated successful genome modification of iPSC 
harboring known disease-causing mutations in several genetic diseases, including sickle cell 
disease 386, beta-thalassemia 387, and spinal muscular atrophy 388. 
While it appears plausible that cell-based approaches could be used to treat enteric 
neuropathies, many challenges remain, including identification of the most appropriate 
diseases to treat, optimal cell sources, strategies for maximizing cell expansion, methods for 
efficient and targeted cell delivery, and issues with immune response. Addressing these 
challenges will usher in a new era in the treatment of enteric neuropathies and offer hope to 
patients with these difficult conditions.  
 
Take-home messages of this review article: 
• Enteric neurons arise from neural crest cells and regulate gastrointestinal function. 
• Congenital neurointestinal diseases result from abnormal development of enteric 
neurons. 
• Acquired neurointestinal diseases are due to neurodegeneration, inflammation, or 
infection. 
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• Treatment of neurointestinal diseases represents an unmet need for patients and 
clinicians alike due to incomplete understanding of underlying pathophysiology.  
• Therapeutic options include nutritional support, prokinetics and antibiotics (for 
underlying bacterial overgrowth). Specific treatments may be advocated in very 
particular cases, e.g. anti-inflammatory drugs in case of ganglionitis / leiomyositis; 
surgery in HSCR; stem cells represent the forefront of future therapies.  
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Chapter 6. 
CHRONIC INTESTINAL PSEUDO-OBSTRUCTION 
CIPO represents the most severe form of GI dysmotility with diabling and potentially lethal 
consequences. Symptoms are non-specific, and as a result this condition is usually diagnosed 
incorrectly or too late with consequences for morbidity and even mortality. Although 
pediatric and adult CIPO have many common clinical features, distinctive features can also 
be identified. There is no single diagnostic test or pathognomonic finding for CIPO. 
Therefore, a multidisciplinary stepwise approach including radiology, endoscopy, laboratory, 
manometry and histopathology should be considered in the diagnostic work-up. Treatment of 
this condition is challenging and often requires a collaborative effort with participation of 
appropriately experienced gastroenterologists, pathologists, dieticians, surgeons, 
psychologists, and other subspecialists.  
 
6.1 Diagnosis and therapeutic options 
Modified from 
Chronic intestinal pseudo-obstruction in children and adults:  diagnosis and therapeutic 
options 
Giovanni Di Nardo, Carlo Di Lorenzo, Augusto Lauro, Vincenzo Stanghellini, 
Nikhil Thapar, Tennekoon B. Karunaratne, Umberto Volta and Roberto De Giorgio 
Neurogastroenterol Motil. 2017 Jan;29(1). 
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Introduction 
Chronic intestinal pseudo-obstruction (CIPO) is a rare condition characterized by a severe 
impairment of gastrointestinal (GI) propulsion, which results in symptoms suggestive of 
partial or complete intestinal obstruction in the absence of any lesion restricting or occluding 
the intestinal lumen.24,254,389-391 CIPO can involve any segment of the GI tract (although the 
small bowel and colon are mainly affected) and represents the most severe form of GI 
dysmotility with potentially lethal consequences.24,390 Symptoms can be non-specific with 
CIPO mistaken for other diseases and consequently not diagnosed for long periods of 
time.392,393 The chronicity of the severe digestive symptoms, the inability to maintain an 
adequate nutritional status without specialist support, the suboptimal efficacy of medical 
treatments, and the limited knowledge of the syndrome by physicians constitute some of the 
main factors contributing to the poor quality of life and the high morbidity and mortality rate 
of patients with CIPO.392-395 
Much like other rare diseases with poorly defined diagnostic criteria, CIPO has a largely 
unknown prevalence and incidence.24 One nationwide survey in the U.S. reported that about 
100 infants were born with CIPO every year.396 A more recent nationwide survey in Japan 
found a prevalence of 3.7 in one million children (1 in 270,000 children younger than 15 
years of age) with equal sex incidence.397 These studies most likely underestimate the true 
number of new cases per year, as they do not include patients who develop symptoms of 
CIPO later in life. In another survey of 378 institutions belonging to the Japanese Society of 
Gastroenterology, CIPO prevalence in adult patients was estimated to be 1.0 and 0.8 cases 
per 100,000 males and females, respectively. The incidence in the same population was 0.21 
and 0.24 cases per 100,000 males and females, respectively.398 
The purpose of this paper is to provide a broad review of CIPO ranging from the pediatric to 
adult age selectively highlighting the main clinical aspects such as symptoms / signs, 
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diagnosis and therapeutic options in the different age groups. Deliberately, we did not address 
the putative mechanisms underlying severe gut dysfunction as well as the attendant 
histopathological features and the reader is referred to published comprehensive articles on 
these topics. In Table 2  summarize the classification of CIPO in relation to etiopathogenetic 
factors. 
 
Disease spectrum 
CIPO is not a single clinical entity, rather an umbrella term for a range of different diseases 
leading to severe, end-stage gut motor failure. The most severe cases of the CIPO spectrum 
are those involving pediatric patients with antenatal (in utero) evidence of multivisceral 
dilation of the hollow viscera (e.g. digestive and urinary systems), often characterized by 
inability to tolerate enteral feeding and poor prognosis (Fig. 12 A-B).394,399-401 This clinical 
subset represents the most common group of pediatric CIPO patients with diffuse 
involvement of the GI tract. In these cases, the neuromuscular abnormalities (either genetic or 
acquired) of the GI tract do not preclude birth, but can be severe enough to generate the onset 
of symptoms in the early newborn period with reported mortality rates ranging from 10% to 
32%.394,399,400 
More rarely, some cases appear to be acquired after birth, being characterized by a variable 
period of normality followed by rapid progression to intestinal failure with bowel (and often 
urinary tract) dilatation. In some of the most aggressive forms of acquired CIPO, the 
histopathological analysis may detect a massive inflammatory (mainly lymphocytic) neuro-
muscular infiltrate, reminiscent of the autoimmune pancreatic 'insulitis' underlying insulin-
dependent diabetes mellitus of the childhood 402 (Fig. 12 C-D). These cases of CIPO may 
respond to an immunosuppressive treatment if the immune-mediated insult has not 
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completely damaged regulatory cells, i.e. enteric nerves, interstitial cells of Cajal (ICC), and 
smooth muscle.403-408 
Other cases of pediatric and adult CIPO may occur in patients who experience more insidious 
mild and nonspecific symptoms (either 'irritable bowel syndrome’ - or 'dyspepsia’- like) 
thought not to carry a risk to evolve into severe dysmotility. Nonetheless, some of these 
patients do progress on to a classic CIPO phenotype over time (Figure 1E-G). We consider 
them the 'dark-side' of adult CIPO spectrum, i.e. cases in whom a number of factors, 
including an altered gut microbiota, intestinal epithelial barrier dysfunction, immune 
dysregulation and other poorly defined mechanisms may operate, individually or in concert, 
to impair the neuro-muscular homoestasis.392 Patients with acute onset of CIPO after 
abdominal surgery, i.e. mimicking a prolonged postoperative ileus, remain a largely 
unexplained subset. Other striking examples are those cases occurring after ileal bypass 
performed to treat morbid obesity, suggesting that surgical manipulation may by itself evoke 
neuro-myoelectrical abnormalities in predisposed alimentary tracts.409 A synoptic view of this 
section is reported in Fig. 13. 
 
Clinical findings 
CIPO may involve any segment of the GI tract and therefore symptoms can vary from patient 
to patient based on the location and the extent of the gut segment involved. Also, extra-
intestinal manifestations and malnutrition contribute to the clinical features. 1,391,393,410-412 
Prenatal signs are only detected in about 20% of cases, whereas 50-70% of patients show 
clinical signs perinatally (i.e. within the first month of age). Most patients (80%) show 
clinical manifestations by the first year of age, while the remaining 20% have sporadic onset 
during the first two decades of life. 394,395,397,399,400 One study indicated that the median age of 
symptom onset in adults is 17 years.406 
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Both pediatric and adult CIPO shares many clinical aspects, although distinctive features can 
be identified (Table 3). In any age group, the clinical picture tends to be dominated by 
abdominal pain and distension (80%), which are particularly severe during acute episodes of 
pseudo-obstruction.406 Associated symptoms include nausea and vomiting (75%), 
constipation (40%), and diarrhea (20%).392,406 Between acute episodes, patients can be 
minimally symptomatic, or continue to experience severe proximal (anorexia, early satiety, 
nausea and vomiting) and distal digestive symptoms (constipation, diffuse abdominal pain 
and / or distension).392,394 Prevalence and severity of acute episodes that recur at irregular 
intervals vary from patient to patient. Malnutrition is another significant clinical aspect in any 
patient with CIPO. This is due to both limited oral intake, because ingestion of food generally 
aggravates symptoms, and intestinal malabsorption related to the altered gut transit, often 
associated with dilated bowel loops. In about 30% of CIPO patients small intestinal bacterial 
overgrowth (SIBO) occurs as a result of intestinal stasis and can cause diarrhea and 
steatorrhea.392 Gastroparesis and urinary bladder dysfunction (with or without megacystis and 
megaureter) are co-morbidities that are likely to share similar pathophysiological mechanisms 
with those underlying CIPO.24 Also, because of the frustrating ineffectiveness of most 
therapeutic interventions, patients with CIPO may develop depression or other psychological 
disorders.413,414 
In children, there is a higher risk of colonic and small bowel volvulus secondary to severe 
dysmotility and gut dilatation, congenital adhesions or concurrent malrotation.394,400,415-417 
Urological involvement is commonly identified in patients with familial and congenital forms 
of CIPO, particularly in the myopathic subgroup, ranging from 36 to 100%.394,418-421 Findings 
include urinary retention secondary to bladder atony, hydronephrosis, vesicoureteral reflux, 
and recurrent urinary tract infections. Megacystis on antenatal ultrasound has been reported 
in up to 59% of CIPO and this finding may require delivery by caesarean section.420,421 
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Megacystis can be associated with a microcolon, a phenotype referred to as megacystis-
microcolon-intestinal-hypoperistalsis syndrome.4 Other syndromic form of CIPO are 
represented by the mitochondrial disorders which in a large adult series account for 19% of 
all CIPO patients. They are characterized by severe intestinal dysmotility, poor nutritional 
status and neurologic manifestations, e.g. peripheral neuropathy (with mild to moderate 
hypoesthesia), proprioceptive ataxia, progressive external ophthalmoplegia with ptosis and 
hearing loss.2 GI manifestations are common at presentation and positive family history 
together with the progressive neurological and nutritional deterioration should alert clinicians 
to search for mitochondrial disorders.422-425 
Secondary systemic forms (i.e. related to underlying conditions) of CIPO are more common 
in adult patients in whom they occur at much older age.24 A proximal muscle weakness may 
indicate the presence of polymyositis and dermatomyositis. Scleroderma is usually associated 
with skin abnormalities, while the suspicion of a paraneoplastic syndrome should prompt 
investigations aimed at uncovering an occult malignancy of the lung, ovary and breast. 
Finally, forms of CIPO associated with Chagas' disease are common in Latin America and 
are characterized by combination of dysphagia and cardiomyopathy. 319,392,393,396,402,426,427 
 
Diagnosis 
The diagnosis of CIPO is mainly clinical. The diagnostic work u.p of both children and adults 
with suspected CIPO has the following goals: 1) rule out mechanical causes of bowel 
obstruction. This can be achieved by abdominal CT or plain X-ray; 2) identify any underlying 
diseases by an accurate laboratory test profile; 3) evaluate the possibility of a drug-induced 
CIPO-like presentation (e.g. opioids, tricyclic antidepressants, anti-cholinergic agents, anti-
Parkinsonian agents, phenothiazines); and 4) understand the pathophysiological features that 
may improve management or bear prognostic information in selected cases (particularly by 
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performing GI manometry in cases without bowel dilation). Thus, a stepwise approach (as 
outlined above) is commonly recommended in CIPO and includes radiology, endoscopy, 
laboratory, manometry and histopathology. 
 
Radiology 
A plain radiograph of the abdomen usually identifies the typical signs of intestinal 
obstruction, i.e. air-fluid levels and dilated bowel loops.24, 397,400 Air-fluid levels are better 
visualized in the upright position, but lateral views can be useful. In symptomatic patients 
without these radiographic findings, other conditions (e.g. chronic constipation, irritable 
bowel syndrome and functional dyspepsia) should be considered. 
Fluoroscopic studies should be performed using water-soluble contrast solutions in order to 
avoid complications related to barium concretions and, at the same time, enhance hydration 
and transit of intestinal contents. Upper GI series with small bowel follow-through can 
unravel dilated bowel loops (often involving the stomach and duodenum) with very slow 
transit, although the latter finding may not be detectable in some pediatric cases. Intestinal 
malrotation may be identified in up to a third of children with CIPO.394 Less common 
findings include diverticulosis of the small intestine (in 53% of patients with mitochondrial 
neurogastrointestinal encephalomyopathy, MNGIE, and 42% of scleroderma), and intestinal 
pneumatosis.24 
Contrast medium radiologic tests have been recently superseded by dedicated enterography 
with high-resolution CT or MRI, which more accurately detect mechanical obstruction and 
intestinal adhesions. Cine-MRI is emerging as a non invasive, radiation-free method for 
assessing and monitoring GI motility particularly in the pediatric population. 241,243,428 
Excretory urograms should be performed in patients with urinary symptoms, since neuro-
myopathies may affect both the GI tract and urinary system. A chest CT may be necessary to 
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exclude small cell lung cancer in adult patients with suspected paraneoplastic CIPO. Finally, 
imaging of the brain can identify leukoencephalopathy in CIPO related to MNGIE.423-425 
 
Endoscopy 
Upper GI endoscopy may be useful to exclude a mechanical occlusion of the proximal small 
intestine as well as to collect duodenal biopsies in cases where celiac disease or eosinophilic 
gastroenteropathy are suspected.389 Colonoscopy can be used to rule out mechanical 
obstruction and decompress the large intestine, although this manoeuvre rarely provides long-
term satisfactory results.429 The wireless motility capsule measures intraluminal pH, 
temperature, and pressure; however, the role of this technique in the diagnosis of CIPO has 
not been established yet and its use is thought to be even hazardous when a mechanical 
obstruction has not been definitely ruled out.430 
 
Laboratory tests 
Laboratory exams are aimed to unveil secondary causes of CIPO. Blood tests for diabetes 
mellitus (i.e. hemoglobin A1C and / or postprandial blood glucose concentration), celiac 
disease (anti-tissue transglutaminase IgA and anti-deamidated gliadin peptides IgG), 
connective tissue and skeletal muscle disorders (anti-nuclear antibody, anti-double-stranded 
DNA and SCL-70, creatine phosphokinase, aldolase), and hypothyroidism should be 
performed. Other tests include serology for Chagas’ disease, urinary catecholamines for 
pheochromocytoma, and enteric neuronal autoantibodies (anti-Hu or type 1 anti-neuronal 
nuclear antibodies) in patients with suspected paraneoplastic syndrome. Urinary porphyrins 
should be assayed in patients with severe, otherwise unexplained abdominal pain. A complete 
blood cell count, electrolytes, albumin, liver enzymes, vitamin B12, fasting cortisol, 
inflammatory indexes (C-reactive protein and erythrocyte sedimentation rate) are useful in all 
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cases.414 Patients receiving parenteral nutrition (PN) should be carefully monitored with 
particular attention to fluid, electrolytes and circulating levels of trace elements. In patients 
with symptoms and signs suggestive of an underlying mitochondrial disorder, serum lactate 
and thymidine phosphorylase activities should be performed. If thymidine phosphorylase 
activity is markedly reduced / absent and nucleosides are increased, then thymidine 
phosphorylase (TYMP) (in MNGIE), and polymerase DNA-gamma (POLG) (in sensory 
ataxic neuropathy dysarthria and ophthalmoparesis) gene mutations should be tested.424,425 
 
Manometry 
Intestinal manometry can be useful to define the pathophysiological (neuro-muscular) 
mechanisms involved in CIPO (e.g. neuropathy or myopathy), although it has a low 
diagnostic specificity and in some pediatric and adult patients does not influence treatment. 
Nonetheless, intestinal manometry can differentiate mechanical from functional forms of sub-
occlusion, provided that the organic cause is at an early stage.392,393,410,411,431-435 In fact, the 
presence of postprandial, prolonged, high pressure, non-propagated contractions is a pattern 
suggestive of a recently occurred mechanical obstruction.5,7,10,11 A neuropathy is 
characterized by contractions showing a normal amplitude, although with uncoordinated 
pattern 391,393,396 (Fig. 14), whereas coordinated contractions with a reduced amplitude are 
indicative of an enteric myopathy. However, a careful interpretation is mandatory since low-
amplitude contractions could be secondary to the inability of the manometric catheter to 
register non-occlusive contractions when bowel loops are dilatated.24 Antroduodenal 
manometry has been applied extensively in children in order to assess prognosis, response to 
treatment and tolerance to oral feeding.431-433 In children with chronic symptoms suggestive 
of CIPO, a normal manometry essentially excludes CIPO and should lead to the consideration 
of emotional or factitious disorders (e.g. Munchausen syndrome by proxy).434,435 Amiot et al. 
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have identified an abnormal esophageal manometry in 73% (51% with severe ineffective 
dysmotility) adult CIPO cases.436 Similar findings have been also documented in paediatric 
cases of CIPO.400 Notably, only esophageal motor disorders had a significantly negative 
predictive value in terms of survival, home PN requirement, and inability to maintain 
sufficient oral feeding, suggesting the presence of a more generalized disease.436 Also, 
esophageal manometry can be useful in CIPO associated with scleroderma. Anorectal 
manometry is indicated when the clinical picture is characterized by intractable constipation 
and marked colonic dilatation, suggestive of Hirschsprung's disease.24 A careful manometric 
assessment of the entire GI tract, including the colon, has been deemed helpful in helping to 
plan for an isolated or a multivisceral transplantation in the most severe forms of pediatric 
CIPO.396 
 
Histopathology 
Collection of gut full-thickness biopsies is aimed at providing clinicians with a 
histopathological correlate which may unravel abnormalities related to: a) extrinsic and/or 
intrinsic neurons controlling gut functions; b) the ICC networks; and c) enteric smooth 
muscle cells. Changes affecting these cellular systems are tightly linked to the 
pathophysiology of CIPO and may have prognostic and sometimes therapeutic implications. 
437,438 Minimally invasive procedures, e.g. laparoscopic surgery or - very recently - 
endoscopic approaches (for example natural-orifice translumenal endoscopic surgery), have 
shown a high diagnostic yield and safety.439 In addition, guidelines proposed by the Gastro 
2009 International Working Group have helped to find consensus about technical aspects 
(including tissue collection and processing) and histopathological reporting of results in a 
variety of gut neuro-muscular disorders, including CIPO.2,440 
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In the absence of clinical guidelines, we suggest that ideal CIPO patients who should be 
referred to laparoscopic surgery for full-thickness biopsies fall into these two major 
categories: 1) idiopathic cases characterized by an acute onset likely of post-infectious origin; 
2) patients with progressive, rapidly evolving forms of CIPO who are not under treatment 
with opioids and do not respond to any therapeutic options. In contrast, CIPO patients with 
severe pain, not uncommonly treated with opioids, should not undergo intestinal biopsy. In 
those cases it is advisable to taper down opioids and change with other non-opioidergic 
analgesic compounds. This measure is directed to avoid useless and often misleading 
histopathological analysis. In CIPO cases with a clear origin (i.e. secondary forms of CIPO), 
tissue sampling may be less clinically meaningful as many systemic diseases are known to 
affect the gut neuro-muscular layer. 
 
Natural history 
A severe clinical course can be expected for both pediatric and adult patients with CIPO 
when an underlying treatable disease is not identified.392,410-412,419 In a single-centre study of 
59 adult patients with idiopathic CIPO followed up for a long time (13 years), it was 
demonstrated that the average time between the first sub-occlusive episode and the diagnosis 
of CIPO was 8 years, with 88% of patients undergoing an average of 3 unnecessary surgical 
procedures.392 Similar rates of questionable surgery are seen in the pediatric setting.400 The 
digestive symptoms worsened over time with abdominal pain becoming intractable or 
responsive only to major analgesics (e.g. opioids - always used parsimoniously and with 
extreme caution in our own experience) in approximately 25% of cases.392 Most patients had 
oral feeding restrictions, while 30%-50% of patients needed long term PN.392,410,411 A study 
by Amiot et al., which examined all patients with CIPO on PN at home, revealed that the 
lowest mortality was associated with the ability to restore oral feeding and with the presence 
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of symptoms before 20 years of age, while an increased mortality was associated with the 
presence of scleroderma.410 
Manometric parameters, such as inadequate or absent motor response to meals, absence of 
migrating motor complex (MMC) during fasting, and generalized hypomotility have been 
shown to be predictive of poor outcome in patients with CIPO.410,433 Finally, detection of 
esophageal dysmotility in CIPO seems to have negative prognostic implications in terms of 
mortality and need for home PN.436 In children with CIPO, a myopathic etiology, coexisting 
urinary involvement, and concurrent intestinal malrotation are poor prognostic factors.394 In 
both adults and children, the risk of death is increased by the absence of a specialist team and 
in the early phases after the diagnosis of intestinal failure has been established.441 
 
Therapy 
Treatment of patients with CIPO is challenging and requires a multidisciplinary effort. The 
management of both children and adults with CIPO should be directed to avoid unnecessary 
surgery, restore fluid and electrolyte balance, maintain an adequate caloric intake, promote 
coordinated intestinal motility, and treat complications e.g. sepsis, SIBO and associated 
symptoms. In general, current therapeutic approaches are not very effective; however, recent 
advances in nutritional, pharmacological and surgical treatment has helped to improve the 
management of patients with CIPO. 24,390,391,393  
 
Nutritional support 
Patients with CIPO are often malnourished, due to malabsorption and insufficient food 
intake. Patients with sufficient intestinal absorption capacity should be encouraged to take 
small, frequent meals (5-6 / day), with an emphasis on liquid calories and protein intake, 
while avoiding high-fat and high-residue (fiber containing) foods. Carbohydrate containing 
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foods, rich in lactose and fructose, may worsen abdominal bloating and discomfort.389 
Vitamin levels, i.e. A, D, E and K as well as B12 and folic acid, should be supplemented 
when needed. In cases of inadequate oral intake, enteral nutrition with standard non-
elemental formula may be considered. In children, extensively hydrolysed and elemental 
formulas are often empirically used to facilitate intestinal transit and absorption390,391,442. 
Before a permanent feeding tube is placed, a trial with a nasogastric or nasojejunal feeding 
tube should be attempted using an enteral formula at a rate sufficient to provide an adequate 
caloric support 441,443,443. When delayed gastric emptying is present, bypassing the stomach 
and directing the feeding into the small intestine is generally preferred. Jejunal feeding tubes 
were tolerated in all patients with manometrically detectable MMC vs. 33% of those without. 
Enteral nutrition should be started with a slow infusion given continuously or, preferably, in a 
cyclical manner (during the night).389 In the most severe cases, PN is necessary to maintain 
nutritional support and an adequate level of hydration.443,444 If adult patients are exclusively 
dependent on PN, they should receive approximately 25 kcal / kg / day, and lipids should 
approximately supply 30% of total parenteral calories with 1.0-1.5 g / kg / day of proteins and 
dextrose covering the remaining caloric amount.443,444 Complications of PN, including liver 
failure, pancreatitis, glomerulonephritis, thrombosis and sepsis, are frequent causes of 
morbidity and mortality in any form of pediatric and adult CIPO.441,443 Individualized PN 
formulations with minimal amount of intravenous lipids can help reducing metabolic 
complications. A long-term PN does not seem to be associated with a significant increase in 
morbidity and mortality in CIPO.443 A retrospective analysis of 51 adult patients receiving 
PN for an average of 8.3 years showed 180 episodes of catheter-related sepsis, 9 of acute 
pancreatitis, 5 encephalopathy, and 4 patients progressing to cirrhosis.410 Oral intake was a 
major independent factor associated with better survival; thus, patients receiving PN should 
be allowed and encouraged to maximize oral intake as tolerated.443,445 
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Pharmacologic therapy 
The main aim of pharmacological treatment in patients with CIPO is to promote GI 
propulsive activity, thereby improving oral feeding, decreasing symptom severity, and 
minimizing SIBO24,389,390. 
The efficacy and main features related to various drugs, such as erythromycin, 
metoclopramide, domperidone, somatostatin analogues (octreotide and lanreotide), 
cholinesterases inhibitors (neostigmine and pyridostigmine), serotoninergic agents (such as 5-
hydroxytryptamine receptor 4 - 5-HT4 - agonists, e.g. prucalopride), prostaglandins and 
gonadotropin-releasing hormone analogues (leuprolide), have been reported in a number of 
pediatric and adult CIPO studies (Table 4).446-462 Erythromycin is a macrolide antibiotic 
mimicking the prokinetic hormone motilin that induces phase III of the GI MMC. It has 
shown to be effective (at a dose of 1.5-2 g/day in adults or 3-5 mg/kg/dose in children) in 
accelerating gastric emptying and improving symptoms of CIPO in case reports.390,446 
Metoclopramide and domperidone are two orthopramides which exert their prokinetic effects 
via type 2 dopamine receptor antagonism and increasing acetylcholine release from 
myenteric neurons. Although widely used in patients with functional gut disorders,393 there 
are no clinical data of for their use in CIPO. In addition, metoclopramide has a boxed 
warning by the Food and Drug Administration given the risk of tardive dyskinesia.447 
Octreotide, a long-acting analogue of somatostatin, is known to evoke phase III of the MMC 
in the small intestine of patients with scleroderma-related CIPO.448 Subcutaneous octreotide 
at a dose of 50 mcg / day resulted in a significant beneficial effect by relieving bacterial 
overgrowth in those patients.448 Further studies confirmed its efficacy showing reduction of 
nausea, vomiting, bloating, and abdominal pain, in a subset of idiopathic CIPO.449 The 
acetylcholinesterase inhibitor neostigmine has proven efficacy in colonic decompression in 
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adult and pediatric acute colonic pseudo-obstruction.450 Repeated use was successful in an 
adult patient with colonic pseudo-obstruction, although chronic use in children with CIPO 
has not been reported.451 The longer acting pyridostigmine has also been used with success in 
adult patients with CIPO.452 Among the newly discovered highly selective 5-HT4 receptor 
agonists, prucalopride has shown high bioavailability and lack of major interactions with 
other drugs as it is not metabolized by the cytochrome P3A4.453 Prucalopride exerts a 
significant enterokinetic effects 454 and a recent randomized, controlled trial on CIPO patients 
(3 patients had visceral myopathy; 1 visceral neuropathy; all treated with 2-4 mg once daily 
and followed for 48 weeks), showed beneficial symptomatic effects and lower use of 
analgesic drugs.455 Although the sample size was very small, the results of this study lend 
support to future multicenter controlled trials. 
SIBO is known to cause mucosal inflammation, which further impairs GI motility thereby 
contributing to nausea, bloating and abdominal distension.24,456.461 Various antibiotic 
regimens have been recommended.459 The treatment of choice usually involves the use of 
non-absorbable antibiotics, such as rifaximin.460 Nonetheless, most clinicians use 1- to 2-
week rotation of broad-spectrum antibiotics such as amoxicillin and clavulanic acid, 
gentamicin, and metronidazole, often combined with an antifungal compound (e.g., nystatin 
or fluconazole) followed by antibiotic-free periods.24 Notably, amoxicillin-clavulanate has 
been shown to combine antibiotic and enterokinetic properties in children.461 
Non-narcotic pain modulators, such as tricyclic antidepressants and serotonin-norepinephrine 
reuptake inhibitors, should be used with caution in CIPO patients due to their significant side 
effects (i.e. constipation and / or drowsiness). Starting with low doses followed by gradual 
increase is advisable to optimise the beneficial / side effect ratio. Gabapenentinoids 
(gabapentin and pregabalin) as well as peripherally acting μ-opioid receptor antagonists 
(PAMORAs) may represent promising alternatives to antidepressants; however studies on 
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CIPO patients are lacking. If visceral pain is untreatable, an extremely careful and cautionary 
use of opiates may be attempted. In children with CIPO and significant abdominal pain, 
transdermal buprenorphine (5 mcg / h), a μ- partial agonist and κ- and δ-opioid receptor 
antagonist, has shown adequate pain relief in 3 out of 4 patients.462 
In CIPO characterized by histopathological signs of marked inflammation / immune response 
within myenteric ganglia or throughout the neuromuscular tract, immunosuppressive drugs 
(e.g., steroids and azathioprine), might be an effective therapeutic options.403,404,407 Treatment 
of secondary forms of CIPO is mainly directed toward the underlying diseases (e.g., 
scleroderma, paraneoplastic syndrome, endocrine related disorders and many others) in 
addition to gut-directed therapy such as antibiotics, prokinetics and laxatives. 
 
Endoscopic and surgical therapy  
Decompression of distended GI segments via intermittent nasogastric suction, rectal tubes or 
endoscopy in both adults and children is an important therapeutic target.24,389,463 In some 
cases a “venting” enterostomy,464 typically placed endoscopically in the intestine, may be 
necessary. Recently, repetitive colonoscopic decompression has been successfully used as a 
bridge therapy before surgery in a pregnant woman with CIPO.465 In adult patients needing 
multiple endoscopic decompression, percutaneous endoscopic colostomy has been recently 
proposed as a feasible therapeutic option since it leads to durable symptom relief without risk 
of surgical intervention.466 The role of surgery in CIPO has been debated over the years. 
Although its use may be indicated as a tool to collect gut biopsy specimens for 
histopathology, the need for surgical therapy is sometimes required in emergency situations 
(massive bowel distension and perforation / ischemia). In a retrospective study on 63 adult 
patients there was an overall postoperative mortality rate of 7.9%, while CIPO-related re-
operation rate was 66% at 5 years.467,468 In children palliative procedures such as feeding / 
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venting gastrostomies and jejunostomies are mainly used to relieve symptoms in half of the 
patients.395, 469,470 It is important to keep in mind that when a surgical procedure is performed 
in a CIPO patient, full-thickness biopsies should be obtained and processed in dedicated 
centres. 
 
Transplantation 
Intestinal transplantation (isolated or multivisceral) is thought a reasonable therapeutic 
alternative for patients with CIPO who experience serious complications of PN (e.g. liver 
failure or recurrent sepsis arising from a central venous catheter). Other indications to 
transplantation are the inability to obtain venous access for PN and a poor quality of life 
while on PN.471 Patients with CIPO account for approximately 9% of the total intestinal 
transplants in both adults and children.472-475 Patients with CIPO should be evaluated for 
urological abnormalities and antibiotic prophylaxis for urinary tract infections is often 
required following transplant in these patients. The development of new immunosuppressive 
agents such as tacrolimus and novel induction agents (basiliximab, alemtuzumab, daclizumab 
and anti-lymphocyte globulins) have been associated with an increased overall survival rate 
and reduced graft rejection rate.476,477 Complications include acute rejection, opportunistic 
infections, e.g. cytomegalovirus and Epstein-Barr virus, and surgical morbidity including 
wound infections, stoma-related complications, graft ischemia, intestinal perforations, 
delayed gastric emptying, intestinal obstruction and biliary tract dilatation. 
In the presence of gastric involvement, modified multivisceral transplantation (stomach-
duodenum-pancreas plus small bowel) should be performed, even though some reports 
described the possibility to overcome this issue by transplanting the bowel and modifying 
surgically the stomach in order to facilitate gastric emptying.477 In children, PN-related liver 
failure represents an indication for combined transplant (liver and bowel), but a full 
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multivisceral transplantation (modified multivisceral graft plus liver) is rarely required. While 
isolated small bowel and liver-bowel transplantation have reasonable long term-results, 
multivisceral transplant should be performed only in very selected cases and in experienced 
centers. A study by the University of Miami including 98 adult patients undergoing 
multivisceral transplantation showed patient and graft survival rates of 49% and 47%, 
respectively, at a 5-year follow up.475 Italian experiences in adult patients with CIPO showed 
that isolated intestinal transplantation performed with different surgical approaches (in order 
to reduce the delayed post-surgical gastric emptying) had patient survival rates of 70% at 5 
years.477 These results are comparable to those of intestinal transplant in patients with 
underlying diseases distinct from CIPO.478-479 The same data have been reported by the 
United Network for Organ Sharing in children transplanted for CIPO with a 5-year survival 
rate of 57%, which is comparable to the overall survival rates for intestinal transplant.473 
These data were also recently confirmed by an Italian study with a reported survival rate for 
recipient of intestinal grafts, in any combination, of 75% at 2-year follow up.480 Notably, the 
catch-up growth seen in children following liver transplantation has not been demonstrated in 
children with intestinal transplantation. This is probably related to the severity of the illness 
at the time of presentation and the use of intense immunosuppression, including long-term 
steroids.472 
Concerning extra-digestive organ transplant, the allogeneic haematopoietic stem cell 
transplantation (AHSCT) can be used to restore thymidine phosphorylase enzyme function 
which is the key biochemical deficit in patients with MNGIE. However, so far the results of 
AHSCT at a 10-year follow up show that only about 30% of transplanted MNGIE patients 
are alive. This finding prompted research to focus on alternative tissue source of TP.481 Based 
on recent data displaying that the liver has high thymidine phosphorylase expression, we have 
recently transplanted a MNGIE patient with promising results.482 
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Table 2. Etiology and classification of CIPO. 
 
Primary Secondary Familial forms 
• No demonstrable 
etiopathogenetic causes 
• Neurological disorders 
• Metabolic diseases 
• Paraneoplastic syndromes 
• Neurotropic viruses 
• Autoimmune disorders  
• Celiac disease 
• Neuro-muscular disorders 
• Radiation enteritis 
• Endocrinological 
disorders 
• Drugs 
• Autosomal dominant 
✓ SOX 10* 
 
• Autosomal recessive 
✓ RAD21* 
✓ SGOL1* 
✓ TYMP* 
✓ POLG* 
 
• X-Linked 
✓ FLNA* 
✓ L1CAM* 
 
 
Notes: *, denotes mutation(s) to the indicated genes. FLNA, filamin; L1CAM, L1 cell 
adhesion molecule; POLG, polymerase DNA gamma; RAD21, cohesin complex component; 
SGOL1, shugoshin-like 1; SOX10, SRY-BOX 10; TYMP, thymidine phosphorylase.  
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Table 3. Main similarities and differences of CIPO in children and adults. 
 
 Children Adults 
Etiology Mainly idiopathic Half of cases are secondary to 
acquired diseases. 
Histopathology Myopathies and neuropathies Mainly neuropathies. 
Symptom onset In utero, from birth or early infancy 
with 65-80% of patients 
symptomatic by 12 months of age 
Median age of onset at 17 years. 
Clinical features Occlusive symptoms at birth and/or 
chronic symptoms without free 
intervals 
Urological involvement is 
commonly encountered ranging 
from 36-100% pediatric case series 
High risk of colonic and small 
bowel volvulus secondary to severe 
gut dilation, dysmotility, congenital 
bridles or concurrent malrotation 
Chronic abdominal pain and 
distension with superimposed 
acute episodes of pseudo-
obstruction.  
Urinary bladder involvement 
not so often reported 
Natural history Myopathic CIPO, urinary 
involvement and concurrent 
intestinal malrotation are poor 
prognostic factors 
The ability to restore oral 
feeding and the presence of 
symptoms < 20 years of age is 
associated with a low mortality; 
while, systemic sclerosis and 
severe/diffuse esophageal and 
intestinal dysmotility are 
associated with a high mortality 
Diagnostic approach Specialized tests (e.g. intestinal 
manometry) often difficult to 
perform; non-invasive, radiation-
free imaging tests are warranted 
Various methodological 
approaches usually starting from 
endoscopy and radiological tests 
up to more sophisticated 
functional exams 
Nutritional therapy To ensure normal growth 
extensively hydrolysed and 
elemental formulas are often 
empirically used to facilitate 
intestinal absorption 
To improve nutritional status 
and prevent malnutrition 
Pharmacological 
therapy 
Small number / sample size 
controlled trials 
Small number / sample size 
controlled trials; few 
conclusions can be drawn for 
most drugs. 
Surgical therapy Venting ostomies (although 
characterized by high complication 
rates) possibly helpful; surgery as a 
'bridge' to transplantation may be 
indicated in highly selected cases 
Venting ostomies can be 
helpful; resective surgery may 
be indicated in accurately 
selected patients (i.e. cases with 
proven segmental gut 
dysfunction) 
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Table 4. Compounds used for the treatment of CIPO in isolated cases or in small series of 
pediatric and adult patients. 
 
Drug and study Type of study Number and 
type of patients 
Dose and period 
of treatment 
Results Side effects 
Erythromycin 
Emmanuel et al. APT 2004 
 
Retrospective case 
series 
 
15 adults 
 
1.5-2 g/day, oral 
or i.v. 
 
6 responders (4 
myopathy) 
 
Not reported 
Metoclopramide No reported studies ----------- ---------- ---------- -------- 
Domperidone No reported studies ----------- ---------- ---------- -------- 
Octreotide 
Soudah et al. N Eng J Med 
1991 
 
 
 
 
Verne et al. Dig Dis Sci 
1995 
 
Case series 
 
 
 
 
Prospective case 
series 
 
5 adults with 
scleroderma 
related CIPO and 
SIBO 
 
14 adults 
 
100 mcg/day sc 
 
 
 
 
50 mcg/day sc, 
20-33 weeks in 
association with 
erythromycin 
 
reduces SIBO 
and improved 
symptoms 
 
 
5 responders 
 
Not reported 
 
 
 
 
Not reported 
Neostigmine 
Calvet et al. Am J 
Gastroenterol 2003 
 
Case report 
 
1 adult with 
chronic colonic 
pseudo-
obstruction with 
autonomic 
paraneoplastic 
neuropathy 
 
2 mg i.v. every 6 
hours 
 
Improvement 
of abdominal 
distension and 
discomfort and 
enteral diet 
could be 
resumed 
 
Not reported 
Pyridostigmine 
O’Dea et al. Colorectal Dis 
2010 
 
Case series 
 
7 adults 
 
10 mg b.i.d. and 
increased if 
required (max 30 
mg) orally 
 
7 responders 
 
Not reported 
Prucalopride 
Emmanuel et al. APT 2012 
 
RCT cross-over 
trial 
 
4 adults 
 
2-4 mg 
 
 
3 responders 
 
Not reported 
Antibiotics No reported studies ---------- ------------ --------- ---------- 
Non-narcotic pain 
modulators 
No reported studies ---------- ------------ --------- ---------- 
Buprenorphine  
Prapaitrakool et al. Clin J 
Pain 2012 
 
Case Series 
 
4 children 
 
10-15 mcg/h, 
transdermal, 1-3 
years 
 
3 responders 
 
Pruritus and 
erythema on 
the application 
site 
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Fig. 12. Synoptic view of the CIPO spectrum. 
A-B: illustrate the most severe pediatric cases with antenatal (in utero) evidence of multivisceral 
dilation (ultrasound picture A - from ref 60) i.e. often gut (B) and urinary system, commonly 
associated with an extremely poor prognosis. C-D: exemplify the CIPO phenotype with a rapid 
progression to intestinal dilatation (± urether / bladder) and failure often occurring as a result of an 
anamnestically reported gastroenteritis. Specifically, C depicts one of such case with massive bowel 
dilatation at the operative room and histopathology (inset to figure D) revealed an intense 
inflammatory (mainly lymphocytic) neuropathy (hence, myenteric ganglionitis. Alkaline phosphatase 
antialkaline phosphatase immunohistochemical technique using specific anti-CD8 monoclonal 
antibodies to identify a subset of T lymphocytes). E-G: are representative examples of another 
phenotype of the syndrome which may be observed in patients who experience more insidious mild 
and nonspecific symptoms progressing up to a classic CIPO over time. E shows a markedly distended 
abdomen of a 32-year old male patient who presented with a sub-occlusive episodes after some years 
of unspecific (dyspeptic-/irritable bowel syndrome-like) symptoms. Note the evident air-fluid levels 
detectable in up-right position at a conventional plain abdominal X-ray (F and G, antero-posterior and 
latero-lateral view, respectively). 
 
 
 
 
 
F 
B D 
G 
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Fig. 13. Manometric findings in CIPO. 
A: illustrates a monotonous pattern of phasic and tonic contractions in the small bowel of a 3-year old 
boy with a congenital CIPO. No migrating motor complexes (MMC) were detected during a 4-hour 
fasting study. B: shows an abnormal migration of the phase 3 of the MMC with a simultaneous 
component in the duodenum in a 7-year old girl affected by a non-congenital form of CIPO. 
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Take home messages: 
 
• There is no single diagnostic test or pathognomonic fidings for CIPO. The diagnostic 
work up aims to: i) exclude bowel mechanical obstruction; ii) identiy underlying 
diseases; iii) understand the underlying pathophysiological features. 
• Treatment is challenging and requires a multidisciplinary effort. 
• Key objectives in the management of patints with CIPO are to avoid unnecessary 
surgery, restore fluid and electrolyte balance, maintain an adequate caloric intake, 
promote coordinated intestial motiity, and treat bacterial overgrowth. 
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6.2 Management 
 
Modified from 
 
Chronic intestinal pseudo-obstruction:  
Progress in management?  
Giovanni Di Nardo, Tennekoon B. Karunaratne, Simone Frediani and  
Roberto De Giorgio 
Neurogastroenterol Motil. 2017 Dec;29(12). 
 
 
 
Introduction 
Chronic intestinal pseudo-obstruction (CIPO) is a rare and debilitating condition affecting 
about 100 infants per year and with an estimated incidence of 0.2-0.24 per 100,000 adults per 
year.24,25,390,392,398 CIPO patients show severe impairment of gastrointestinal (GI) propulsion 
ensuing symptoms / signs suggestive of partial or complete intestinal obstruction in the 
absence of any lesion occluding the intestinal lumen.24,25,390 Abnormalities in the GI neuro-
muscular region, including neuropathy (either intrinsic or extrinsic), myopathy and / or 
interstitial cells of Cajal (ICC) network changes, individually or in combination, contribute to 
severe dysmotility in CIPO. CIPO is still a challenge for clinicians and surgeons because of 
several reasons. First, most physicians fail to recognize CIPO patients early due to their 
limited experience; secondly, symptoms shown by CIPO patients are non-specific, thus they 
can be mistaken with other functional GI disorders. This drawback may lead patients to be 
subjected to inadequate management consist of ineffective, and potentially dangerous, 
surgical procedures; thirdly, CIPO is an ‘umbrella term’ covering a wide heterogeneity of 
patients, i.e. idiopathic, with no apparent cause underlying dysmotility, vs. secondary to 
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metabolic / endocrinological, neurological and paraneoplastic disorders; fourthly, the 
majority of CIPO patients have a sporadic disease, while few have a genetically-related 
background (latter presents with a syndromic phenotype, i.e. in addition to the GI tract, other 
organs, such as heart, brain and hematopoietic system, can be affected); finally, most CIPO 
patients show a variable outcome, i.e. some cases may remain stable over time, whereas 
others rapidly worsen to unavoidable parenteral nutrition as a unique measure to contrast 
severe malnutrition and death. Taken together these challenges and intrinsic difficulties 
surrounding CIPO hinder thorough phenotyping of patients, mechanistic studies and, more 
importantly, patients’ management.4,5 Nonetheless, recent data by Ohkubo et al., in the 
current issue of Neurogastroenterology and Motility, propose percutaneous endoscopic 
gastro-jejunostomy (PEG-J) as a method to alleviate symptoms (including pain) and 
nutritional consequences related to intestinal distension, a key feature of CIPO.483 
Prompt by the promising results of Ohkubo et al., the purpose of this minireview is to provide 
the readers with an update on clinical, diagnostic and management aspects of CIPO patients. 
 
Clinical features and diagnostic aspects 
Usually CIPO patients show severe symptoms and signs.413 Abdominal pain and distension 
are reported / detected in most (80%) cases. Although predominantly chronic in nature, these 
symptoms worsen during acute sub-occlusive episodes.24,392 Nausea and vomiting occur in 
75% and 40-50% of those cases can be associated with test-proven gastroparesis; constipation 
occurs in 40%, while diarrhea (rarely steatorrhea) occurs in about 20-30% of cases.24,406 The 
latter can be related to small intestinal bacterial overgrowth (SIBO) due to intestinal 
stasis.24,25392 Malnutrition, often requiring parenteral nutrition, is another significant clinical 
aspect in most CIPO cases.24,392,413 Esophageal dysmotility has been reported in 
approximately 70% of CIPO patients.436 Urinary bladder dysfunction (with or without 
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megacystis and megaureter) is a co-morbidity of CIPO, more commonly detectable in 
children with an underlying myopathic derangement of the GI tract.24,25,392,406 Finally, CIPO 
patients may develop depression and / or other psychological disorders as a consequence of 
the disabling nature of this condition as well as of the frustrating ineffectiveness of most 
prokinetic drugs.413 
So far, there is no single diagnostic test or pathognomonic finding indicative of this 
condition. A stepwise diagnostic approach, aimed to rule out mechanical causes of bowel 
obstruction, identify underlying diseases and understand the pathophysiological features, is 
recommended. Evidence of air-fluid levels and dilated bowel loops in a plain radiograph of 
the abdomen with patients in upright position is mandatory to suspect CIPO. In current 
clinical practice, computerized tomography (CT) scan of the abdomen is more accurate than 
conventional radiology to demonstrate air-fluid levels, while ruling out mechanical causes as 
well as intestinal wall adhesions. Transit time examination with contrast medium has been 
largely replaced by dedicated enterography with high-resolution CT or magnetic resonance 
imaging (MRI).243,42, Cine-MRI is an emerging, non-invasive, radiation-free method to assess 
and monitor GI motility. Using cine-MRI, Fuyuki et al. studied 33 patients and showed that 
the mean luminal diameter and contraction ratio in the CIPO group differed significantly 
from healthy volunteers. Their data suggest that cine-MRI is useful in detecting even subtle 
contractile impairment of the gut in patients with CIPO.242 Upper and lower GI endoscopy 
can contribute to exclude mechanical occlusions and collect routine biopsies. Mucosal 
sampling in the duodenum can help to rule out those very rare cases in which an underlying 
celiac disease can be associated with dysmotility, whereas biopsies throughout the upper and 
lower gut can be useful to unravel an eosinophilic gastroenteropathy.389 Mucosal biopsies can 
also be exploited to obtain the submucosal layer with associated neural plexuses.484 This 
approach may become of aid to show neural changes in patients with severe dysmotility. 
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Finally, wireless motility and endoscopy capsules have been proposed for evaluating patients 
with functional bowel disease.245,430 However, the role of these techniques in the diagnosis of 
CIPO has not yet been established and their use can be even potentially hazardous if a 
mechanical obstruction has not been firmly excluded. When imaging and endoscopy fail to 
show causes of intraluminal or extraluminal mechanical obstruction, secondary causes of 
potentially treatable pseudo-obstruction should be excluded. Screening tests for diabetes 
mellitus, neurotropic viruses (e.g., cytomegalovirus or Epstein-Barr virus), celiac disease, 
connective tissue and skeletal muscle disorders (antinuclear antibody, anti-double-stranded 
DNA and SCL-70, creatine phosphokinase, aldolase), and thyroid function should be 
performed. Other tests include serology for Chagas’ disease, urinary catecholamines and 
porphyrins to rule out pheochromocytoma and porphyria, respectively, and enteric neuronal 
autoantibodies (e.g. anti-nuclear neuronal antibodies – ANNA-1 – also referred to as anti-Hu 
antibodies based on molecular target) for paraneoplastic syndrome.24,25 
Small bowel manometry provides pathophysiologically relevant information on the 
mechanisms underlying dysmotility in CIPO patients (e.g. neuropathic vs. myopathic 
patterns).24,392,413 In some exceptional cases with an apparently unremarkable imaging, an 
accurate manometric assessment may reveal a pattern (i.e., discrete clustered contractions) 
suggestive of a recent stenosis of the gut not yet accompanied by bowel loop dilatation above 
the blockade.24,25,392 Manometric findings does not affect management strategies in CIPO 
patients, although the evidence of a propulsive pattern (i.e. migrating motor complexes) 
predicts successful adaptation to jejunal feeding.433 Esophageal manometry can be useful to 
predict survival, home parenteral nutrition requirement and inability to maintain sufficient 
oral feeding.436 Anorectal manometry is indicated when the clinical picture is characterized 
by intractable constipation and marked colonic distension in order to exclude Hirschsprung's 
disease.24 A manometric assessment of the entire GI tract, including colon, has been deemed 
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helpful to plan for isolated or multivisceral transplantation in the most severe forms of 
pediatric CIPO.25 
Minimally invasive procedures, e.g. laparoscopic surgery or endoscopic approaches have 
contributed to refuel interest for histopathological analysis of full-thickness biopsies.485 
Recently, Valli et al. used endoscopic, full-thickness resection (eFTR) with a full-thickness 
resection device under moderate propofol sedation in four CIPO patients with suspected 
neuromuscular gut disorders. Large colonic full-thickness tissue samples of excellent quality 
did identify neuro-muscular changes in all four patients with no adverse events. These data 
suggest that eFTR allows safe and minimally invasive collection of full-thickness biopsies 
suitable for histological analysis in patients with neuromuscular gut disorders.486 Guidelines 
proposed by an international working group have helped standardizing technical aspects 
(tissue collection and processing) and histopathological reporting of a variety of gut 
neuromuscular disorders, including CIPO.2 
 
Management 
The management of CIPO patients is aimed to avoid unnecessary surgery, restore fluid and 
electrolyte balance, maintain an adequate caloric intake, promote coordinated intestinal 
motility, and treat SIBO and associated symptoms (i.e. abdominal pain and distension). As 
experienced in daily practice, current therapeutic approaches are not very effective and this 
generate frustration in patients and physicians. The following are some indications 
recommended to improve the management of patients with CIPO. 
Patients with adequate intestinal absorption should be encouraged to take small, frequent 
liquid meals (5-6 / day), while avoiding high -fat, -residue (delaying gastric emptying) and 
high -lactose / -fructose (evoking bloating / discomfort) foods. Vitamins A, D, E and K as 
well as B12 and folic acid should be supplemented when needed. Elemental feedings and 
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dietary supplements with medium-chain triglycerides can be used in combination with 
aforementioned dietary changes.24,25,389,390 In cases with inadequate oral intake, enteral 
nutrition with standard, non-elemental formula should be considered. Before placing a 
permanent feeding tube, a trial of nasogastric or nasojejunal feeding should be attempted 
using an enteral formula at a rate sufficient to provide an adequate caloric support. When 
delayed gastric emptying is present, bypassing the stomach and directing the feeding into the 
small intestine is recommended. Enteral nutrition starting with a slow infusion and 
continuous feeding or cyclical feeding (e.g. overnight) is preferred to large bolus 
feedings.24,25,389,445 In most severe cases, total parenteral nutrition (TPN) is necessary to 
maintain nutritional support and an adequate level of hydration. Complications of TPN, 
including liver failure, pancreatitis, glomerulonephritis, thrombosis and sepsis, are frequent 
causes of morbidity and mortality in CIPO. 24,25,389,445 Personalized TPN formulations, with 
minimal intravenous lipid infusion, can help reducing metabolic complications. In any case, a 
long-term TPN does not seem to be associated with a significant increase in morbidity and 
mortality in CIPO as compared to other conditions requiring TPN.410,441 
Pharmacological treatment should be one of the most important options for patients with 
CIPO since it is aimed to restore gastrointestinal propulsion, thereby leading to tolerate oral 
feedings, while decreasing symptom severity and the occurrence of SIBO. Unfortunately, due 
to limited number of trials, most of which based on few patients, the overall efficacy of 
prokinetics yielded unsatisfactory results.24,25 Nonetheless, some data should be mentioned as 
a basis to help clinicians in practice. Erythromycin, a macrolide antibiotic, showed efficacy at 
a dose of 1.5-2 g / day in adults, or 3-5 mg / kg / day in children, in accelerating gastric 
emptying and ameliorating symptoms of CIPO.390,446 Metoclopramide and domperidone are 
known to exert their prokinetic effects via type 2 dopamine receptor antagonism and by 
increasing acetylcholine release in the enteric nervous system. Although widely used in most 
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dysmotilities, clinical data for their use in CIPO are lacking. Metoclopramide should be used 
only for short-term period, as its chronic administration leads to a significant risk of tardive 
dyskinesia.447 Octreotide is a long-acting analogue of somatostatin that at a dose of 100 mcg 
subcutaneously / day resulted in a significant beneficial effect by relieving bacterial 
overgrowth and reducing pain, nausea and bloating in scleroderma-related CIPO patients.448 
Repeated intravenous use of acetylcholinesterase inhibitor neostigmine (at a dose of 8 mg / 
day) was successful in an adult patient with chronic colonic pseudo-obstruction.451 The oral 
formulation of acetylcholinesterase inhibitor, pyridostigmine (at a starting dose of 20 mg / 
day), has also been used with success in some adult CIPO patients.452 Prucalopride, a highly 
selective 5-hydroxytryptamine-4 (5-HT4) receptor agonists lacking cardiotoxicity (which 
caused cisapride to be withdrawn), exerts significant enterokinetic effects. In a recent 
randomized controlled trial with CIPO patients, prucalopride showed beneficial effects on 
symptoms.455 In practice, the association of different prokinetic drugs and / or their rotation 
may be a strategy useful to increase therapeutic efficacy, while minimizing tachyphylaxis and 
side effects. Various antibiotic regimens have been recommended for SIBO treatment.459 
Non-absorbable antibiotics, such as rifaximin, are nowadays the first choice, although broad-
spectrum antibiotics, such as amoxicillin and clavulanic acid, gentamicin, and metronidazole, 
often with an antifungal compounds (e.g., nystatin or fluconazole), can be used for 1- to 2-
week cycles alternated with antibiotic-free periods.34,389,459 Recently, amoxicillin-clavulanate 
has been demonstrated to accelerate intestinal transit in children, thus representing an 
interesting therapeutic option combining antibiotic and prokinetic effects.461 
Visceral pain is major concern in patients with CIPO. The ideal treatment would be the use of 
non-narcotic pain modulators, such as tricyclic antidepressants, serotonin-norepinephrine 
reuptake inhibitors and GABA analogues, that anyway require caution because of their 
significant side effects, such as constipation and / or drowsiness. Starting with low dose 
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followed by gradual increase is recommended to optimise the beneficial effect. In patients 
with chronic and unsustainable visceral pain, physicians may carefully consider the use of 
opiate drugs paying attention to the known anti-motility effects of these compounds.25 
Since bowel distension is commonly associated with pain and other symptoms in CIPO 
patients, decompression therapy represents one of the key aspects in CIPO management. 
Apart from neostigmine (mentioned above) proved to be useful in reducing dilatation in 
patients with acute colonic pseudo-obstruction (also referred to as Ogilvie’s syndrome),487 so 
far there are no pharamacological remedies to achieve an effective, non-invasive 
decompression in CIPO. Current therapeutic strategies include conventional methods, i.e. 
intermittent nasogastric suction, rectal tubes or colonoscopic decompression, and surgical 
procedures, such as feeding / venting gastro- / jejunostomies (or other intestinal ‘ostomies’), 
which overall evoke symptom relief in about half of the patients.429,464,465,468,469 However, 
conventional methods are limited by temporary efficacy in GI decompression, whereas 
surgery shows a high rate of stoma prolapse along with a considerable risk of dehydration 
due to enteric fluid loss.468,469 Nonetheless, recent data in this issue of Neurogastroenterology 
and Motility provide new insights into the management of patients with CIPO by using 
percutaneous endoscopic gastrostomy (PEG), a commonly applied method for long-term 
home enteral nutrition.483,488 However, PEG is often associated with aspiration pneumonia, 
therefore current management suggests a gastro-jejunostomy tube insertion via PEG (hence, 
PEG-J) as a measure to prevent such a life-threatening complication.489 Furthermore, both 
PEG / PEG-J have been exploited to decompress patients with mechanical occlusion of the 
bowel, such as cases with malignant bowel diseases.488 Based on this background, Ohkubo 
and co-workers tested whether PEG-J could be an effective measure for intestinal 
decompression and symptom improvement in CIPO patients. The authors enrolled seven 
CIPO patients with a severe symptom profile / manifestations refractory to any 
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pharmacological treatment. All patients required at least once nasogastric tube or trans-nasal 
small intestinal tube insertion for intestinal decompression. PEG tube (24F caliber) was 
placed using the introducer method.483,488 If distended small bowel loops were interposed 
between the stomach and the abdominal wall, a preceding decompression was obtained via 
trans-nasal small intestinal tube. After 7 days of gastropexy, a PEG-J tube (with a caliber of 
24F and length of 60 cm) was inserted through the PEG fistula under fluoroscopy upon 
removal of the PEG button. Evaluation of subjective symptoms (number of days without 
abdominal symptoms in a month) and the assessment of objective nutritional status (body 
mass index and serum albumin level) were evaluated in each patient before and 3 months 
after PEG-J. PEG placement and PEG-J tube insertion were performed without major 
procedure-related complications and both were well tolerated by all patients. Also, oral intake 
was well maintained or improved in all patients after the procedure. A significant decrease in 
the number of days without abdominal symptoms was observed in 6 out of 7 patients, along 
with the improvement of wasting and malnutrition in all patients. Plain abdominal 
radiographs demonstrated a reduction of abdominal distension, whereas the total volume of 
the small intestine did not significantly change compared to pre-PEG-J status. One patient 
developed severe reflux esophagitis, while another had a chemical dermatitis around the 
PEG-J fistula during follow-up and in both cases conservative therapy with proton-pump 
inhibitors and ointment therapy, respectively, was effective. None of the treated CIPO 
patients had ulcer formation and perforation due to the tube placement at 1-year follow-up 
after the procedure. PEG-J is therefore suggested as a safe and minimally invasive method to 
improve abdominal symptoms, including pain, and nutritional status in CIPO.6 Depending on 
symptom fluctuation, the use of PEG-J can be modulated (open vs. closure intervals) ensuing 
control of fluid output and avoiding dehydration, a common complication of conventional 
jejunostomy / ileostomy. Clearly, this study, based on few cases of CIPO, requires further 
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investigation. First, a better characterization of CIPO patients is required. For example, the 
study by Ohkubo et al. does not specify which patient category is more suitable to PEG-J 
insertion based on underlying pathology (e.g., most severe cases - myopathic CIPO - may 
have a worse outcome than neuropathic CIPO to the procedure). Second, a thorough and 
better symptom and objective data assessment is highly recommended. Overall, patients with 
CIPO are unlikely to show a complete remission of symptoms, therefore new studies using 
this endoscopic approach should require symptom questionnaire and severity score to 
determine the actual beneficial effect due to PEG-J. Finally, long-term trials designed on a 
larger cohort of CIPO patients are necessary to minimize the ‘heterogeneity effect’ of CIPO, 
which may hinder the plausible efficacy of PEG-J. 
 
 
Take homes messages: 
• Since most drugs failed to restore gastrointestinal coordinated motility, nutritional 
support, fluid/electrolyte replacement, and antibiotics are still mandatory as life-
saving measures. 
• Promising data indicate that percutaneous endoscopic gastro-jejunostomy (PEG-J) can 
be proposed as a measure for intestinal decompression in CIPO, thereby improving 
symptoms and preventing malnutrition. 
 
  
103 
 
Chapter 7. 
 
COMPARISON BETWEEN SMALL BOWEL MANOMETRIC PATTERNS AND 
FULL-THICKNESS BIOPSY HISTOPATHOLOGY IN SEVERE INTESTINAL 
DYSMOTILITY 
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ABSTRACT 
Background: Intestinal manometry is the current standard for direct evaluation of small 
bowel dysmotility. Patients with abnormal motility can either be diagnosed of pseudo-
obstruction when there are radiological findings mimicking mechanical intestinal obstruction 
or of enteric dysmotility when these findings are absent. The aim of the present study was to 
prospectively compare small bowel manometric abnormalities with histopathological findings 
in intestinal full-thickness biopsies in patients with severe dysmotility disorders. 
Methods: We investigated 38 patients with intestinal manometry and a subsequent full-
thickness intestinal biopsy. Manometric recordings were read by 4 investigators and a 
diagnostic consensus was obtained in 35 patients. Histopathological analysis, including 
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specific immunohistochemical techniques of small bowel biopsies was performed and 
compared to manometric readings. Key Results. Patients with abnormal intestinal 
manometry had abnormal histopathological findings in 73% of cases. However, manometric 
patterns did not match with the specific neuromuscular abnormalities. Among patients with a 
neuropathic manometry pattern and abnormal histopathology, only 23% had an enteric 
neuropathy, whereas 62% had neuromuscular inflammation and 15% an enteric myopathy. 
On the other hand, patients with a myopathic manometry pattern all had abnormal 
histopathology, however none of them with signs of enteric myopathy. 
Conclusion & Inferences: Small bowel dysmotility detected by intestinal manometry is 
often associated with abnormal neuromuscular findings in full-thickness biopsies. However, 
there is no correlation between the specific manometric patterns and the histopathological 
findings. 
 
INTRODUCTION 
Intestinal manometry remains the current standard for recognition of gastrointestinal motility 
disorders, although other methods such as transit scintigraphy, functional magnetic resonance 
and endoluminal image motility analysis are further expanding diagnostic capabilities and 
general understanding of these conditions.244,245,490-492 Beyond the classic clinical picture of 
chronic intestinal pseudo-obstruction (CIPO), characterized by recurrent episodes or 
sustained radiological findings mimicking mechanical obstruction,393 intestinal manometry 
has documented an additional group of patients suffering from disabling abdominal pain and 
other severe abdominal symptoms in the absence of clinical signs of mechanical bowel 
obstruction. This group of patients with abnormal contractile activity has been named enteric 
dysmotility (ED).16,411 The clinical presentation of ED corresponds to that of severe 
functional gastrointestinal disorders (SFGID).413 Both CIPO and ED are associated with 
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enteric neuromuscular abnormalities shown by histological and immunopathological analysis 
of full-thickness biopsies of the small bowel usually obtained via laparoscopy.1,485  
Neither intestinal manometry nor small bowel neuromuscular pathology are fully 
standardized diagnostic methods and both, technical details and criteria for interpretation vary 
from center to center.25,493 To some extent, this uncertain status results from the relative rarity 
of patients with a clinical expression of gastrointestinal dysmotility severe enough to justify 
invasive diagnostic procedures such as intestinal manometry and full-thickness biopsy. It also 
derives from the relative sophistication and complexity of both technologies, manometry and 
neuromuscular pathology, that confines them to a relatively small cluster of university 
medical centers around the world. Moreover, only a handful of published studies over the last 
15-20 years have attempted to correlate intestinal dysmotility patterns, recorded 
manometrically, with morphological changes subsequently investigated in full-thickness 
bowel biopsies.11,392,485,494,495  
The aim of the present study was to prospectively compare small bowel manometric 
abnormalities with subsequent histopathological findings in full-thickness intestinal biopsies. 
The former were evaluated by consensus, among an international group of academic 
gastroenterologists routinely applying intestinal manometry for diagnostic purposes. Enteric 
neuromuscular abnormalities were assessed by a group of experienced gut neuromuscular 
pathologists at a single medical center. The comparison between manometric findings and 
neuromuscular pathological findings was performed on a group of patients presenting with 
severe and chronic clinical manifestations of gastrointestinal dysmotility. Our hypothesis was 
that abnormal manometric patterns would predict histopathological abnormalities found on 
subsequently obtained intestinal tissue specimens. 
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MATERIAL AND METHODS 
Patients 
Thirty eight patients (16 to 65 years old; 32 females and 6 males) with severe and chronic 
clinical manifestations of gastrointestinal dysmotility participated in the study. Patients were 
recruited and clinically evaluated at the Vall d’Hebron University Hospital in Barcelona 
between November 1999 and November 2009. During this time span, all consecutive patients 
who underwent a manometric study and subsequently a full-thickness biopsy were included 
in the study. Full-thickness intestinal biopsy was obtained only in patients with a clinical 
diagnosis of an idiopathic severe intestinal motility disorder. Therefore, high severity was the 
enforced selection criterion that delimited the consecutive series of patients included in this 
study. Patients with motility disorders secondary to infectious, neurological, metabolic, 
systemic-autoimmune and paraneoplastic conditions were excluded. Anorexia nervosa was 
specifically excluded in all patients with malnutrition by a psychiatric examination. 
The clinical diagnosis of CIPO was established on the basis of a chronic (>3 months), severe 
symptom complex mimicking mechanical small bowel obstruction, as well as (at least on one 
occasion) radiological evidence of air-fluid levels or dilated small bowel loops. Thus, patients 
presented with abdominal pain and distension associated with nausea, vomiting, bloating and 
malnutrition. These clinical manifestations occurred episodically or continuously. Presence of 
mechanical obstruction had been excluded by conventional imaging studies or by prior 
exploratory abdominal surgery.  
The clinical diagnosis of SFGID with inability to maintain normal body weight was 
established on the basis of chronic (>3 months) persistent or recurrent symptoms in the 
absence of episodes mimicking mechanical intestinal obstruction and of associated organic, 
systemic or metabolic diseases potentially responsible for the digestive manifestations. 
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Inability to maintain a normal body weight was defined by a BMI <18.7 Kg m-2 (in women) 
or <20.1 Kg m-2 (in men). 
The study protocol was approved by the Ethics Committee of the University Hospital Vall 
d’Hebron and all patients gave written informed consent. 
Intestinal manometry 
All study patients underwent intestinal manometry according to a standard stationary 
procedure. After an overnight fast, a manometric tube (9012X1106 Special Manometric 
Catheter; Medtronic, Skovlunde, Denmark) was orally introduced into the jejunum under 
endoscopic guidance. Eight water-perfused manometric ports (five at 10 cm intervals and the 
proximal three at 1 cm intervals) were positioned from the proximal duodenum to the mid-
jejunum with fluoroscopic assistance. Recordings were obtained for 3 hours during fasting 
and 2 hours after ingestion of a solid-liquid meal (450 kcal). Patients with gastroparesis or 
unable to finish the meal alternatively received a liquid meal (Ensure HN; Abbott, Zwolle, 
The Netherlands; 1 kcal/mL) infused through the most proximal intestinal manometric port at 
2 kcal/min throughout the two-hour postprandial period. 
Manometric recordings were made available to each of 4 investigators for review in both 
paper and electronic format. All 4 investigators are academic gastroenterologists (F.A., 
JR.M., R.C., V.S.) whose names and institutions are provided in the heading as co-authors. 
Investigators read each manometric recording without prior knowledge of patient’s identity 
and clinical details. All assigned investigators reviewed the entire group of manometric 
recordings and classified each case as neuropathic, myopathic, occlusive, indeterminate or 
normal based on the established criteria (listed in Table 5). The occlusive pattern was 
considered indicative of intestinal neuropathy in the absence of mechanical obstruction.496   
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Intestinal tissue samples 
Full-thickness biopsy specimens were obtained from the small bowel either by laparoscopy or 
laparotomy subsequently to the performance of the intestinal manometric studies. The time 
interval between the manometric study and collection of intestinal biopsies at surgery ranged 
from 3 to 38 months, median 10 months. 
In each patient a single circular segment (5 cm long) was obtained from the proximal 
jejunum, except in those cases with segmental dilatation in whom the biopsy was obtained 
from the most dilated segment. Immediately after resection, tissue samples were placed in 
10% formalin to later be embedded in paraffin wax according to standard protocol for tissue 
processing. Histopathological review was conducted by one of the investigators (R. De G) 
and his team (A. G. and E. B.) at the University of Bologna, Italy. Histopathological material 
was examined without prior information about clinical and motility test outcomes. All 
biopsies were first analyzed to exclude associated pathological findings such as malignancy, 
dysplasia, villous atrophy or mucosal inflammation. Specific enteric neuromuscular 
evaluation was performed on the hematoxylin and eosin (H&E)-stained sections to assess the 
overall structure of ganglia, myenteric and submucosal neuronal cell bodies and fibers, glia 
and smooth muscle cells. When needed, other standard histological stains (e.g. Masson 
trichrome) were applied to detect additional tissue changes such as fibrosis. Finally, 
immunohistochemical techniques to analyze structural markers of the enteric neuromuscular 
component were used. We used specific antibodies to: neuron specific enolase (NSE) and 
synaptophysin (both general neuronal markers), BCL-2 (as a marker of cell survival), S100  
(glial cells), c-Kit (interstitial cells of Cajal, ICC), alpha-smooth muscle actin ( -SMA) 
(smooth muscle cells), CD45 (leukocytes), CD3 (general T lymphocyte marker), CD4 and 
CD8 (markers of T lymphocyte subsets, i.e. “helper” and “suppressor”, respectively). Finally, 
an anti-tryptase antibody was used to detect mast cells (all antibodies are listed in the Table 
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6). The immunohistochemical techniques used in this study have been performed according 
to standardized and widely validated protocols.440  
Four histopathological patterns, identified according to the London classification were 
recognized.2 Main findings for each of these patterns are detailed: 
- Apparently normal: no detectable changes in the neuromuscular layer using 
conventional histochemical staining and immunohistochemistry; 
- Myopathy: muscular degeneration with cell swelling, vacuolization or atrophy; 
fibrotic replacement of smooth muscle (detectable by conventional staining, such as 
H&E, and immunohistochemical approaches, e.g. alpha-SMA immunoreactivity 
abnormalities); 
- Neuropathy: overt ganglionic abnormalities as identified by traditional tinctorial 
staining (H&E) and immunohistochemical approaches (pan-neuronal markers); 
altered neuronal survival was identified by assessing BCL-2 expression in perikarya 
and nerve fibers (a feature which has been already associated with increased neuronal 
apoptosis);497 
- Inflammatory neuro-myopathy:  characterized by lymphocytic infiltrate in muscle 
layers (leiomyositis) and / or neuronal ganglia (ganglionitis) (visualized by anti-CD3, 
-CD4 / -CD8 immunolabeling); or mast cell or eosinophil infiltration  throughout the 
neuromuscular structures (detected by tryptase immunolabeling or via conventional 
H&E staining, respectively).402 
 
Statistical analysis 
Statistical analysis was performed using the SPSS 12.0 for Windows statistical package. 
Distribution of abnormalities between groups was evaluated by the chi-square test. Predictive 
values (with 95% exact confidence intervals) were calculated as the probability of abnormal 
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histopathology when manometry was abnormal (positive predictive value) and of normal 
histopathology when manometry was normal (negative predictive value). Concordance 
between the outcomes of manometry and histology was evaluated with Cohen’s Kappa (κ) 
agreement analysis. Differences were considered significant at a P value < 0.05. 
 
RESULTS 
Clinical features 
Patients were classified into two categories depending on the predominant clinical pattern: 21 
patients (18 females; age range: 16-77) presented with symptoms and signs of CIPO and the 
remaining 17 (14 females; age range: 24-61) manifested a variety of symptoms compatible 
with SFGID, i.e. patients that could not maintain a normal body weight along with severe 
upper and lower GI symptoms (Table 7). 
Manometric study 
Manometry recordings obtained from the 38 patients included in the study were reviewed by 
each of the expert investigators. Investigators were instructed to read each patient 
manometric tracing according to the strict criteria described in Table 5. A diagnostic 
consensus was obtained in 35 of the 38 patients (92% agreement). These 35 patients were 
included in the subsequent comparison manometry vs. histopathology results. 
We found no apparent correlation between manometric features and clinical presentation. As 
shown by Table 3, there was a similar proportion of patients with a neuropathic or an 
undetermined manometric pattern in both the CIPO and SFGID clinical groups. The 
myopathic or occlusive patterns were only observed in patients with CIPO. It should be noted 
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that all 3 patients who showed a myopathic pattern on manometry had dilated small bowel 
loops on imaging studies. 
Histopathological findings 
Ten of the study patients (7 females; age range: 24-61) showed an apparently normal small 
bowel histopathology. Another group of 5 patients (3 females; age range: 32-70) showed 
histological features compatible with enteric neuropathy (Fig. 14) and other 4 patients (3 
females; age range: 29-53) showed features of myopathy (Fig. 15). All remaining 16 patients 
(12 females; age range: 16-77) had an inflammatory neuro-myopathy with a predominantly 
lymphocytic or eosinophilic or mast cell infiltrate in the neuro-muscular layer (Fig. 16 and 
17). 
There were no differences in terms of pathological findings between CIPO and SFGID 
groups (Table 7). 
Comparison between manometric findings and histopathological features 
Among the 21 patients with a neuropathic pattern on manometry (Fig. 18), there were 3 
patients with histological evidence of enteric neuropathy, 8 patients with inflammatory neuro-
myopathy and 2 patients with myopathy. The remaining 8 had an apparently normal 
architecture of the neuromuscular layer at the histopathological evaluation. 
Two of the 3 patients with a myopathic motility pattern on manometry (Fig. 19) showed 
histopathological features of neuropathy and the third patient showed an inflammatory neuro-
myopathy. Furthermore, all 3 patients with an occlusive manometric pattern (Fig. 20) also 
showed an inflammatory neuro-myopathy at histology. 
All 3 patients with an indeterminate manometry had abnormal histopathology: 1 myopathy 
and the other 2 an inflammatory neuro-myopathy. Finally, among the 5 patients who 
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displayed a normal manometric pattern there was a mixture of histopathological features: 2 
patients were apparently normal, 2 showed inflammatory neuro-myopathy, and the remaining 
patient showed myopathy.  
Cross tabulation between manometric and histopathological findings is shown in Table 8. 
The degree of agreement between both techniques was non-significant by Cohen’s κ test (κ = 
0.09, p = 0.541). The positive predictive value of manometry to detect abnormal 
histopathology was 73% (66-79), whereas the negative predictive value was 40% (12-77).  
 
DISCUSSION 
The present study addresses a relevant clinical question, that is, what is the value of 
manometric findings to predict abnormal histopathology on a subsequent full-thickness 
biopsy performed in patients with a major chronic intestinal motor disorder. 
The results suggest that about three quarters of patients with a definitely abnormal intestinal 
manometry will show an abnormal intestinal histopathology if biopsied. This observation 
may be particularly useful when clinicians ponder whether to biopsy a patient with a 
symptomatic motility disorder given the fact that full-thickness intestinal biopsy, be it 
performed via laparoscopy or laparotomy, is an invasive procedure with significant 
morbidity. On the other hand, the small number of patients with a normal manometry in our  
study is insufficient to either support or challenge Törnblom et als observation that patients 
with or without abnormal manometry show similar histological degrees of inflammatory 
neuromyopathy.6  
We found no correlation between the manometric pattern and the histopathological findings. 
The so called myopathic manometric pattern did not correspond with a myopathic condition 
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in any of the three patients in whom it was observed. The predictability of the neuropathic 
pattern was not more specific since it corresponded with a mixture of histopathological 
patterns: myopathy, neuropathy, or inflammatory neuro-myopathy. The present observations 
suggest that the various manometric patterns currently accepted as indicative of abnormal 
intestinal motility do not consistently match each of the various histopathologic patterns 
observed in biopsy tissue as currently defined. However, one may argue that manometry only 
records occlusive contractions and thus the so called myopathic pattern may simply reflect 
the inability of overdistended bowel loops to produce occlusive contractions, which is not 
necessarily due to a muscular disorder. On the same line, a clear cut enteric neuropathy was 
detected at histopathology in only a minority (about 14%) of patients with a neurogenic 
manometric pattern. Nonetheless, it is possible that neuro-muscular inflammation may affect 
neuronal activities and thereby induce neuropathic patterns on manometry. Clustered 
contractions have been recorded not only in mechanical obstructions, but also in severe forms 
of irritable bowel syndrome.498,499 These data may link with our observation of inflammation 
at histology in all 3 patients with an occlusive manometric pattern. 
Concerning inflammation, a special consideration goes to the mast cell infiltrate detected in 
tissue biopsies of about half of the investigated cases. Since mast cells play an important role 
in mucosal inflammation and immune activation, their localization within the gut neuro-
muscular compartment provides support to gastrointestinal sensory-motor dysfunction and 
symptom generation. A predominant mast cell infiltration in the deeper layers of the gut has 
been reported in patients with severe gut dysmotility, including those with severe slow transit 
constipation undergoing surgery.500  
It is of interest to examine the relevance of clinical features in relation to both manometric 
patterns and histopathology. Manometric data gathered by Cogliandro et al. suggest that 
CIPO patients exhibited more frequently a manometric pattern characterized by intestinal 
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hypomotility, abnormalities in activity fronts and an inadequate response to the meal by 
comparison to patients with SFGID.9 However, our study does not show substantial 
differences between CIPO and SFGID clinical groups. Indeed, all the reported abnormal 
manometric patterns and indeterminate patterns of uncertain significance were observed in 
similar proportions. Clinical features also did not seem to reflect specific histological 
findings. Both CIPO and SFGID groups had similar proportions of patients with each of the 
four characteristic morphological patterns identified in the present study. 
We recognize some weaknesses in our study. First, the small number of patients included due 
to the relative rarity of gut motility disorders, even at established referral centers, with a high 
enough degree of clinical severity and quality of life impairment to warrant invasive 
diagnostic procedures such as those applied in our patient cohort, could have contributed to a 
“limited challenge bias”. Moreover, the rarity of some conditions in adulthood, for instance 
degenerative myopathies (4 cases in our study), could make our sample size insufficient to 
assert the predictive value of manometry in these small groups of patients. Second, to 
standardize the manometric procedure employed in our patient cohort, we included only 
patients studied in one of the participating centers. We do not know whether other intestinal 
manometry protocols, such as 24-hour ambulatory manometry, would provide similar 
information or produce different outcomes. In addition, contrary to the consensus approach 
adopted for assessment of manometric evidence, histopathology was evaluated by a single 
investigator, albeit supported by a team of pathology associates. Finally, histopathological 
analysis, although supported by immunohistochemical techniques, did not include 
quantitative, e.g. assessment of number of perykaria / ganglion in each section for each 
biopsy. The quantitative approach was beyond the purpose of the present study which will be 
the objective of further studies. 
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Even accepting the above shortcomings, our data suggests that intestinal manometry helps to 
objectively diagnose intestinal dysmotility in patients with severe and long-standing 
abdominal symptoms of uncertain origin. In addition, an abnormal manometry implies a 
relatively high probability of subsequently finding neuro-muscular histological abnormalities 
on full-thickness intestinal biopsies. 
Table 5. Diagnostic criteria for abnormal intestinal manometry. 
NEUROPATHIC PATTERN 
- Abnormal configuration of Phase III: Tonic rises of baseline pressure over 30 mmHg 
amplitude ≥ 3 minute duration.  
- Abnormal propagation of Phase III: Simultaneous or retrograde propagation over ≥ 20 cm 
segment of small bowel. 
- Inability of an adequate meal to induce a normal feed pattern: No changes in activity during 
postprandial period (no fed pattern) or phase III-like activity during postprandial period 
(while disregarding the first 20 minute after beginning of meal). 
- Bursts: At least one period of ≥3 minutes, or two periods of ≥2 minute duration with 
continuous high amplitude (≥20 mm Hg) and high frequency (10 -12/min) phasic pressure 
activity not followed by motor quiescence. 
- Sustained contractions: Prolonged (≥30 minutes duration), high amplitude (≥20 mm Hg) and 
high frequency (10/min) phasic pressure activity that occurs in a segment of intestine while 
normal or reduced contractility is simultaneously recorded at other levels. 
 
MYOPATHIC PATTERN 
- Hypomotility: Low amplitude contractions (i.e., contractions with amplitude <10 mm Hg) or 
contractions with amplitude <20 mm Hg also during phase III. 
 
OCCLUSIVE PATTERN 
- Minute rhythm: intermittent periodic activity (shorts bursts repeating every 1-3 min) 
occurring simultaneously in recording sites at least 20 cm apart, at least during 30 minutes in 
postprandial period. 
- Prolonged contractions (PC): prolonged (>20 sec duration) contractions occurring 
simultaneously in recording sites at least 20 cm apart, at least during 30 minutes in 
postprandial period. 
 
INDETERMINATE PATTERN 
- Not fulfilling above criteria but with some abnormal findings (i.e.: isolated PC, postprandial 
hypomotility, hypermotility, etc). 
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Table 6. Antibodies used for immunohistochemical analysis of small bowel full-thickness 
biopsies. 
Primary Antibody Host Code Dilution Source 
Neuron-specific 
enolase 
Rabbit PA1-28217 Ready to use 1:1 Thermo Fisher 
Scientific° 
Synaptophysin Rabbit A0010 1:100 DAKO* 
BCL-2 oncoprotein 
(clone 124) 
Mouse M0887 1:100 DAKO 
S100b Rabbit Z0311 1:400 DAKO 
C-Kit / CD117 Rabbit A4502 1:400 DAKO 
Smooth muscle actin Mouse M0851 1:400 DAKO 
CD45R0 (clone 
OPD4) 
Mouse M0834 1:40 DAKO 
CD8 (clone 
C8/144B) 
Mouse M 7103 1:50 DAKO 
CD3 (clone F7.2.38) Rabbit A0452 1:25 DAKO 
Mast cell tryptase 
(clone AA1) 
Mouse M7052 1:800 DAKO 
Notes: °Thermo Fisher Scientific, Rockford, USA; *Dako, Glostrup, Denmark 
 
 
 
 
Table 7. Clinical, manometric and histopathological features in CIPO and SFGID. 
 
 CIPO 
(n=20) 
SFGID 
 (n=15) 
P value 
Clinical features 
 Esophageal involvement 
 Gastroparesis 
 Small intestinal bacterial overgrowth 
 Urinary tract involvement 
 Psychiatric comorbidities 
 Enteral nutrition 
 Parenteral nutrition 
 
 
3 (15.0%) 
5 (25.0%) 
10 (50.0%) 
2 (10.0%) 
5 (25.0%) 
4 (20.0%) 
4 (20.0%) 
 
2 (13.3%) 
7 (46.7%) 
6 (40.0%) 
2 (13.3%) 
2 (13.3%) 
1 (6.7%) 
7 (46.7%) 
 
0.889 
0.181 
0.557 
0.759 
0.393 
0.265 
0.093 
Manometric pattern 
 Neuropathy 
 Myopathy 
 Occlusive 
 Indeterminate 
 No abnormalities 
 
 
10 (50.0%) 
3 (15.0%) 
3 (15.0%) 
1 (5.0%) 
3 (15.0%) 
 
 
11 (73.3%) 
0 (0.0%) 
0 (0.0%) 
2 (13.3%) 
2 (13.3%) 
 
 
0.163 
0.117 
0.117 
0.383 
0.889 
 
Histological subgroup 
 Neuropathy 
 Myopathy 
 Inflammatory neuro-myopathy 
 Apparently normal 
 
4 (20.0%)  
1 (5.0%) 
10 (50.0%) 
5 (25.0%) 
 
 
1 (6.7%) 
3 (20.0%) 
6 (40.0%) 
5 (33.3%) 
 
 
0.265 
0.167 
0.557 
0.589 
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Table 8. Cross-tabulation of manometric findings and histopathological features. 
 
 
 
 
Values indicate number of patients per subgroup. 
 
Fig. 14. Representative photomicrographs showing NSE (A and B) and Bcl-2 (C and D) 
immunolabeling in the neuromuscular component of a jejunal biopsy. Compared to controls (A and 
C), note the clear-cut reduction of the NSE (B) and Bcl-2 (D) immunoreactivity in a patient with 
severe dysmotility; both features support an underlying neuropathy. Also, note that myenteric neurons 
and nerve fibers are much less detectable in both photomicrographs, either labeled by NSE (B) or Bcl-
2 (D) further supporting degenerative mechanisms leading to neuronal impairment. Original 
magnification: 200x in A-D. 
 
Histological 
subgroup 
   Manometric 
subgroup Neuropathy Myopathy Inflammatory 
Apparently 
normal 
Neuropathic 3 2 8 8 
Myopathic 2   1   
Occlusive     3   
Indeterminate   1 2   
Normal   1 2 2 
A B 
C D 
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Fig. 15. Representative photomicrographs showing smooth muscle α-actin (SMA) immunostaining in 
a jejunal biopsy. Compared to control (A), note the marked reduction of SMA immunostaining in the 
circular layer of a patient with severe intestinal dysmotility (B). Original magnification: 100x in A 
and B. 
 
 
Fig. 16. Representative photomicrographs showing CD3 immunolabeling in the neuromuscular 
component of a jejunal biopsy. Pictures show a dense CD3 positive lymphocytes within a myenteric 
plexus (hence the term of myenteric ganglionitis) (A) and throughout the circular muscle adjacent to 
nerve fibers (axonitis) (B). Original magnification: 200x in A and B. 
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Fig. 17. Representative photomicrographs showing tryptase immunolabeling in the jejunal 
neuromuscular layer. Compared to a control subject (A), note the presence of tryptase 
immunoreactive mast cells infiltrating longitudinal (B) and circular (C) muscle layer, surrounding (D) 
and within (E) a myenteric plexus of patients with intestinal dysmotility. Original magnifications: 
100x in A and C; 200x in D and E. 
 
 
Fig. 18. Intestinal manometry: neuropathic pattern. Bursts of unpropagated activity are observed 
in the last three channels. Histopathology of full-thickness small bowel biopsies showed signs of 
lymphocytic neuro-myositis. 
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Fig. 19. Intestinal manometry: myopathic pattern. Note reduced amplitude of intestinal 
contractions during phase III activity fronts. Small bowel full-thickness biopsies revealed an 
underlying intestinal neuropathy.  
 
 
 
Fig. 20. Intestinal manometry: occlusive pattern. The manometric recording shows a minute 
rhythm activity characterized by short bursts of contractions repeating every 1-2 min during the 
postprandial period. An extensive mast cell infiltration was detected in the neuromuscular layers of 
the small bowel wall. 
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Take home messages: 
• Intestinal manometry and / or histopathology are the current standard for the 
diagnosis of severe small bowel dysmotility disorders. However, the degree of 
correlation between the two methods is unknown. 
• Results of this study indicate that more than two-thirds of these severe clinical 
cases with abnormal manometry also have abnormal histopathology 
underlying gut dysmotility.  
• Nonetheless, we detected no correlation between the specific manometric 
patterns and histopathological findings. 
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Chapter 8. 
QUANTITATIVE CHANGES OF ENTERIC NEURONS CORRELATE WITH 
CLINICAL FEATURES IN PATIENTS WITH SEVERE DYSMOTILITY 
 
Modified from 
Quantitative changes of enteric neurons correlate with clinical features in patients with 
severe dysmotility 
Boschetti E1*, Karunaratne TB1*, Gori A1*, Malagelada C2,3, Accarino A2,3, Azpiroz F2,3,  
Malagelada JR2,3, Bianco F1, Giancola F1, Bonora E1, Clavenzani P4, Mazzoni M4,  
Sternini C5, Stanghellini V1 and De Giorgio R6 
* These authors share co-first authorship 
Submitted / under revision 
 
 
ABSTRACT 
Severe gastrointestinal symptoms are often associated with markedly perturbed enteric 
motility, a finding related to underlying enteric neuropathies. Current methods used to 
demonstrate enteric neuropathies are mainly based on classic qualitative 
histopathological/immunohistochemical evaluation. This standard approach, however, is 
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hampered by data interpretation, inter-observer variation and lack of expertise among 
pathologists. Objective: We assessed quantitatively the enteric innervation in patients with 
severe dysmotility (SD) and correlate the data with clinical features. Methods: Jejunal full-
thickness biopsies were collected from 32 well characterized SD patients (16-77 years; 22 F); 
and from n=8 controls (47-73 years 4F). A symptom questionnaire was fulfilled prior to 
surgery. Patients were subdivided according to a previous qualitative histopathological 
evaluation: n=10 with an apparently normal (AN) neuro-muscular layer; n=14 with 
inflammatory (INF) changes throughout the neuromuscular layer; and n=8 with degenerative 
neuro-muscular alterations (DEG). Myenteric plexus (MP) and submucosal plexus (SMP) 
neurons were stained using neuron specific enolase antibody and neuronal cell 
bodies/ganglion were counted in at least three sections by 3 independent and skilled 
operators. Mean numbers of neuronal cell bodies/ganglion were analyzed by student’s t-test 
and the correlation with symptoms/signs via Spearman correlation test. Results: The final 
concordance among the 3 operators was 80%. MP and SP neuronal cell bodies were 
decreased in SD vs. controls (P<0.001). Also MP and SP neurons decreased in AN, INF and 
DEG vs. controls (P<0.0001 in MP and P<0.05 in SP). Furthermore INF and DEG showed 
less MP (but not SP) neuronal cell bodies compared to AN (P=0.0224 and P=0.0044). Both 
the reduced MP and SP neuronal cell bodies correlated with abdominal distension/pain, early 
satiety, constipation and gastroparesis (P<0.05). Conclusions: The proposed method, showing 
a low discordance rate (20%), identified an overall 50% decreased of MP and SP neuronal 
cell bodies implying a critical loss of the neuronal mass. The 50% neuronal reduction 
correlated with a variety of symptoms / signs of SD patients. Notably, quantitative neuronal 
abnormalities can be demonstrated in patients with AN histopathology. 
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INTRODUCTION 
Dysmotility represents an important clinical subgroup of the gastrointestinal (GI) 
neuromuscular disorders characterized by changes in the speed, strength or coordination of 
the muscles in the GI tract. Abnormal motility in the small intestine can lead to symptoms / 
signs suggestive of partial or complete intestinal obstruction.1 The most severe form of 
intestinal dysmotility is represent by chronic intestinal pseudo-obstruction (CIPO) which 
typically shows a severe and recurrent episodes of impaired GI propulsion with sustained 
radiological findings mimicking mechanical obstruction.24,25,393 Enteric dysmotility (ED) 
encompass an additional group of patients with abnormal intestinal motor activity and severe 
symptoms but no radiological signs of pseudo-obstruction and the clinical presentation of ED 
corresponds to that of severe functional GI disorders (SFGID).16,411,413  
Both CIPO and ED are associated with abnormalities in enteric neurons, interstitial cells of 
Cajal (ICC) networks and enteric smooth muscle cells and their interactions with other cell 
types such as cells in the immnue system5-6. These alterations in the neuro-muscular systems 
are tightly linked to the contractile abnormalities detected in intestinal dysmotility. Intestinal 
manometry can be used to assess the contractile activity of the gut over long periods of time 
and to define the pathophysiological mechanisms involved in dysmotility (e.g. neuropathy or 
myopathy)1,485. Recently we published a study prospectively comparing small bowel 
manometric abnormalities with subsequent histopathological findings in full-thickness 
intestinal biopsies.501 Notably, 38% of the patients who presented a neuropathic manometric 
pattern in that study showed apparently normal histopathology in the full-thickness biopsies. 
However, currently used methods to demonstrate pathological abnormalities of the enteric 
neuromusculature in full-thickness biopsies are not fully standardized and the technical 
details and criteria for interpretation may be subjected to observer variation. In particular, 
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these methods use a qualitative approach which misses the quantitative metrics in the 
histologic tissue. In a complex condition like severe dysmotility, total histologic evaluation 
for subtle alteration in the microanatomy, rather than defining biopsies exclusively on 
broader microscopic architecture, may impact diagnosis. This may be especially true in 
neuropathy, since for an optimal neurological function, it is imperative to have the neurons in 
good quality as well as in a good quantity.  
Clearly, whole-mount preparations represent the most suitable approach for neuronal cell 
count,502,503 however, formalin-fixed paraffin-embedded tissue specimens are easier to 
prepare and routinely collected in histopathology archives. Therefore these specimens 
represent the only material available for examination and are precious resources for 
retrospective clinical studies.503,504 Accordingly, standard methodological criteria must be 
established for accurate evaluations of neuron cell populations in paraffin-embedded 
intestinal samples. In an attempt to address this issue, in the present study we analyzed the 
number of neurons per ganglion in sub mucosal plexus (SP) and myenteric plexus (MP) in a 
group of patients with severe and chronic clinical manifestations of GI dysmotility and 
another group of individuals who severed as controls. Subsequently, we evaluated the 
possible correlation between the severity of symptoms and the number of neurons per ganglia 
in SP and MP, our hypothesis being that as the number of neurons per ganglia in SP and / or 
MP reduces, dysmotility symptoms will become more severe. 
 
MATERIAL AND METHODS 
 
Patients 
Thirty eight patients with severe dismotility (SD) of the GI tract were recruited and clinically 
evaluated at the Vall d’Hebron University Hospital in Barcelona between November 1999 
and November 2009. During this time span a subgroup of thirty two patients (16 to 77 years 
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old; 22 females and 10 males) underwent full-thickness biopsy. Patients with motility 
disorders secondary to infectious, neurological, metabolic, systemic-autoimmune and 
paraneoplastic conditions were excluded. Anorexia nervosa was specifically excluded in all 
patients with malnutrition by a psychiatric examination. 
The clinical diagnosis of SD with inability to maintain normal body weight was established 
on the basis of chronic (>3 months) persistent or recurrent symptoms in the absence of 
episodes mimicking mechanical CIPO and of associated organic, systemic or metabolic 
diseases potentially responsible for the digestive manifestations. Inability to maintain a 
normal body weight was defined by a BMI <18.7 Kg m-2 (in women) or <20.1 Kg m-2 (in 
men). Within the n=32 SD patients n=19 had recurrent sub-occlusive episodes. The clinical 
diagnosis of CIPO was established on the basis of a chronic (>3 months), severe symptom 
complex mimicking mechanical small bowel obstruction, as well as (at least on one occasion) 
radiological evidence of air-fluid levels or dilated small bowel loops. Thus, patients presented 
with abdominal pain and distension associated with nausea, vomiting, bloating and 
malnutrition. These clinical manifestations occurred episodically or continuously. Presence of 
mechanical obstruction had been excluded by conventional imaging studies or by prior 
exploratory abdominal surgery. 
Controls (CTR) patients n=8 (47-73 years old; 4 females and 4 males) underwent abdominal 
surgery for non complicated neoplastic tumor. Full thickness biopsies were collected in the 
flanking jejunal tissue without infiltration and preserved architecture. 
For patients and controls a symptoms questionnaire was fulfilled prior to the surgical 
intervention. Particularly the following data were collected: age; sex, BMI, CVC and related 
infections; the requirement of parenteral nutrition; the number of sub-occlusive episodes, the 
presence of abdominal distension; the presence and entity of the abdominal pain; the 
incidence of nausea, vomiting, fullness; the sensation of early satiety; the presence of 
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constipation and / or diarrhea according to the Bristol stool scale; the possible esophageal 
involvement; the occurrence of gastroparesis; the presence of small intestinal bacterial 
overwrought (SIBO), the occurrence of urinary symptoms; and finally the age of symptoms 
onset. 
The study protocol was approved by the Ethics Committee of the University Hospital Vall 
d’Hebron and all patients gave written informed consent. 
 
Intestinal tissue samples 
Full-thickness biopsy specimens were obtained from small bowel either by laparoscopy or 
laparotomy. In each patient a single circular segment (5 cm long) was obtained from the 
proximal jejunum, except in those cases with segmental dilatation in whom the biopsy was 
obtained from the most dilated segment. Immediately after resection, specimens were fixed in 
10% formalin overnight, embedded in paraffin and sectioned (4 m) according to standard 
protocol for tissue processing. 
Histopathological review was conducted by one of the investigators (R. De G) and his team 
(A. G. and E. B.) at the University of Bologna, Italy. Histopathological material was 
examined without prior information about clinical and motility test outcomes. All biopsies 
were first analyzed to exclude associated pathological findings such as malignancy, dysplasia 
or villous atrophy. Specific enteric neuromuscular evaluation was performed on the 
hematoxylin and eosin (H&E)-stained sections to assess the overall structure of ganglia, 
myenteric and submucosal neuronal cell bodies and fibers, glia and smooth muscle cells. 
When needed, other standard histological stains (e.g. Masson trichrome) were applied to 
detect additional tissue changes such as fibrosis. Finally, immunohistochemical techniques to 
analyze structural markers of the enteric neuromuscular component were used. We used 
specific antibodies to: neuron specific enolase (NSE) and synaptophysin (both general 
128 
 
neuronal markers), BCL-2 (as a marker of cell survival), S100 (glial cells), c-Kit (interstitial 
cells of Cajal, ICC), alpha-smooth muscle actin (-SMA) (smooth muscle cells), CD45 
(leukocytes), CD3 (general T lymphocyte marker), CD4 and CD8 (markers of T lymphocyte 
subsets, i.e. “helper” and “suppressor”, respectively). Finally, an anti-tryptase antibody was 
used to detect mast cells (antibodies feature and experimental dilution are listed in Table 9). 
The immunohistochemical techniques used in this study have been performed according to 
standardized and widely validated protocols.440  
Three histopathological patterns, were recognized according to the London classification.2 
Main findings for each of these patterns are detailed: 
Apparently normal (AN): (n=10; age range 24-61; 3 male) no detectable changes in the 
neuromuscular layer using conventional histochemical staining and immunohistochemistry; 
Inflammatory neuro-myopathy (INF): (n=14; age range 16-77; 4 male) characterized by 
lymphocytic infiltrate in muscle layers (leiomyositis) and / or neuronal ganglia (ganglionitis) 
(visualized by anti-CD3, -CD4 / -CD8 immunolabeling); or mast cell or eosinophil 
infiltration throughout the neuromuscular structures (detected by tryptase immunolabeling or 
via conventional H&E staining, respectively).497  
Degenerative neuro-myopathy (DEG): (n=8; age range 29-70; 3 male) overt ganglionic 
abnormalities as identified by traditional tinctorial staining (H&E) and immunohistochemical 
approaches (pan-neuronal markers); altered neuronal survival was identified by assessing 
BCL-2 expression in perikarya and nerve fibers (a feature which has been already associated 
with increased neuronal apoptosis);14muscular degeneration with cell swelling, vacuolization 
or atrophy; fibrotic replacement of smooth muscle (detectable by conventional staining, such 
as H&E, and immunohistochemical approaches, e.g. -SMA immunoreactivity 
abnormalities); 
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Table 9. Antibodies used for immunohistochemical analysis of small bowel full-thickness 
biopsies. 
 
Primary Antibody Host Code Dilution Source 
Neuron-specific enolase Rabbit 
PA1-
28217 
1:1 Thermo Fisher Scientific° 
Synaptophysin Rabbit A0010 1:100 DAKO* 
BCL-2 oncoprotein (clone 124) Mouse M0887 1:100 DAKO 
S100b Rabbit Z0311 1:400 DAKO 
C-Kit / CD117 Rabbit A4502 1:400 DAKO 
Smooth muscle actin Mouse M0851 1:400 DAKO 
CD45R0 (clone OPD4) Mouse M0834 1:40 DAKO 
CD8 (clone C8/144B) Mouse M 7103 1:50 DAKO 
CD3 (clone F7.2.38) Rabbit A0452 1:25 DAKO 
Mast cell tryptase (clone AA1) Mouse M7052 1:800 DAKO 
 
Notes: °Thermo Fisher Scientific, Rockford, USA; *Dako, Glostrup, Denmark. 
Immunoperoxidase secondary detection system (IHC Select HRP/DAB), (Millipore, Canada) 
was performed using chromogen substrates to obtain the typical brown-dark product 
indicative of immunolabeling. Furthermore, alkaline phosphatase anti-alkaline phosphatase 
immunohistochemical technique was used to detect the lymphocytic infiltrate by applying 
anti-CD3, -CD4 and -CD8 rabbit and mouse antibodies. 
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MP and SP neuronal cell count 
MP and SP neurons per ganglion were counted at 400X final magnification with a light 
transmission microscope (Olympus AX 70; Olympus, Melville, NY, USA) by three 
investigators (E.B, A. G. and R. De G. unaware of the diagnosis of the assessed slides). At 
least three jejunal cross sections from one specimen per patient and control were examined. 
Focusing along the neuromuscular ridge of the myenteric ganglia and submucosa, all the 
consecutive microscopic fields (at least 20) were considered for each analyzed section. Each 
operator counted the total amount of neurons NSE immunoreactive per ganglion. The final 
number of neuron per ganglion per patient was compared among the three operators to assess 
the inter observer variability of this technique. The concordance among the three operators 
was reached when the deference between counted averages was ≤ 5 neurons, otherwise the 
sample was considered discordant. The final concordance of 80% was reached in analyzed 
cases (n=40). Figure 1 shows an example of the operative magnification of the neuronal 
count in the neuromuscular layer (Fig. 21 A) and in the submucosa (Fig. 21 B). 
 
 
Fig. 21. Neuronal count in MP and SP. The two pictures are a representative view of the 
operative neuronal count on a CTR sample. Black arrow indicates neurons identified with 
NSE staining in A) MP and B) SP.  
 
A B 
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Statistical analysis 
The non parametric student’s t-test was used to define differences between means (± SD) of 
MP and SP neurons from ED patients (together or divided in the tree subgroups) and control 
specimens; and also to evaluate distribution of patients with CIPO episodes among the whole 
cohort. In both cases the analysis of variance was calculated by a two tailed ANOVA test. 
The correlation among the number of MP or SP neurons and symptoms was performed using 
the non parametric correlation test of Spearman. Where possible, the linear regression and the 
95% confidence interval were calculated. 
 
RESULTS  
MP and SP neuronal cell count in SD and SD subgroups vs CTR 
 
Number of neurons per ganglion measured in MP (Fig. 22 A) and SP (Fig. 22 B) was 
decreased in all SD patients (P<0.001 both) vs CTR. Subdividing patients into the three IHC 
subgroups identified, neurons in MP were drastically decreased in AN, INF and DEG vs CTR 
(P<0.0001). Furthermore, INF and DEG showed less MP neurons compared to AN 
(P=0.0224 and P=0.0044 respectively). In SP, neurons in AN, INF and DEG were decreased 
equally vs CTR (P= 0.0024; P=0.0005; P=0.0366 respectively). 
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Fig. 22. MP and SP neuronal cell count in SD and SD subgroups vs CTR. A) MP neuron counted 
in the total SD group *P<0.0001; B) SP neuron counted in the total SD group *P<0.0001; C) MP 
neuron counted diving SD in AN, INF and DEG *#§=P<0.0001; $P= 0.0044 and °P=0.0224; ANOVA 
P<0.0001 D) SP neuron counted diving SD in AN, INF and DEG *P<0.0024; #P= 0.0005 and 
§P=0.0366; ANOVA P<0.0001. 
 
 
Distribution of patients with CIPO episodes among total SD patients 
59% of SD patients had CIPO episodes. CIPO patients were distributed in the 3 subgroups 
with a non-significant statistic trend to increase from AN (40%) to INF (64%) and DEG 
(75%) (Fig. 23 A). The number of episodes had a trend to increase among groups, but 
without statistic significance. Only the 30% of AN patients showed more than 2 episodes, 
otherwise in INF the percentage increased to 56% and the totality of DEG cases with CIPO 
had more than 2 episodes (75%) (Fig. 23 B). Patients with 3 or more sub-occlusive episodes 
were 10% in AN, 36% in INF and 37.5% in DEG (Fig. 23 C). 
C
TR S
D
0
10
20
30
40
50
60
70
*
n
e
u
ro
n
s 
/ 
g
a
n
g
lio
n
 M
P
C
TR A
N
IN
F
D
E
G
0
10
20
30
40
50
60
70
* #
* # §
§° °$ $
n
e
u
ro
n
s 
/ 
g
a
n
g
lio
n
 M
P
C
TR S
D
0
2
4
6
8
*
n
e
u
ro
n
s
 /
 g
a
n
g
li
o
n
 S
P
C
TR A
N
IN
F
D
E
G
0
2
4
6
8
* # §
* # §
n
e
u
ro
n
s
 /
 g
a
n
g
li
o
n
 S
P
A B
DC
133 
 
 
Fig. 23 Distribution of sub occlusive episodes among the tree groups of SD patients. A) 
Percentage of patients with almost one sub occlusive episode B) Percentage of patients with 2 or more 
sub occlusive episodes C) Percentage of patients with tree or more sub occlusive episode. 
 
 
MP and SP neuronal cell count in SD with or without sub occlusive episodes vs CTR 
 
Since SD group encompass patients with a severe impairment of GI motility with or without 
sub-occlusive episodes, the neuronal count was performed also by subdividing the cases as 
patients without CIPO episodes (SD-NON-CIPO) and patients with one or more CIPO 
documented episodes (SD-CIPO). Fig. 24 shows that neuron equally decreased between SD-
NON-CIPO and SD-CIPO vs CTR.  
 
Correlation between the number of MP and SP neurons and reported symptoms. 
There is a direct correlation among the decrease of MP and SP neurons (P=0.0062 R=0.4418 
Fig. 25 A). The MP neuronal decrement did not showed a trend for association with the 
severity of CIPO episodes (P=0.0574 R=-0.3030 Fig. 25 B). Symptoms that increase with the 
MP neurons reduction (Fig. 25 C) are: abdominal distension (P<0.0001 R=-0.6238); 
abdominal pain (P=0.0037 R=-0.4490); early satiety sensation (P=0.0264 R=-0.3509); 
constipation (P=0.0490 R=-0.3132) and gastroparesis (P=0.0128 R=-0.3901). Symptoms that 
increase with the SP neurons decline are abdominal distension (P=0.0012 R=-0.5124); 
abdominal pain (P=0.0033 R=-0.4709), and constipation (P=0.0152 R=-0.3961). 
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Fig. 24 MP and SP neuronal cell count in SD with or without sub-occlusive episodes vs CTR. 
Neurons counted in patients subdivided considering the presence or the absence of pseudobstruction 
episodes in A) MP *#P<0.0001 and ANOVA P<0.0001; and in B) SP *#P=0.0004 and ANOVA 
P<0.0001. 
 
 
Fig, 25 Association among MP neurons and symptoms. A) Linear regression illustrating the 
quantitative correlation among MP and SP neurons Spearman P=0.0062 R=0.4418. B) Linear 
regression illustrating the trend (not significant) among MP neurons and the number of sub-occlusive 
episode Spearman P=0.0574 R=-0.3030. C) Illustration that highlights symptoms that worsens when 
MP neurons decrease. 
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DISCUSSION 
Minimally invasive procedures such as laparoscopic surgery and natural orifice trans luminal 
endoscopic surgery have enabled, with a relative safety, the demonstration of derangements 
occurring in the enteric neuro-muscular system in full-thickness biopsies of patients with 
severe dysmotility. Despite these technical and safety advancements, often biopsying patients 
with severe GI dysmotility has been discouraged by reasons such as an ‘apparently normal’ 
neuro-muscular layer reported even in cases characterized by severe symptoms / signs and / 
or manometric abnormalities. Degeneration of neurons in the ENS is still not completely 
understood and therefore in the present study we used quantification of neurons in SP and 
MP ganglions to divulge neuronal degeneration in severe intestinal dysmotility, especially in 
cases where apparently normal neuro-muscular architecture was observed with standard 
staining methods. 
 
The quantitative results in this study show that the group of patients who were labeled AN 
has significant reduction in number of neurons in the enteric ganglions. The loss of 
approximately a half of neurons per ganglion in both SP and MP may explain the clinical 
manifestations and the abnormal manometric patterns detected in the AN group, which we 
have published previously.7 The significant difference in neuronal counts per ganglion 
between the AN and DEG or between AN and INF hints that the AN group may be at the 
initial stage of the neurodegeneration or inflammation process and may develop into either 
inflammatory or degenerative neuropathy / myopathy identifiable with standard staining 
methods in histopathology as the neuronal count declines. Further experiments are warranted 
in order to clarify the biochemical pattern of the three groups with the aim to find predictive 
molecules that may stratify CIPO patients, and possibly reveal if AN really represent the 
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early stage of INF and DEG. In this line, it would be possible to identify potential biomarker 
to develop a targeted therapy. 
 
Furthermore, the differences in neuronal counts among histological subgroups highlight the 
importance of number of neurons in the generation of sub-occlusive episodes and dysmotility 
symptoms. In fact, we could identify an increase in number of sub-occlusive episodes as the 
neuronal count declines. Though we could not establish a statistically significant correlation 
between number of sub-occlusive episodes and the neuronal count with our data, it could be 
inferred that a significant correlation may be reached if the sample sizes are increased. 
Abdominal pain and distension, two very important clinical manifestations of SD, positively 
correlated with the declined neuronal count. In our clinical assessment of these SD patients, 
we did not consider the subjective severity of the pain according to a pain scale or the 
distention. Therefore, with our data we cannot conclude on variation of abdominal pain and 
distension according to the neurons per ganglion in the ENS, although this could have put 
some emphasis on the neuronal count as a predictive marker. However, based on our results 
we could tentatively propose the number of neurons per ganglion in the SP and MP as a 
predictive marker for symptom / sign generation and their severity.  
 
One limitation of the neuronal count technique is the inter-observer-variability. The 
discordance among evaluators of neuronal count in this study was 20% and the differences 
between the averages more than five neurons. Among the patients who had discordance in 
their neuronal counts, only one patient had a difference in average neuronal counts which was 
greater than 10 while in all others, the differences were less than 9. The differences between 
the counted average of CTR and any group of CIPO were  24 neurons. Even if this 
technique is influenced by operators, the estimated discordance is considered to be very low 
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to affect the results. We used a pan neuronal marker, therefore we were unable to identify if 
the decrement involved one or more neuronal subtypes. The use of specific staining for 
different neuronal classes will clarify if the neuronal loss is generalized or affect a specific 
neuron subtype. 
 
Our data indicate that altered GI propulsion and the generation of dysmotility symptoms are 
associated with at least 50% of neuronal loss in the small intestine. Furthermore, it appears 
that the clinical manifestations and their severity may increase as the neuronal count decrease 
in the ENS. This finding in the gut reflects a neuronal impairment characteristic of other 
pathological conditions involving central nervous system, such as Parkinson’s or Alzheimer 
diseases. 
 
 
Take home messages: 
• Qualitative approach used to demonstrate pathological abnormalities of the 
enteric neuromusculature in full-thickness biopsies are not fully standardized 
and does not account for the quantitative metrics in the histologic tissue. 
• The quantitative results in this study show that the group of patients who had 
no detectable changes in the neuromuscular layer using qualitative approach 
had significant reduction in number of neurons in the enteric ganglions.  
• The loss of approximately a half of neurons per ganglion in both submucosal 
and myenteric plexus correlated with a variety of symptoms / signs of SD 
patients 
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CONCLUSIONS 
 
The ENS serves a vast array of regulatory functions through which the physiology of the GI 
tract occurs to preserve body homeostasis and ultimately life. However, mounting evidence 
clearly indicate that the ENS is reminiscent of the CNS organization, not only for the neuro-
bioelectrical properties and function, but also for the important glial cell component 
reminiscent of astrocytes of the CNS. Any changes that could alter this finely tuned and 
highly integrated system could result in gut dysfunction. The diagnosis of enteric 
neuromuscular disorders has seen many advances since the first identification of an enteric 
neuropathic disorder by the Danish physician Harald Hirschsprung in 1886. These technical 
advances achieved in microscopy and enteric histopathological staining techniques have 
made it possible to identify subtle neuropathies, myopathies or ICCpathies that underlie the 
most severe intestinal motility disorders, such as CIPO. This condition is part of GINMDs 
with still unclear pathophysiological aspects, which impact on the clinical practice in terms of 
their diagnosis and treatment. The physiological characterization of CIPO currently relies on 
manometric findings that are suggestive of underlying neurogenic or myogenic pathological 
conditions. However, none previous studies have reported on manometric finds and 
histopathology and small intestinal dysmotility in CIPO. In this thesis, I tackled this question 
by investigating patients with severe dysmotility using both standard manometry and 
intestinal full thickness biopsy samples. I showed that there is no apparent correlation 
between the manometric patterns and the underlying qualititative histopathological pictures 
although the abnormal manometry most likely suggests an underlying pathology detectable 
by histochemical / immunohistochemical approaches. Three histopathological subgroups 
have been identified: a) degenerative feature of neurones and / or muscle; b) inflammatory 
with an infiltrate spreading throughout the neuromuscular layer; and c) an appatently normal 
neuromusculat architecture (at elast at a qualitative assessment by expert pathologists). The 
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latter group was very intriguing since they present with severe symptoms and manometric 
abnormalities. Therefore, I further considered these subgroups using quantitative method to 
count the number of neurones present within myentric and submucosal ganglia. In this study I 
found that in all three histological subgroups number of neurones per ganglia was reduced by 
at least half compared to that in controls. Furthermore, I also showed the correlation of 
predominant symptoms (e.g. abdominal pain and distention) with the diminishing neuronal 
count in the ganglia. The data presented in this thesis therefore could infer neuronal 
dengeneration in the ENS not visible by the currently available qualititative histopathological 
techniques along with pushing forward the concept of a ‘critical neuronal mass’ below which 
symptoms arise in patients with severe gut dysmotility, i.e. CIPO.  
 
At last, I would state strongly that the present thesis clearly manifests my willgness to 
continue to investigate pathophysiological mechanisms that impact on diseases affecting gut 
homeostasis. Over the years, I learned that perseverance and enthusiasm in research pave the 
way to better patients’ management and treatment.  
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